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Abstract
Before 1990, options were limited for couples who were at risk for transmitting a genetic disease or a structural chromosomal 
abnormality to their children . Couples traditionally underwent invasive procedures such as amniocentesis and chorionic villus sam-
pling, after which termination was offered if the fetus was found to be affected . Many couples chose not to have children at all . 
Since then, technological advances have allowed preimplantation genetic testing (PGT) to be offered to these couples . Couples who 
choose PGT undergo in-vitro fertilization (IVF) with intracytoplasmic sperm injection (ICSI), where the oocyte is injected by a single 
sperm and is then implanted into the mother a few days later . However, in PGT, a few cells are removed and genetically analyzed 
before implantation to determine whether the embryo has a specific genetic defect or aneuploidy. The purpose of this paper is 
to determine whether PGT causes adverse clinical outcomes by critically analyzing PGT research studies . Current research does 
not seem to show any major adverse clinical outcomes after PGT especially in cases of singleton pregnancies . It is important to 
continue to examine the effects of an embryo biopsy in terms of neonatal and obstetric outcomes, as well as future development .
Does Preimplantation Genetic Testing Increase the Risk of 
Adverse Clinical Outcomes?
Robyn Weiss
Robyn Weiss graduated in June 2020 with a Bachelor of Science degree in Biology and is accepted into the Master 
of Science in Human Genetics program at Sarah Lawrence College.
Introduction
Preimplantation genetic testing (PGT) has become an 
integral part of assisted reproductive technology (ART) 
and over a third of ART Centers in the United States are 
utilizing PGT technology (Kuliev, Rechitsky, 2017). There 
are three kinds of PGT. The first, PGT-M, analyzes the em-
bryo for monogenic diseases. This is generally used when 
one or both parents carry a mutation, such as those 
linked to Huntington’s disease or cystic fibrosis. Testing is 
performed to ensure the single-gene trait has not been 
passed to the embryo. It is often used after a previous 
child has been diagnosed with a specific genetic condition. 
PGT-M may also be used for sex selection, such as when 
a parent is a carrier of an x-linked disorder (Pastore, et. 
al. 2019). The second, PGT-A, and third, PGT-SR, are not 
standard procedures and were developed to improve the 
success rate of IVF. PGT-A is used to look for embry-
onic aneuploidy and PGT-SR is used to look for chro-
mosomal structural rearrangements such as inversions 
or translocations. PGT-A and PGT-SR are usually only 
recommended in cases of previous failed rounds of IVF, 
severe male infertility, recurrent pregnancy loss, in cases 
where one or both parents have a balanced chromosome 
structural rearrangement, or for patients at high risk for 
embryo aneuploidy, such as those of advanced maternal 
age. While all forms of PGT come with many ethical ques-
tions, in general PGT-M is considered more acceptable, 
especially when it is used to prevent severe genetic dis-
eases with few treatment options. Genetic counseling is 
recommended before any form of PGT to ensure that 
the couple understands the risks and limitations of the 
procedure (Eskew, Jungheim, 2017).
There are multiple methods of performing PGT. Polar 
body biopsy (PBB) is a common method for genetical-
ly analyzing an embryo. Polar bodies are formed during 
meiosis of an oocyte and are not required for fertiliza-
tion or embryo development. Therefore, they can be re-
moved safely and screened without harming the embryo. 
Additionally, PBB avoids errors due to the presence of 
mosaicism that other methods of PGT incur. Mosaicism is 
when different cells have different genotypes within one 
organism and is not present at the zygote stage. PBB is 
considered a less invasive procedure and is a good option 
for patients who view more invasive procedures as un-
ethical. However, PBB can only provide maternal genetic 
information. Because PBB does not include paternal ge-
netic information and cannot be used to determine gen-
der, this method can only work in certain cases (Schenk, 
et. al. 2018).
PGT can also be done through a blastomere biopsy 
during the cleavage stage. This is done three days after 
fertilization, when the embryo is between six to eight 
cells. A blastomere biopsy is an invasive procedure where 
cell-to-cell adhesions are loosened and one or two blas-
tomeres are aspirated. The blastomeres are then genet-
ically analyzed for either aneuploidy or specific genetic 
mutations (Kalma, et. al. 2018). A blastomere biopsy al-
lows both maternal and paternal genetic information to 
be analyzed, which makes determining the gender of the 
embryo possible. However, given that this is an invasive 
procedure, this method may affect the growth and devel-
opment of the embryo. While there is evidence that a day 
three embryo can tolerate and overcome the possible 
resultant damage, it is likely that embryos that would oth-
erwise progress to implantation will be lost at this stage 
of embryo development. Additionally, a blastomere biopsy 
may not always be reliable since it is affected by both the 
technical and biological problems associated with single 
cell analysis. Specifically, mosaicism, which is at the high-
est level at this stage of development, can lead to false 
positive and false negative errors. In order to compen-
sate, two blastomeres can be removed. While this may 
increase the accuracy of the genetic testing, around 25% 
of the embryonic mass is removed, which may impact 
clinical outcomes (Cimadomo, et. al. 2016).
A third method of PGT is a blastocyst biopsy. It is 
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usually done five to six days after fertilization, when the 
embryo is about one hundred cells. During a blastocyst 
biopsy, five to six cells of the trophectoderm are removed 
and analyzed. This method allows more cells to be test-
ed, compared to the only one or two cells that can be 
removed during a blastomere biopsy, and allows for im-
proved accuracy of the genetic testing. Additionally, this 
procedure removes a smaller proportion of embryo cell 
mass when compared to the day three biopsy and only 
removes cells from the trophectoderm, not the inner 
cell mass. However, blastocyst biopsies have limitations 
as well. Only 50% of IVF embryos develop to the blasto-
cyst stage and waiting for a day five biopsy may result in 
no transfer at all. Additionally, following a day five biopsy, 
embryos typically need to be cryopreserved and then 
thawed which precludes the transfer of a fresh embryo. 
While there are many methods of performing PGT, each 
method has its own benefits and limitations (Wang, et. al. 
2018). Once the cells are removed, they are genetically 
analyzed by either polymerase chain reaction (PCR), flu-
orescence in situ hybridization (FISH), array-comparative 
genomic hybridization, and more recently, next-genera-
tion sequencing, in order to determine if there are any 
genetic defects (Heijligers, et. al. 2018). 
Because PGT is an invasive procedure, researchers have 
wondered if it increases the risk of adverse clinical out-
comes. It is especially important to monitor the safety of 
PGT since the majority of the PGT couples, specifically 
couples undergoing PGT-M, have no fertility issues and have 
the alternative of a natural conception with or without in-
vasive prenatal testing. This review is aimed at determining 
whether PGT increases the risk of adverse obstetric and 
neonatal clinical outcomes as well as future development.
Methods
The research discussed in this paper was collected using 
EBSCO, ProQuest, PubMed and Google Scholar with ac-
cess provided by the Touro College Library. All articles 
included are original, peer reviewed research papers that 




A study was aimed at evaluating the safety of PGT and 
focused on the rate of congenital malformations as well 
as other adverse perinatal outcomes. In this study, embry-
os for PGT analysis were produced by intracytoplasmic 
sperm injection (ICSI) and subjected to blastomere biop-
sy. Parents filled out a questionnaire regarding their preg-
nancy and the health of their child. Medical information, 
such as age of both parents at embryo transfer, gravidi-
ty, parity, number of previous in vitro fertilization (IVF)/ 
PGT cycles, whether the embryo(s) was fresh or frozen/ 
thawed, how many blastomeres had been removed, and 
how many embryos were transferred, was also obtained 
from their doctor. The largest proportion of couples in 
this study opted for PGT-M, in order to avoid passing an 
autosomal dominant disease to the child. In this study, 
more girls than boys were born after PGT with a ratio 
of 1.2. This may be due to sex-selection, where a female 
embryo is transferred to reduce the risk of inheriting an 
X-linked condition. Major congenital malformations were 
found in nine of the 364 live births (2.5%). Four of these 
children had multiple congenital anomalies and five chil-
dren (1.4%) had minor malformations. Three pregnancies 
were terminated because of diagnoses of exencephaly, 
trisomy 18, and trisomy 21. The major malformation rate 
when including pregnancy terminations due to congen-
ital malformations was 3.3%. A report by the European 
Surveillance of Congenital Anomalies stated a prevalence 
of 261.45 major and minor birth anomalies per 10,000 
births (2.6%) between 2008 and 2012, which is similar 
to the rate in this study. According to these results, the 
risk of major malformations in children born after PGT 
does not seem to be increased when compared to the 
general population. The study also found that perinatal 
deaths were reported in 3 out of 364 PGT pregnancies 
studied. Two of the pregnancies were of a twin and a trip-
let. Additionally, at 37 weeks gestational age, a singleton 
was stillborn, after an uncomplicated pregnancy. With a 
perinatal mortality rate of 0.8%, no evidence for a poten-
tial increased risk in fetal or neonatal death was found 
after PGT (Heijligers, et. al. 2018).
Similar results were found in a study that looked at the 
health of 49 children conceived after PGT compared to 
66 naturally conceived (NC) controls. Control children 
were matched for age, sex, ethnicity, maternal educational 
level and socioeconomic status. A majority of PGT sub-
jects had undergone PGT-A, however the study did not 
distinguish between subjects who had undergone PGT-
M, PGT-A, or PGT-SR. However, all PGT subjects were 
born after an embryo biopsy at the eight to ten cell stage. 
Pediatricians that assessed the children were blinded to 
the conception status of the children, strengthening the 
results of this study. The study found that two children 
born after PGT had congenital anomalies, one with a 
minor ear deformity and the other with mild hypospadias 
(Banerjee, et. al. 2008).
Another study examined whether PGT blastomere bi-
opsies impacted the health of infants up to two months of 
age by comparing the data of 995 children born after PGT 
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and 1507 children born after IVF and ICSI. Twenty-three 
PGT children (2.3%) and 40 ICSI children (2.7%) present-
ed major malformations. Major genital malformations 
were recorded in seven PGT children and 9 ICSI children. 
Four stillborns conceived after PGT and seven stillborns 
conceived after ICSI presented major malformations. The 
total major malformation rate, including stillborn and live 
born, was comparable in the PGT group (2.6%) and the 
ICSI group (3%). These results do not indicate that the 
added cleavage-stage biopsy procedure increases the risk 
of major birth defects compared to the ICSI procedure 
(Desmyttere, et. al. 2012).  
In another study, data from the PGT pregnancies of 158 
singletons, 42 pairs of twins, and 1 set of triplets was com-
pared to data obtained from 242 children born after IVF/ 
ICSI and 733 randomly selected NC children born during 
the same time period. The mothers in all groups were 
matched for age, preconception body mass index, and pari-
ty.  Data collected included parental demographic informa-
tion, type of biopsy performed (polar body and/ or blas-
tomere biopsy), number of embryos transferred, whether 
the embryo(s) were fresh or frozen/ thawed, gestational 
age and mode of delivery. At two to four months, parents 
also filled out a questionnaire regarding any malformations 
that had not been diagnosed at birth. In both single and 
multiple pregnancies, the type of embryo biopsy had no 
significant influence the neonatal outcome. Four of the 
PGT children (1.7%) presented congenital malformations. 
One intrauterine fetal death occurred at 33 weeks with a 
subsequent diagnosis of thrombophilia. The congenital mal-
formation rate for PGT pregnancies is similar to the rates 
found in other studies (Eldar-Geva, et. al. 2014). Additionally, 
in another Israeli study completed around the same time 
of 213,288 NC births, the rate of congenital malformations 
was 1.9% which is similar to the rate of malformation after 
PGT in this study (Farhi, et. al. 2013).
Another study looked at the health of 581 children 
born after a blastomere biopsy. Questionnaires were sent 
to both physicians and parents at conception and deliv-
ery and children were examined at two months of age, 
usually by a clinical geneticist. The researchers followed 
484 pregnancies, with three terminations for major mal-
formations seen on prenatal ultrasounds. Of these, 385 
were singleton pregnancies, 92 were twin pregnancies 
and four were triplet pregnancies leading to a total of 
581 PGT children. There were no differences in any of 
the studied properties between biopsies done for PGT-M 
or PGT-A and the results were therefore combined. As 
seen in many other studies, sex distribution of live born 
children was uneven with 54% girls for 46% boys and is 
due to sex selection for X-linked diseases. Of the 581 
children in the PGT cohort, eighteen were stillborn and 
nine died neonatally.  Of these 27 perinatal deaths, four 
were in singleton pregnancies and 23 in multiple pregnan-
cies. The rate of perinatal deaths in singletons is compa-
rable to the ICSI cohort, however the ICSI multiple birth 
cohort had a higher perinatal death rate. Major malfor-
mations were seen in 17 PGT fetuses which led three to 
be terminated. This led to a malformation rate in born 
and unborn children of 2.9%. Of the fourteen children 
with malformations, two were stillborn and both were 
from a multiple pregnancy. This leaves one inherited and 
eleven sporadic mutations in the 563 PGT children born 
alive with a rate of 2.13%. The major malformation rate 
in the ICSI cohort was 3.13%. The main finding of this 
study is that a day three embryo biopsy does not seem 
to increase the risk of major malformations. When these 
results are compared with the data collected from IVF/ 
ICSI children born within the same timeframe, the rate of 
malformations is comparable. (Liebaers, et. al. 2010)
Gestational Age/ Birth Weight
Studies also looked at the gestational age and birthweight 
of children conceived through PGT. In the study by 
Heijligers et al. (2018), eighty percent of the PGT children 
were born full term. Eight children, all from twin preg-
nancies (2.2%), were born very premature (<32 weeks). 
The study distinguished very premature children from 
premature children to show that the very premature 
children were all from twin pregnancies. Less than 15% of 
the PGT children had a low birth weight and were either 
twins or triplets. Only one singleton had a very low birth 
weight. The child was born at 35 weeks through caesari-
an section because of HELLP syndrome in the mother. A 
z-score of + 0.17 was calculated for the singletons which 
indicates a comparable birth weight between this cohort 
and the rest of the Dutch population. In concordance 
with other studies on PGT there is an evident increase in 
prematurity and low and very low birth weight in multi-
ples when compared to singletons. This strongly supports 
the current Dutch single embryo transfer policy. Overall, 
data from this study on pregnancy duration and birth 
weight in the Dutch PGT population, especially in the sin-
gletons, seems similar to the published data on naturally 
conceived children.
In the study performed by Eldar-Geva et. al. (2014), 
the difference in mean birth weight for singleton preg-
nancies between the three groups was statistically sig-
nificant. Singleton NC children had a significantly higher 
birth weight than those born after ICSI (P=.006) but not 
compared to the PGT singletons. Low birth weight was 
also more frequent in the ICSI group than in the PGT and 
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NC singletons. Also, significantly more ICSI twins (58%) 
presented with low birth weight compared to 41.0% of 
PGT twins and 44.2% of NC twins.  Very low birth weight 
(<1,500 g) was rare in all groups. There was also a sta-
tistically significant difference among the groups when 
examining intrauterine growth for singleton pregnancies 
(P=.001). Intrauterine growth restriction was more fre-
quent in ICSI pregnancies (9.5%) than in NC (5.5%) or 
PGT pregnancies (5.1%). Children born large for their 
gestational age was more frequent in the PGT group 
(16.5%) than the NC group (8.8%). The mean gestational 
age, rates of preterm birth and intrauterine growth re-
striction for twin and triplet pregnancies were similar for 
the three groups.  
 These results show that there are no increased risks of 
intrauterine growth restriction or low birth weight in sin-
gleton or twin pregnancies after PGT compared to NC. 
However, ICSI pregnancies did show an increased risk for 
both of these complications. These results remained true 
even after controlling for factors such as maternal age, 
parity, BMI, number of embryos transferred and whether 
the embryo was cryopreserved, which can affect preg-
nancy outcomes. The increased likelihood of adverse 
outcomes in ICSI pregnancies may be due to the fertility 
status of the parents. Infertile women are more prone 
to adverse outcomes even when conceiving naturally, in-
dicating that infertility itself is what increases the risk of 
adverse outcomes such as low birth weight and preterm 
delivery (Basso, Baird, 2003). This may explain the similar-
ity of the results in birth weight and intrauterine growth 
from PGT and NC pregnancies, since the majority of PGT 
couples usually do not struggle with fertility. 
The difference in pregnancy duration for singleton 
pregnancies between the three cohorts was also statis-
tically significant. NC pregnancies were longer, than both 
the PGT and the ICSI pregnancies. However, for the PGT 
group, these findings had no clinical significance because 
the frequency of preterm deliveries, both <37 (7.4%) and 
<34 weeks (1.3%) was comparable with NC pregnancies 
(5.7% and 2.0%, respectively). However, 11.4% of the ICSI 
cohort were born prematurely. PGT and ICSI pregnancies 
may have been shorter for different reasons. Women who 
undergo PGT are at high risk for autosomal recessive, 
X-linked, or dominant genetic disease and therefore have 
a higher incidence of previous pregnancy terminations for 
affected fetuses. Complications associated with induced 
abortions include premature delivery of future children 
and cervical incompetence. Additionally, some of the PGT 
women in the study had autosomal dominant diseases 
such as myotonic dystrophy, achondroplasia, neurofibro-
matosis and tuberous sclerosis and because of this chose 
to have a cesarean delivery at 37 to 38 weeks. In fact, 
the PGT cesarean delivery rate was more than double in 
PGT pregnancies. Additionally, some of the families had 
critically ill children which may have placed an emotional 
and physical burden on the family and pregnant mother 
(Eldar-Geva, et. al. 2014).  The preterm birth rate for the 
IVF/ ICSI group is unsurprising. As discussed above many 
studies have found that preterm birth is associated with 
children conceived through IVF/ ICSI because of the par-
ents underlying fertility issues (Wisborg, et. al. 2010). 
Another study looked at the health of 49 PGT children 
and 66 NC children. The PGT cohort had a significant-
ly lower gestational age at birth (P = 0.0001) and more 
preterm births than the NC group. The PGT group was 
also more likely to have a lower birth weight and a higher 
number of births with a birth weight of less than 2500 
grams. Interestingly, this finding is consistent with other 
studies of assisted reproduction outcomes such as IVF/ 
ICSI. In most cases PGT conception is closest to natu-
ral conception and not assisted reproduction concep-
tion, with regard to the reproductive health of parents. 
Parents who opt to undergo the most common form of 
PGT, PGT-M, usually do not have fertility issues but are 
concerned with passing a genetic disease to their chil-
dren. However, in this study, the majority of PGT patients 
had undergone PGT-A in which parents bear closer risk 
and resemblance to couples undergoing other assisted 
reproductive conception. PGT-A is usually used after 
failed IVF cycles or because of other fertility issues, such 
as advanced maternal age. It is therefore unsurprising that 
the age of the PGT mothers was significantly higher than 
the NC mothers, (P = 0.0001)  as was the rate of preterm 
birth and low birth weight in the PGT group, which is 
commonly seen in other assisted reproduction outcome 
studies (Banrjee, et. al. 2008). 
The study performed by Desmyttere et. al. (2012), 
found that the average birthweight for PGT singletons 
and PGT multiples with a very low birth weight (<1500 g) 
was comparable with the ICSI children. However, signifi-
cantly more ICSI multiples presented a low birthweight 
(<2500 g), more specifically 268 (17.8%) ICSI compared 
to 161 (16.2%) PGT babies. Again, this may be due to the 
fertility status of the parents, since the ratio of infertile 
couples was higher in the ICSI cohort than in the PGT 
cohort. Measurements of height and head circumfer-
ence showed no significant differences between the two 
groups.  Mean gestational age at birth for PGT singletons, 
twins and triplets showed no difference compared to the 
ICSI group. Additionally, the number of PGT singletons 
and multiples born prematurely (<37 weeks) showed 
no differences compared with their ICSI counterparts 
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(all P-values > 0.05). Twenty-one ICSI and four PGT sin-
gletons versus 67 ICSI and 31 PGT multiples were born 
very prematurely (<32 weeks) which is not significant 
(P = 0.056 and P = 0.43 for singletons and multiples). 
Admission after delivery to the neonatal intensive care 
unit was comparable for both the PGT and ICSI groups 
for singletons and multiples. These results show that sin-
gletons and multiples born after a PGT embryo biopsy 
had similar neonatal outcomes in terms of auxological 
data, gestational age and neonatal hospital admission, to 
the control group of singletons and multiples with no 
embryo biopsy. Additionally, in this study, PGT multiples 
appear to be at a lower risk for low birthweight when 
compared to IVF/ ICSI multiples. 
The study by Liebaers et al. (2010) found that in the 
PGT cohort, 11.5% of singletons and 65.7% of multiples 
were born premature. In the ICSI cohort, 8.4% of single-
tons and 57.9% of multiples were born premature. Low 
birthweight was observed in 7.4% of PGT singletons and 
very low birth weight in 3 (0.8%) PGT children. Multiple 
PGT births of a low birth weight (62.5%) were signifi-
cantly lower than ICSI multiple births (49.4%).  Very low 
birth weight was observed in 19 of the PGT multiples. 
These results suggest that a three day PGT biopsy does 
not seem to add significant health risks for singleton PGT 
children since when these results were compared to the 
data collected from IVF/ ICSI children born within the 
same years, gestational ages and birthweights were similar. 
However, PGT multiples appeared to be at an increased 
risk of low birthweight, preterm birth, and perinatal death 
compared to ICSI multiples. Multiple pregnancies should 
be avoided when possible and may potentially solve prob-
lems especially regarding perinatal death.
A similar study looked at whether women who con-
ceived after PGT and their children have greater risks of 
adverse pregnancy and birth outcomes compared with 
children conceived spontaneously or after IVF with or 
without intracytoplasmic sperm injection (ICSI). The study 
looked at factors such as pre-eclampsia, preterm prima-
ry rupture of membranes, placenta previa, abruption of 
placenta, preterm birth, low birth weight, major malfor-
mations, and neonatal admission. It was found that com-
pared to women conceiving spontaneously, women who 
had undergone PGT or IVF/ ICSI were older, more often 
uniparous, had a higher BMI and smoked less often during 
pregnancy. The children conceived after IVF/ ICSI had a 
lower birth weight, shorter gestational age, longer neonatal 
hospital admission and an increased risk of preterm birth 
and malformations. Children born after PGT had a compa-
rable risk of the same complications, however, the results 
were just short of statistical significance for many of the 
outcomes. Nonetheless, PGT children were found to have 
a significant increased risk of preterm birth, shorter ges-
tation, and longer neonatal hospital admission. The study 
also looked at the difference in outcomes between PGT-
M, PGT-A and PGT-SR. When compared to NC children, 
PGT-SR and PGT-A children did not have an increased risk 
of adverse neonatal outcomes. When compared to IVF/ 
ICSI children, PGT-SR and PGT-A children had comparable 
neonatal outcomes and were found to have a higher mean 
birth weight.  However, compared to NC children, children 
born after PGT-M had a significantly lower birth weight, 
shorter gestation and increased risk for longer neonatal 
hospital admission. These results show an increased risk 
of neonatal complications in PGT pregnancies when com-
pared to spontaneous pregnancies. However, the risk of 
adverse outcomes was generally comparable to IVF/ ICSI 
pregnancies, indicating that the actual embryo biopsy does 
not add additional risks. Additionally, when separating 
PGT-SR and PGT-A pregnancies from PGT-M pregnancies, 
adverse neonatal outcomes were only found in children 
conceived through PGT due to a parental monogenetic 
disorder (PGT-M) and not in children born after PGT-SR 
and PGT-A. These results make it likely that the risk of ad-
verse outcomes is not related to PGT itself, but to the un-
derlying condition of the parents. These factors can include 
the known genetic disorder, associated comorbidities or 
any medications taken during pregnancy. (Bay, et. al. 2016)
A study compared the growth data at birth and two 
years for 70 singletons born after PGT, ICSI or natural 
conception. Children were matched for gender, language, 
birth order and maternal education level. At birth, height 
and head circumference data were comparable for the 
PGT, IVF/ ICSI and NC cohorts. While the PGT singletons 
tended to have a lower birthweight and gestational age 
compared with the NC children, these differences did not 
reach statistical significance. When comparing children 
born after a biopsy of one or two blastomeres, weight, 
height and head circumference measurements were 
comparable for the two groups. Additionally, admission 
to a neonatal ward was comparable in the three concep-
tion groups and PGT children did not experience more 
hospital stays for medical reasons than the ICSI and NC 
groups. PGT children were also reported to have under-
gone more complementary examinations (with normal 
results) compared with NC and ICSI babies. However, 
this is probably due to precautionary measures for ‘spe-
cially conceived’ children (Desmyttere, et. al. 2009).
Obstetric Outcomes
In the study performed by Eldar-Geva et. al. (2014), the in-
cidence of pregnancy complications such as hypertension 
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and diabetes were similar in the PGT, IVF/ ICSI and NC 
groups. Of the PGT mothers 1% had hypertension and 
2% had gestational diabetes. Of the ICSI and NC moth-
ers, 1% had hypertension and 6% had diabetes, and 3% 
had hypertension and 4% had diabetes, respectively. 
Additionally, the differences in mode of delivery for sin-
gleton pregnancies was statistically significant. The cesar-
ean delivery rates were 28.5% in the PGT group, 31.6% in 
the ICSI group, and 11.0% in the NC group (P<.005). As 
discussed earlier, the cesarean rate for the PGT cohort 
was more than double the rate of the NC group in this 
study and was probably due to the fact that women with 
autosomal dominant diseases in the PGT cohort opted 
to have a cesarean delivery at 37 to 38 weeks.
In the study performed by Desmyttere et. al. (2009), 
increased rates of cesarean births were found when PGT 
mothers were compared to IVF/ ICSI mothers. Results 
also showed that when compared to NC mothers, PGT 
mothers experienced more pregnancy complications 
such as gestational diabetes, thyroid pathology, pregnan-
cy-induced hypertension, placental pathology and prema-
ture contractions. However, there were no differences 
regarding pregnancy complications when comparing PGT 
and IVF/ ICSI mothers.
In the study performed by Bay et. al. (2016) the IVF/ 
ICSI cohort showed an increased risk of placental dis-
orders, including placenta previa, pre-eclampsia, placental 
abruption, preterm primary rupture of membranes, and 
induction of labor or cesarean section. The women who 
gave birth after PGT had a comparable risk for most of 
the same complications when compared to the NC co-
hort, although for most of the outcomes the results were 
just short of statistical significance. However, the PGT 
cohort did show a significant increased risk of placenta 
previa and cesarean section. Because the risk of adverse 
outcomes was generally comparable to IVF/ ICSI preg-
nancies in many of these studies, it seems like the actual 
embryo biopsy does not add additional risks. 
When the study separated PGT-M subjects from PGT-A 
and PGT-SR subjects interesting results emerged. PGT-SR 
and PGT-A children did not have an increased risk of any 
adverse obstetric outcomes, except for a higher risk of 
placenta previa when compared to NC controls. When 
compared to IVF/ ICSI children, PGT-SR and PGT-A chil-
dren had comparable obstetric outcomes.  However, 
compared to NC children, children born after PGT-M 
had a significantly increased risk for preterm primary 
rupture of membranes, cesarean section and placenta 
previa. Again, these results make it likely that the risk of 
adverse outcomes is not related to PGT itself, but to the 
underlying condition of the parents. However, there was 
a consistent increased risk of placenta previa after both 
PGT and IVF/ICSI, which suggests that parental factors do 
not explain all the adverse outcomes. 
Follow up Study 
Growth
A study assessed whether PGT causes adverse outcomes 
by comparing findings at birth and at 2 years of age for 
singletons born after PGT, IVF/ ICSI, and NC. The study 
also investigated whether the body size of children born 
after biopsy of one blastomere was different from that of 
children born after biopsy of two blastomeres. Subjects 
in all groups were matched for gender, maternal educa-
tional level, mother tongue and birth order.  A strength to 
this study is that all children were examined by the same 
pediatrician in a standardized way. At a two year follow 
up, weight, height, head circumference, and waist and arm 
measurements were comparable for the three cohorts. 
These results show that PGT singletons do not appear 
to be at a higher risk of growth retardation compared 
with IVF/ ICSI and NC singletons. In PGT children, the 
mean BMI was statistically significantly lower compared 
with NC children. Growth parameters of the PGT chil-
dren born after biopsy of one blastomere were compa-
rable to children born after a biopsy of two blastomeres. 
(Desmyttere, et. al. 2009) 
The study performed by Banerjee et. al. (2008) found sim-
ilar results. When assessed at the mean age of 18 months, 
growth parameters for all PGT children were within the 
normal range including the children who had been born 
preterm and/ or with a low birthweight. Furthermore, 
Desmyttere et. al. (2009) found that in their follow up study 
that rates of chronic disease and chronic use of medication 
were similar between PGT and NC children. 
Socio-emotional and Language Development
A study was performed to assess the socio-emotional 
and language development of children at age two born 
after PGT, IVF/ ICSI, and NC, as well as parental wellbe-
ing. A small number of children (n= 10) that were born 
before between 33-36 weeks gestations were included 
in the study and were equally distributed among the co-
horts. Most of these children had a normal birth weight 
(<2500 g), and none of them had a very low birth weight 
or obtained an Apgar score of less than nine after ten 
minutes. Twins were excluded from the study because 
developmental outcome is affected by prematurity and 
low birth weight, which are known to be more com-
mon in twins and triplets. NC and ICSI controls were 
matched for gender, maternal education level, native lan-
guage, and birth order. All members of the PGT cohort 
11
Does Preimplantation Genetic Testing Increase the Risk of Adverse Clinical Outcomes?
had a blastomere biopsy at the eight-cell stage. Parents 
were asked to complete the Short Temperament Scale 
for Toddlers (STST) and the Child Behavioral Checklist 
(CBCL) in order to assess the child’s socio-emotional 
development. The STST, placed children into one of three 
temperament categories, easy, average or difficult. The 
CBCL answers questions about the child’s emotional and 
behavioral problems. Parents answered if the problem 
presented is ‘not true’, ‘somewhat or sometimes true’ or 
‘very true or often true’ of their child,  with item scores 
of 0, 1 or 2.  A total score of 60 is at the bottom of 
the clinical range, and a score of 64 or more represents 
larger issues. Language comprehension and production 
were rated according to the McArthur Communicative 
Developmental Inventories.
The CBCL scores showed no difference in the pro-
portion of children above the clinical threshold points 
according to mothers and fathers.  After controlling for 
socio-demographic variables, PGT and ICSI mothers 
reported significantly fewer problems than the NC co-
hort. According to the STST scores, a similar proportion 
of parents from all three conception groups reported 
their child’s temperament as easy, average or difficult. 
This remained true even after controlling for socio-de-
mographic variables.  Additionally, the mean Language 
Comprehension score and Language Production score 
did not differ significantly among the cohorts.
This study had some weaknesses. Firstly, results were 
obtained exclusively from parental reports and more valid 
reports could have been obtained from a multiple infor-
mant approach. Additionally, the PGT cohort had members 
that had undergone PGT-M and PGT-A. Since these pro-
cedures are usually done for different reasons, PGT-M and 
PGT-A populations have different medical histories and 
family backgrounds, which may influence socio-emotional 
and language results (Nekkebroeck, et. al. 2008a). 
Additionally, the study by Banerjee et al. (2008) found 
that the PGT cohort had significantly higher scores on 
the Hearing and Language subscale, than the NC group. 
These studies suggest that PGT does not cause adverse 
neurodevelopmental outcomes.
Mental and Psychomotor Development
In the study by Banjeree et al. (2008), children up to age 
four were evaluated with a focus on neurodevelopmental 
screening which was measured using the Griffiths Scales 
of Mental Development. The mean Griffiths quotient for 
both the PGT and NC groups were in the normal range 
and did not differ significantly. The only significant differ-
ences were for the Locomotor subscale, where the PGT 
group was significantly lower than the NC group.
A similar study aimed at assessing the mental and psy-
chomotor developmental outcomes in two-year-old chil-
dren conceived through PGT compared to children born 
after IVF/ ICSI and natural conception (NC). ICSI and NC 
controls were matched for gender, maternal education, 
birth order, and native language. All PGT subjects had a 
blastomere biopsy at the eight-cell stage of the embryo. 
At two years of age, the children were all tested by a psy-
chologist using the Dutch version of the Bayley Scales of 
Infant Development (BSID). The psychologist was blinded 
to the status of the subject’s conception while conduct-
ing the evaluation. Parents were questioned regarding 
socio-demographic characteristics. The BSID consists 
of two major scales. The mental scale measures visual 
and auditory information procession, imitation, memory, 
hand-eye coordination, and problem solving. The motor 
scale appraises control of gross and fine motor skills.
There were no significant group differences regarding 
mental and motor scale scores. Additionally, equal numbers 
of PGT, ICSI, and NC subjects were represented in each 
level (accelerated, normal, delayed) of psychomotor and 
mental development. Interestingly, when compared across 
all three cohorts, psychomotor and mental development 
scores were very similar for males and females. However, 
when compared within each cohort, ICSI boys obtained 
lower scores on both scales than the ICSI girls (P = 0.061). 
The mode of delivery had no impact on psychomotor or 
mental development even after controlling for sociodemo-
graphic factors. (Nekkebroeck, et. al. 2008b).
 From the results of these two studies, it can be con-
cluded that the embryo biopsy done in PGT has no im-
pact on the mental and psychomotor development of 
two-year-old children, compared to ICSI and NC children
Parent-Child Relationship
The study by Banerjee et. al. (2008), used the Parental 
Stress Index and the Parental Acceptance-Rejection 
Questionnaire to assess differences in the parent-child 
relationship. The Parental Stress Index, which asked par-
ents about parental distress, parent–child dysfunctional 
interaction, and the difficulty of the child, showed no 
significant difference between the PGT and NC groups. 
In the Parental Acceptance-Rejection Questionnaire, 
the PGT group had significantly higher scores on the 
warmth-affection subscale, and significantly lower scores 
on the aggression-hostility and rejection subscales than 
the NC group. 
In another study parental stress and health status were 
measured with the Parent Stress Index and the General 
Health Questionnaire (GHQ). No differences in parental 
stress were found for mothers and fathers among the 
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three groups. However, after controlling for socio-demo-
graphic variables, the ICSI mothers and fathers reported 
less stress from parenting (P = 0.048). These results are 
similar to findings in other studies and may be because 
greater efforts are made by ICSI parents to have a child 
compared to parents who conceive naturally.  Another 
theory is that ICSI parents may be inclined to underre-
port behavioral issues because of their need to demon-
strate their abilities as parents and move on from the 
issue of infertility where they struggled. On the other 
hand, there was an equal proportion from all three co-
horts that experienced low, moderate or high levels of 
parenting stress. Scores on the GHQ measuring parental 
health were not significantly different, even after con-
trolling for socio-demographic factors. Parents from all 
three conception groups obtained similar scores on the 
subscales: somatic symptoms, anxiety, social dysfunction 
and severe depression. The results from these studies 
imply that parents seem to cope with the extra stress 
of PGT without it affecting the parent-child relationship 
(Nekkebroeck, et. al.  2008a). 
Conclusion
Overall, it does not seem that preimplantation genetic 
testing causes adverse clinical outcomes. This is especial-
ly important since the majority of couples who undergo 
PGT usually do not have fertility issues and have the op-
tion of natural conception with invasive prenatal testing. 
The results of these research studies show no significant 
increased risk of perinatal death or malformations, espe-
cially when compared to IVF/ ICSI births, indicating that 
the embryo is able to recover from the cells removed 
during the biopsy and it therefore adds no additional risk. 
Furthermore, children conceived through PGT seem to 
be on the same developmental level as their peers and 
show no growth retardation in follow up studies. While 
some studies show an increased risk of preterm delivery, 
low birth weight and some obstetric outcomes, it is im-
portant to determine whether this is because of the em-
bryo biopsy or because of the underlying health condition 
of the parents such as the fertility issues or the genetic 
disease for which they chose to undergo PGT in the first 
place. However, since this technology is fairly new, there 
are few follow up studies that investigate the long-term 
effects of PGT. Additional follow up studies are necessary 
to ensure the long-term safety of this technology. Future 
studies can also investigate the specific outcomes for 
each method of PGT, since most of the research is either 
regarding a blastomere biopsy or combines all methods 
of PGT in the PGT cohort. Furthermore, future studies 
should focus on determining the outcome differences 
between PGT-M, PGT-A and PGT-SR since parents who 
undergo the different forms of PGT have different med-
ical backgrounds which can affect the results of these 
studies. Couples considering PGT should consult their 
physician or a genetic counselor to determine whether 
PGT is the correct option as well as which method of 
PGT should be used.
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Bilateral, profound-severe, congenital deafness causes widespread structural and functional changes of the auditory system . In 
humans, the consequences of these changes are extensive and often include detriments to language acquisition and auditory 
perception. Fortunately, early intervention methods, such as cochlear implantation, can significantly mitigate inevitable auditory 
deficiencies. This review begins by briefly addressing early stages of brain development and associated anatomical discrepancies 
observed in congenitally deaf subjects . Considering the deleterious effects of congenital deafness, neuroplasticity, the ability of the 
brain to rewire itself, is of paramount importance in reversing the auditory impairments . Hence, its incorporation into the methods 
required for successful auditory rehabilitation . Despite this phenomena, assistive devices such as the cochlear implant have shown 
a marked decrease in efficacy after a critical period has elapsed. Although the scientific community has made incredible gains in 
the understanding of neurogenesis and congenital deafness, additional research is required to concretize age-related limitations 
inherent in neural plasticity and provide further advances in congenital deafness intervention methods .
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Introduction
Hearing loss is the third most common health problem 
in the United States. It is estimated that thirty million 
Americans struggle to hear. The disability is not only prev-
alent in America; it is estimated to affect 8.8 percent to 
12.5 percent of the worldwide population (Burkey, 2015). 
The most common cause of this disability which affects 
approximately 2 out of every 1,000 children is sensorineu-
ral hearing loss (Sharma, Campbell, 2011). Sensorineural 
hearing loss is often caused by damage to the inner ear 
or as a result of non-functioning or missing sensory hair 
cells that normally operate within the cochlea. Without 
these cells, an individual is unable to detect and transmit 
auditory sound wave stimuli through the auditory nerve 
to the brain. As cortical development is contingent upon 
stimulus-driven learning, individuals born with sensori-
neural hearing loss are at risk for abnormal neurological 
development and brain connectivity needed for optimal 
auditory sensory function. In 1978, Dr. Graeme Clark 
introduced a revolutionary multi-channel cochlear im-
plant that has developed into an incredibly effective and 
transformational neural prosthesis that allows severe and 
profoundly deaf individuals to achieve similar function to 
their unaffected peers. This device converts sound waves 
into patterns of electrical impulses that bypass the outer 
and middle ear, thereby directly stimulating Cranial Nerve 
VII fibers. The cranial nerve then carries the impulses to 
the brain, which converts and interprets these impulses 
as sound. Although different from typical acoustic stimula-
tion, this electrical stimulation is able to mimic the coding 
of the cochlea and enable recipients to process speech 
and environmental stimuli (Hartmann, Kral, 2000). 
As technology and implantation techniques improved 
in the 1990’s, cochlear implant surgery gained FDA ap-
proval for use in younger subjects. As of 2010, approx-
imately 80,000 of the 300,000 cochlear implant users 
worldwide were either infants or young children (Kral, 
O’Donoghue, 2010). Research studies quickly established 
that “when these children receive a cochlear implant at a 
relatively young age (for example, at 18 months) followed 
by intensive therapy, they tend to hear and speak better 
than those who received implants at an older age (fda.gov, 
2017).” The success associated with such early cochlear 
implant intervention is often assumed to be related to 
a brain characteristic known as neuroplasticity. This fas-
cinating neural capability allows neurons in the brain to 
compensate for injury or disease by restructuring and 
reorganizing neural pathways that affect function. It is 
the aim of the following analysis to explore the nature 
of age-related changes in neuroplasticity as they might 
specifically relate to the efficacy of cochlear implantation 
in subjects at various stages of development. 
Methods
Critical analysis of the literature on age-related neuro-
plasticity in relation to cochlear implantation was con-
ducted and compiled via access to the Touro College 
Library’s online database, using PubMed and ProQuest 
search engines. In addition, Google Scholar was utilized in 
obtaining related research.
Discussion 
Early Stages of Brain Development
Brain development begins around the eighteenth day 
after conception and continues into early adulthood. 
Approximately 2 weeks after conception, part of the ec-
toderm of the back of the embryo thickens and forms a 
neural plate. As the edges of this neural plate curl toward 
each other, eventual fusion occurs thereby forming the 
neural tube. The inner cells of this formation will com-
prise the central nervous system whereas the outer cells 
break away to create the autonomic nervous system. As 
the tube closes and matures, different areas become dis-
tinctive brain structures. In particular, the rostral end of 
the neural tube develops three interconnected chambers 
which become the three major parts of the brain: the 
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forebrain, midbrain, and the hindbrain (Carlson, Birkett, 
2017). Any remaining cells will develop into the spinal 
cord. As the tube undergoes its metamorphosis, progen-
itor cells, descendants of stem cells, lead to the brain’s 
multifaceted and sophisticated cellular network. Given the 
cerebral cortex’s inside-out developmental pathway, the 
most recently formed neurons are more proximal to the 
cortical surface. The six layers of the cortex are formed 
by approximately 25 weeks after conception. The end of 
cortical development is observed when the progenitor 
cells receive a chemical signal which induces apoptosis. 
Once neurons have migrated to their proper locations, 
synaptogenesis occurs. The first synapses are usually de-
tected around the 23rd week of gestation (Molliver et. al., 
1973). Typically, synaptogenesis is followed by a gradual 
reduction of neurons known as pruning due to neural 
overabundance in the ventricular zones. Although this 
process occurs throughout an individual’s lifespan, an ini-
tial explosion of synapse formations occurs during early 
brain development. Synaptic reduction is then significantly 
dependent on environmental exposure. Regions that are 
stimulated by these factors are strengthened and stabi-
lized, whereas reduction occurs in synapses that are not 
sufficiently stimulated (Tierney, Nelson, 2009). 
During the prenatal and early childhood years, the basic 
structure and functional capacity of the brain are formu-
lated with refinement of neural networks persisting over 
time. Research suggests that brain development is hierar-
chical in nature. Higher level processes build on lower level 
processes. For example, language development depends on 
sensory and perceptual development. Infants are born with 
a brain wired for various types of experiences and abilities 
such as speech, language, and facial recognition. Newborns 
are initially programmed to perceive all languages, but with 
environmental experience, become focused and cognizant 
of their native language and lose the ability to perceive 
language that they are not exposed to. In this way, expo-
sure drives subsequent learning (Kuhl, 2004). Research in 
2004 supports the concept that healthy brain development 
requires adequate environmental exposure and that lack 
of these experiences could lead to underspecification and 
miswiring of brain circuits. This study found that children 
raised in Romanian institutions with a lack of stimulating 
experiences demonstrated underdeveloped brain and 
cognitive growth.  Further research (Marshall et al., 2008) 
noted a critical time frame, suggesting that after age two the 
effects of decreased exposure on brain function worsen. 
In early development, external stimulation is an import-
ant means through which significant neural connections 
and networks are created to facilitate behavioral growth 
and development. An absence of any one of the body’s 
senses can have major implications on brain development. 
Animal studies have found that early deafness greatly af-
fects auditory cortical development. Baker et al. (2010) 
performed a research study utilizing deaf cats to determine 
hearing loss related auditory brain stem pathology. Altricial 
animals, cats are born with closed ear canals that only open 
approximately 30 days after birth. The process of ear canal 
opening is the same in deaf and hearing cats; therefore, re-
searchers hypothesized that abnormalities in the deaf cats 
would coincide with the development of hearing in typi-
cal-hearing cats. This would support the notion that lack 
of sound stimuli leads to pathological changes. Through the 
use of intracellular dyes, the Endbulb of Held in deaf white 
cats were examined.  Large and complex synaptic endings, 
the Endbulbs of Held provide a coordinated release of 
neurotransmitters from presynaptic terminals onto the 
soma of bushy cells in the anteroventral cochlear nucle-
us (postsynaptic cell). They are considered to be centrally 
involved in the precise transmission of timing information 
from auditory stimuli. It was discovered at birth that the 
cochlea of the congenitally deaf white cats was void of 
abnormal morphology. The presence of a collapsed scala 
media and a degraded organ of corti appeared one week 
after birth. As time progressed, the deaf cats’ endbulbs 
exhibited flattened and elongated postsynaptic densities 
(PSDs) and increased synaptic vesicle density. Cochlear 
abnormalities in cell synapses and circuitry as a byproduct 
of sound deprivation were exhibited. Human studies have 
subsequently arrived at similar findings. Using cortical audi-
tory evoked potentials (CAEPs) with non-invasive EEGs on 
deaf children, these studies have found delayed or absent 
auditory responses supporting the theory that brain mat-
uration is dependent on appropriate and adequate stimu-
lation (Eggermont et al., 1997; Eggermont & Ponton, 2003).
Neuroplasticity and Developmental Periods
In addition to genetics, environmental factors also play an 
important role during the critical period of brain develop-
ment. While genetics ostensibly play a larger and more sig-
nificant role in prenatal development, environmental expo-
sure is a key contributor to postnatal progression. Neural 
plasticity is the central nervous system’s ability to attempt 
to support optimal performance by recovering functional 
abilities and enabling the body to adapt and learn in changing 
anatomical conditions. The nervous system’s ability to re-
organize its structure, connections, and functional abilities 
in response to intrinsic and extrinsic stimuli is complex. It 
can occur on a variety of levels from molecular to cellular 
during regular development and learning, or in response to 
disease or injury (Cramer et al., 2011).  Plasticity of a brain 
region is affected by the area’s peak synapse production. 
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This occurs at different times for various structures of 
the brain. For example, peak synaptogenesis for the visual 
and auditory cortices occurs between 4 and 12 months, 
whereas the prefrontal cortex that controls reasoning and 
planning increases more slowly and peaks at one year of 
age. The later the peak synapse production, the longer the 
area’s plasticity (Goswami, 2004). 
Neuroplasticity is an area of continuous research and 
hope in many clinical contexts. It is, for instance, widely 
researched in relation to stroke, trauma, and spinal cord 
injury.  Associated studies have highlighted the brain’s 
incredible ability to form representational maps with 
spontaneous intra-hemispheric and inter-hemispheric 
changes. For instance, when brain lesions of the left hemi-
sphere damage important language centers, other areas 
in that hemisphere may be recruited for language function 
(Karbe et al., 1998b; Karbe et al., 1998a; Warburton et al., 
1999). Moreover, in situations where severe impairment 
exists in the left hemisphere region, the right hemisphere 
appears to be capable of assuming some language func-
tions (Warburton et al., 1999; Cramer et al., 2011). 
The central nervous system’s ability to adapt to pathol-
ogy is affected by several parameters. One of the primary 
contributing factors is the age of onset, including critical 
developmental periods (Staudt, 2010). The greatest forms 
of neuroplasticity are available during early development. 
This is thought to relate to the overabundance of neu-
ronal cells and synaptic connections present during early 
childhood which decrease through the pruning process 
with environmental exposure and aging. Additionally, other 
developmental events like inhibition and myelination can 
affect the developmental critical period. In the case of 
early neurological injury, research has found significant 
cross modal plasticity - the ability to reorganize and form 
new sensory maps and pathways. For example, successful 
changes in function from across brain hemispheres have 
led to highly successful behavioral advances for children 
(Cramer et al., 2011). Staudt’s (2002) research supports 
this phenomenon showing that unlike adults, children 
demonstrate moderate to good right hemisphere control 
of language and movement following a significant injury to 
their dominant left hemisphere.  
Data Defining Critical Periods for  
Cochlear Implantation
Adaptive plasticity and its relationship to age-dependent 
recovery of language is an active area of study.  Research 
on children with a hemispherectomy showed a remark-
able shift in motor and language function to the remaining 
hemisphere. Children under six years of age had the most 
significant level of reorganization (Chen et al., 2002b). 
Similar findings have been seen with congenitally deaf 
children. Cortical Auditory Evoked Potential (CAEP) test-
ing - the time it takes for the brain to respond to auditory 
stimulation - was found to increase with age as a result 
of maturation and refinement of the central auditory 
pathways. These markers were tested in a variety of deaf 
children who received cochlear implants at different ages. 
In a study with a subject body of 245 congenitally deaf 
children with cochlear implants, researchers found that 
children implanted prior to 3.5 years of age had normal 
response times within 6 months of implant use. However, 
children whose initial stimulation occurred after age 7 
demonstrated abnormal response times even after years 
of implant usage. Children who received cochlear implants 
between 3.5 and 7 years of age had variable responses 
(Sharma et al., 2002; Sharma & Campbell, 2011). These re-
sults have been supported by other studies utilizing PET 
scan brain imaging and behavioral measures. In addition, 
speech and language studies have demonstrated that chil-
dren implanted under 3-4 years of age display significantly 
better speech and language skills as opposed to those 
children implanted at 6-7 years of age and older (Geers, 
2006; Kirk et al., 2002). These results influenced the FDA 
to lower their age for approval of cochlear implantation 
for children to approximately 12 months. 
Research reports that auditory cortex synaptogenesis 
begins in the first two months after birth with maximum 
density between 4 and 12 months followed by pruning 
(Goswami, 2004). This early synaptogenesis supports the 
need for early implantation and stimulation of the audi-
tory nerve to allow maximal usage of the brain’s regional 
plasticity and ability to learn to process auditory stimuli. 
Research has reinforced this theory. Electrical stimulation 
had a restorative effect on the Endbulb of Held synapse, 
and early electrical stimulation with a cochlear implant 
had significant positive results in congenitally deaf cats 
(Baker et al., 2010; Ryugo, 2015). Ryugo et al. (2005) re-
ported decreased synaptic vesicle density and PSDs fol-
lowing cochlear implantation of congenitally deaf cats sta-
tistically similar to those of normal hearing cats. Auditory 
nerve activation at 3 months of age restored many key 
features of synaptic morphology, whereas less significant 
effects were seen at 6 months and on (Ryugo, 2015). With 
regard to humans, studies illustrate that those children 
who became deaf before the developmental onset of 
language and received early cochlear implant technology 
were successful in their acquisition of spoken language. 
However, those with late implantation displayed less ben-
efit and ability to discriminate complex everyday sounds 
and speech (Svirsky, et al. 2004; McConkey, et al., 2004; 
Tong et al., 1988).
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Cochlear Implant Considerations After  
Critical Periods
Early implantation, within the sensitive and critical pe-
riod, is integral for speech and language development 
and necessary to avoid potentially deleterious re-orga-
nization of the cortex. Kral, 2007 found that in animal 
studies, the primary auditory cortex was partially or 
completely disconnected from the surrounding higher 
order cortex at the end of the sensitive period. This 
leaves the higher order auditory cortex at risk for 
recruitment from other sensory modalities. This has 
been seen in deaf adults where their visual process-
ing may begin to take place in their auditory cortical 
areas. Although cross modal reorganization may allow 
for some enhanced processing, it could also result in 
significant deficits. For example, while deaf adults may 
have enhanced peripheral vision, they may suffer from 
severely impaired auditory processing and auditory-vi-
sual integration (Sharma & Campbell, 2011). Numerous 
studies have consistent data demonstrating notable 
improvement in speech perceptual skills in adolescents 
who received cochlear implants. However, adolescents 
with earlier implantation and shorter lengths of deaf-
ness exhibited significantly greater results in word and 
sentence testing. Children who were implanted after age 
7 were found to demonstrate abnormal brain responses 
to auditory input and poorer language skills. Some relate 
these results to cortical plasticity where colonization of 
the auditory cortex occurs from other sensory modal-
ities during critical periods of central nervous system 
development (Sharma et al., 2009; Zeitler et al., 2012). 
In post-lingual adults, studies relate that the duration of 
auditory deprivation has a negative impact on audito-
ry performance with a cochlear implant, either due to 
cross modal plasticity or due to the limited capability of 
the superior temporal cortex (Anderson et al., 2017)
Cochlear Implant Benefits Before and After 
Critical Periods
Results from human studies report that uncorrected deaf-
ness results in fundamental change in the central auditory 
system so much so that benefit from a cochlear implant 
in later life is hindered. Adult recipients report cochlear 
implant benefits including increased environmental sound 
awareness, better quality of life, and increased psycho-
logical wellbeing. The area most variable is improvements 
in auditory speech perception. Specifically, the trajecto-
ry and rate of auditory performance vary across adult 
individuals (Anderson et al., 2017). Several abnormalities 
that arise in the auditory system include reduced number 
of spiral ganglion neurons, abnormal synaptic structure, 
ectopic projections in ascending pathways, and physiolog-
ical alterations of auditory nerve responses in the cochle-
ar nucleus. These affect synaptic transmission and result 
in decreased responsiveness in the inferior colliculus 
and auditory cortex. These fundamental changes inhibit 
older cochlear implant recipients from gaining true ben-
efit. Although environmental sounds may be processed 
in adult recipients, language recognition is more difficult 
(Ryugo, 2015). Data from the Mayo Clinic’s testing on 
259 adults revealed that adult cochlear implant recipients 
had preoperative scores of 8% on tests of monosyllabic 
words and 7% on sentence recognition. After one year 
of implantation, these scores increased to 58% for word 
recognition and 75% for sentence recognition (Carlson, 
2020). These results support the usefulness of cochlear 
implants in adulthood; however, when compared to the 
percentages and quality outcomes in children with early 
implantation they are markedly low.
Relevant Associated Neural Plasticity Research
For decades, scientists believed that neurogenesis was a 
process that existed in the brains of embryos and infants 
only to cease in adulthood. In the 1980’s, this notion was 
challenged when researchers showed that neurogenesis 
occurs in the brains of certain adult animals. Further trac-
tion against the initial, misguided belief was made when 
signs of newly formed neurons in the adult human brain 
were observed. Alvarez-Buylla and colleagues studied the 
olfactory bulb in rodents and found continuous formation 
of new neurons. However, in humans the formation of 
new olfactory neurons occurs exclusively in infants. This 
dichotomy was also found in the frontal lobe where new 
neurons migrate during early childhood but cease migrat-
ing as age progresses (Pignatelli and Belluzzi, 2010). The 
most thorough study was done by Sorrells and colleagues 
on postmortem and postoperative hippocampal tissue 
from humans. The subjects ranged from fetuses at 14 ges-
tational weeks to 77 years of age. Samples were stained 
with fluorescent marker antibodies to identify progenitor 
cells and young neurons. Definite signs of new neuronal 
formation in the hippocampus of infants and children 
were observed, whereas no such signs were exhibited 
in adult brains. Additionally, young neurons decreased in 
density as age level progressed (Sorrells et al., 2018). 
In humans, it is theorized that neurogenesis occurs 
in the subgranular zone (SGZ) of the dentate gyrus of 
the hippocampus which maintains a neurogenic stem 
cell (NSC) niche. Some propose that the SGZ is an en-
vironment fit for NSC proliferation into granule cells 
from which migration to the granule cell layer occurs. 
Granular cells progress through the developmental 
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stages when specific protein markers are expressed, 
thereby revealing lineage specific cells in the neurogenic 
niche. This occurs before the cells integrate into the hip-
pocampal circuitry and can influence the functions such 
as learning, memory, and spatio-motor performance 
(Kumar et al., 2019). 
There is some research, albeit scarce and preliminary, 
that supports adult neurogenesis. One such study tested 
the brains of 5 cancer patients who had been injected 
with a chemical that incorporates into newly created 
DNA: Bromodeoxyuridine (BrdU). Traces of this chem-
ical were found in the dentate gyrus of the hippocampus, 
thus supporting the theory that cells in this region are 
continuously dividing and creating new neurons (Eriksson 
et al., 1998). Another study also reported evidence of 
neurogenesis after identifying protein markers for various 
stages of neurogenesis in subjects 0 to 100 years of age 
(Knoth et al., 2010). In 2013, using carbon dating methods, 
Jonas Frisén’s lab at the Karolinska Institute reported that 
up to 700 neurons are added each day to the dentate 
gyrus (Kumar et al., 2019). Although these are ground-
breaking findings, many researchers question their validity. 
Asserting the possibility that BrdU can occasionally label 
dying cells instead of cells undergoing division, as well as 
the possibility that protein markers can accidentally label 
brain cells as glia instead of neurons, a body of research-
ers remains hesitant regarding claims of neurogenesis in 
adulthood. Nevertheless, the most robust study support-
ing adult human hippocampal neurogenesis was done by 
Boldrini and colleagues.  Autopsying hippocampi of peo-
ple ages 14 to 79, they found the production of inter-
mediate neural progenitors, immature neurons, mature 
granule neurons, and glia to be similar between all age 
groups. Adhering to biological parameters and utilizing 
unbiased stereology, the researchers ensured that their 
samples were taken from healthy individuals (Boldrini et 
al., 2018). On the other hand, some studies have found re-
sults to be inconclusive. Kumar and colleagues used bio-
informatic methods to study the differential expressions 
of neurogenesis signature markers in the hippocampi of 
prenatal to adult age subjects. Persistent but minimal hip-
pocampal neurogenesis was observed. In addition, they 
initiated the criticism that newborn adult hippocampal 
cells could be glial cells (Kumar et al., 2019). The vast ma-
jority of research points to the stark difference between 
the human brains of infants and adults, with inadequate 
concrete knowledge and inconsistent evidence of adult 
neurogenesis. It is the hope of many scientists that future 
technology with the ability to provide imaging of new 
neuronal formation in the adult human brain will shed 
light on this debate.
Areas of Interest for Future Inquiry
Many factors limit the availability of research and tan-
gible knowledge of adult neurogenesis, including sparse 
availability of ideal human brain tissue and limitations of 
study methods. A clearer understanding of the evidence 
surrounding adult human neurogenesis is crucial, as its 
presence or absence will have significant theoretical and 
practical effects on learning, age-related memory, pathol-
ogy, and injury. Research and innovation are needed to 
produce safe investigatory methods to perform neuro-
genesis related research in living humans. Safe neuroim-
aging approaches to detect growth of newly formed cells 
in neurological niches and their integration into existing 
neural circuitry is needed. Possible stem cell methods of 
generating neural stem cells from the patient’s own cells 
is another area of potential innovation. 
Although the mechanisms of neurogenesis are not fully 
understood, there are a variety of avenues for further re-
search and application. Some researchers have proposed 
a deeper investigation into the role of corticosteroids in 
reducing hippocampal neurogenesis. Others have suggest-
ed avenues related to trophic factors such as the brain 
derived neurotrophic factor, fibroblast growth factor, and 
epidermal growth factor, as well as the neurotransmitter 
serotonin, which have shown enhancement of neurogen-
esis. Additionally, studies have pointed to stress as the 
reason for increasing the production of glucocorticoids 
and decreasing trophic factors, thereby decreasing neu-
rogenesis. On the other hand, environmental enrichment 
increases the secretion of trophic factors which, in turn, 
may facilitate neurogenesis (Kumar et al., 2019). These 
factors, along with further research, could conceivably 
be used as catalysts to promote adult neurogenesis and 
allow for greater recovery of learning and memory in the 
deaf population and beyond. 
Limitations in conventional neuroimaging techniques 
to evaluate cortical plasticity pre- and post-implantation 
have hindered our ability to adequately study the effec-
tiveness of cochlear implantation in the adult population. 
Given the application of powerful magnetic fields in MRI 
scanning, straightforward examination isn’t feasible with 
the ostensible high-risk factor for the magnetic com-
ponent of the cochlear implant. Surgically removing the 
magnet prior to MRI is risky and inconvenient. Removal 
would also impede auditory stimulation through the 
cochlear implant and would consequently distort the 
imaging of auditory cortical function. Unconventional 
neuroimaging techniques such as EEG and MEG are safe 
for cochlear implant users; however, they are unable to 
provide data about cortical processing of speech at the 
level of word identification and sentence comprehension. 
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In contrast, PET can be used to measure neural activity 
based on changes in cerebral blood flow and metabolism. 
Independent of electrical or magnetic cortical signaling, 
PET imaging allows for artefact free functional imaging 
in cochlear implant users. However, due to the use of a 
radioactive medium, testing repetition is limited and im-
pedes on the adequate assessment of cortical changes 
that occur rapidly over a short period of time. The use of 
functional near infrared spectroscopy (fNIRS), a non-in-
vasive optical imaging technique, is a possible area that, 
with further modifications, can be a promising means 
of data collection from cochlear implant recipients. This 
technique does not provide a direct measure of neuronal 
activation. Instead, it measures the consequential hemo-
dynamic response seen in stimulus evoked changes in 
levels of oxygenated haemoglobin (HbO) and deoxygen-
ated haemoglobin (HbR). Through the application of op-
todes, an optical sensor device with fiber-optic bundles, 
on the subject’s scalp, the changes in HbO and HbR can 
be monitored and evaluated using a stimulus presenta-
tion paradigm. Although some limitations currently exist 
and further research is needed, multiple benefits of this 
technique include non-invasive and portable testing na-
ture, high level of resilience to patient’s head and body 
movement, and safe and flexible testing across a diverse 
population. Testing utilizing this technique has displayed 
an ability to measure cross-modal responses within the 
temporal lobes in cochlear implant recipients (Anderson 
et al., 2017).
Another area for further research is the therapeutic 
technique of speechreading prior to implantation. It is 
thought that speechreading in post-lingual deafness has 
the ability to maintain amodal linguistic functions and left 
hemisphere specialization for speech processing. Vision 
may facilitate the restoration of auditory function with 
modifications to the auditory cortex. This audio-visu-
al synergy may enable adult cochlear implant users to 
capitalize on heightened levels of visual cortex activity 
to compensate for decreased auditory input from the 
implant. Consequently, sustainable close cooperation be-
tween the auditory and visual modality that post lingual 
deaf individuals can capitalize on during auditory reha-
bilitation is attainable. Evidence suggests that a synergy 
between modalities within the left temporal lobe may be 
a significant neural correlate in cochlear implant success 
(Anderson et al., 2017). 
While cochlear implantation has opened a whole new 
world of hearing opportunities to the deaf population, the 
success rate is highly variable and still remains somewhat 
unpredictable. Although some basic markers for success 
are noted and understood, more sensitive prognostic 
tools are needed to accurately predict clinical outcomes. 
Growing research supports factors such as cortical plas-
ticity within the temporal and temporo-occipital brain 
regions and synergistic relations between the auditory 
and visual modality and temporo-occipital interaction. 
Investigation on safe, sensitive, and thorough techniques 
to study brain changes pre- and post-implantation is an 
area of research that continues to expand. 
Conclusion
Bypassing damaged peripheral structures, the multi-chan-
nel cochlear implant has provided profound to severe 
hearing-impaired individuals the ability to achieve similar 
auditory function to their unaffected peers. As anatomical 
and functional auditory integrity is of paramount impor-
tance, early cochlear implantation is a crucial determinant 
in the probability of a congenitally deaf individual attaining 
maximum auditory capacity. As supported by extensive 
data, implantation prior to the completion of the critical 
period plays an outsized role in neuroplasticity’s ability to 
rewire one’s neural circuitry while consequently prevent-
ing further recruitment of auditory cortical structures 
by other sensory modalities. As human sensory hair cells 
are incapable of regeneration, further research is needed 
to pursue avenues yet explored in the quest to further 
mitigate the deleterious side effects of congenital, early 
and late onset deafness.
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In the developed world, the trend toward women of advanced age bearing children is very prevalent and seems likely to continue . 
For a variety of reasons, women are delaying pregnancy until 35 years and older when they suddenly seem keenly aware that their 
biological clocks are ticking . A review of various studies obtained from the Proquest and EBSCO databases indicates that there are 
definitely certain risks associated with advanced maternal age (AMA). As females age, the reduced number and quality of their re-
maining eggs contribute to reduced fertility . Congenital anomalies involving the number of chromosomes in the embryo increases as 
well . The risk of miscarriage gradually climbs with the mother’s age and stillbirth is more likely than in younger women . The health of 
the older women prior to pregnancy is often compromised and birth-related complications are more common . Studies of mice have 
shown that maternal age influences the structure and functionality of the uterus. It has been suggested that delayed childbearing 
has an effect on the gene frequency in the general population since the zygotes best able to adapt to the Advanced Maternal Age 
(AMA) uterine environment were favored (Gloria-Bottini et al ., 2005) . Although women who postpone parenthood should take the 
increased risks into account, findings suggest that maternal age, per se, should not be a deterring factor when considering bearing 
a child . Individual health circumstances and behavioral choices are more important than age . With proper prenatal counselling and 
care, AMA women can hope to have normal pregnancies and deliver healthy babies . 
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Introduction
Advanced maternal age is defined as pregnancy in women 
equal to or greater than thirty-five years of age. It is be-
coming a growing trend, especially in high-income coun-
tries, to delay childbearing. Pregnancy in AMA mothers 
constitute 20% of pregnancies in the UK and 16% of 
pregnancies in the US as of 2014. Many women marry 
later, spend a decade or more building up their careers, 
pursue higher education, or enjoy the single life before 
deciding to have a family. Others may find themselves hav-
ing their first child in their thirties because of previous 
fertility complications. Although better socio-economic 
conditions and developments in assisted reproductive 
technology are allowing women to have babies later in 
life, this new trend can possibly present clinical risks both 
to the mother and baby (Lean et al., 2017a).
Prenatal concerns for AMA mothers include fetal 
loss, chromosome anomalies such as Down’s Syndrome, 
multiple births, hypertension, and gestational diabetes. 
Complications in labor and delivery might include placen-
ta previa (when the placenta covers the opening in the 
cervix), caesarean birth, preterm birth, placental abrup-
tion (when the placenta detaches from the womb), low 
birth weight, trisomies, and other non-disjunction prob-
lems. Abnormal functioning of the placenta, due to aging, 
can result in fetal growth restriction and even stillbirths 
(Radhakrishnan, 2016).
It is important to point out that women who are preg-
nant and are older than 35 have some distinct advantag-
es. They are more likely to follow the regimen outlined 
for them by their obstetrician, such as taking a folic acid 
supplement before conception and throughout their first 
trimester which helps decrease the risk of neural tube 
defects. These mothers are more likely to be diligent 
about keeping prenatal appointments. They are usually 
more established in their personal and professional lives 
and are more mature and knowledgeable, with a higher 
degree of personal control and coping strategies. Their 
higher income tends to contribute to more positive re-
sults in terms of their health. Lastly, AMA mothers tend 
to breastfeed more than younger mothers. Breastfeeding 
is considered the most optimal way to feed the infant. 
Its benefits include protecting the baby with passive im-
munity to infections of the respiratory and gastrointes-
tinal tracts. Breastfeeding has maternal benefits as well; 
it reduces postpartum bleeding, returns the mother to 
pre-pregnancy weight faster, and decreases the risk of 
breast and ovarian cancers (Radhakrishnan, 2016).
Notwithstanding all of the above advantages, the ideal 
time for a woman to give birth remains up until the age of 
35, during which time fertility is at its peak. Women who 
are older have a harder time conceiving. They usually also 
have longer work hours and stressful work environments 
and tend to drink more alcohol, putting the fetus at risk 
of Fetal Alcohol Spectrum Disorder, which can cause 
birth defects and neuro-developmental disorders. They 
have also been exposed to environmental toxins for a 
longer time. Most importantly though, their increased age 
makes medical conditions such as cancer, diabetes, hyper-
tension, and arthritis more likely. These conditions, as well 
as their associated treatments and medications, can harm 
the fetus (Radhakrishnan, 2016). 
Many studies have been done in various developed 
countries, investigating the impact AMA has on perinatal 
and neonatal outcomes in these women. These studies 
are important for both the mothers and the healthcare 
providers. The effects of AMA on maternal and fetal mor-
bidity and mortality is of great concern.
Methods
The research was obtained from the online Touro College 
Library. Articles were collected from the Proquest and 
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EBSCO databases. The studies presented a comprehen-
sive analysis of the topic and allowed for a conclusion to 
be reached regarding the research question.
Discussion
A systematic review and meta-analysis were done to de-
termine the risk of stillbirth and other negative pregnan-
cy outcomes in AMA women. It was the largest and most 
comprehensive review investigating pregnancy outcomes 
of AMA mothers and the only one specifically focusing 
on the increased risk of stillbirth. The studies in the re-
view were significant considering that in 2013 the rate of 
births in England and Wales to women of 35 years and 
above was 20% as compared to a rate of 6% in 1980 
(Lean et al., 2017a).
In the review, 63 cohort studies and 12 case control 
studies were included. The studies incorporated control 
groups of mothers younger than 35 years of age and AMA 
groups greater than or equal to 35 years. Primary out-
comes studied were stillbirth and fetal growth restric-
tion. Secondary outcomes were neonatal death, small 
for gestational age, neonatal intensive care unit (NICU) 
admissions, preeclampsia (blood pressure > 140/90 with 
significant amount of protein in the urine), placental 
abruption, preterm birth, and gestational diabetes melli-
tus. Studies that involved pregnancies of multiple fetuses 
or those that focused on chromosomal abnormalities or 
substance abuse were eliminated. Correlations between 
stillbirth rates and maternal obesity, diabetes, hyperten-
sion, and assisted reproductive therapies were recorded 
(Lean et al., 2017a).
AMA was found to increase the rate of stillbirth in the 
population to 4.7%. In addition, AMA increased the risk 
of fetal growth restriction, neonatal death, NICU admis-
sion and gestational diabetes mellitus. The relationship 
between AMA and stillbirth was not found to be asso-
ciated with maternal morbidities, with the exception of 
hypertension which was positively correlated with AMA 
in women between the ages of 35 and 40. The use of 
assisted reproductive therapy (ART) showed no relation-
ship to stillbirths in women equal to or under 35 years 
of age and was negatively correlated to stillbirth rates in 
women over 40. AMA only significantly increased the risk 
of fetal growth restriction in women over 40. The major-
ity of secondary outcomes were more prevalent in AMA 
women but only NICU admissions and neonatal deaths 
had a substantial correlation to the increasing age of the 
mother (Lean et al., 2017a).
Stillbirths in advanced countries are presently thought 
to be related to placental dysfunctions. Accelerated aging 
of the placenta, altered vascular function and altered 
transport of nutrients compared to a control group have 
all been detected. Another theory for the cause of still-
births is the diminished genetic quality of the aging oo-
cyte (Lean et al., 2017a).
Another consideration that may contribute to fetal 
health with an AMA pregnancy is advanced paternal age. 
Research in this area is sparse. One study found a 24% in-
crease in stillbirth rate with paternal age between 40-45 
years old and a 50% increase with paternal age over 45, 
independent of maternal age. More studies are needed 
where paternal age is a co-variate to determine how it 
contributes to increased risk of stillbirth in AMA mothers 
(Lean et al., 2017a).
Future studies should be done to understand the mech-
anisms contributing to the increased risk of stillbirth in 
AMA, specifically in mothers over the age of 40, so that 
proper intervention can be applied to improve positive 
outcomes to those at greatest risk (Lean et al., 2017a).
The increased risks of fetal growth restriction and 
stillbirths in AMA mothers have been found to be inde-
pendent of co-morbidities. These risks also do not seem 
to correlate with factors such as socio-economic status, 
nutritional supplementation prior to conception, good 
prenatal care, and the mothers being non-smokers. A hy-
pothesis was offered that maternal aging was associated 
with utero-placental dysfunction which contributed to 
negative fetal outcomes (Lean et al., 2017b).  
Dysfunction of the placenta is a major cause of fetal 
growth restriction and placental causes are noted in up 
to 65% of stillbirths. In both conditions, major changes 
in placental morphology were found, including lower 
placental weight, irregular shape to the placenta, and 
irregular insertion of the umbilical cord. Placentas from 
fetal growth restriction pregnancies had less vascular 
branching and fewer capillaries. These structural abnor-
malities were found even more in stillbirths related to 
fetal growth restriction (Lean et al., 2017b).  
Abnormal function of the placenta was also apparent 
in fetal growth restriction and stillbirths. Among these 
were reduced amino acid transport in the placenta and 
impaired endocrine function (Lean et al., 2017b).  
A study was done to test the hypothesis that AMA is 
associated with dysfunctions of the uterus and placenta. 
Women of AMA were studied along with young controls 
(20-30 years) with normal pregnancies.  Investigations 
into these pregnancies identified multiple placental and 
utero-placental dysfunctions, potentially linking those 
mechanisms and increased fetal growth restriction and 
stillbirths in AMA women (Lean et al., 2017b).  
The studies revealed increased placental weight but re-
duced placental efficiency in pregnancies of AMA women 
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with changes in placental morphology and function simi-
lar to the phenotype of placentas in fetal growth restric-
tion and stillborn pregnancies. This phenotype was seen 
even in normal pregnancy outcomes which indicate both 
the negative effects of aging on the placenta and potential 
adaptation to achieve a normal birthweight. The abnormal 
placental phenotype was more evident in women >40 
years of age who have a higher risk of adverse pregnancy 
outcomes (Lean et al., 2017b).  
AMA mice displayed an even more exaggerated abnor-
mality in placental phenotype than humans, with reduced 
number of offspring, late fetal deaths, and over half of off-
spring in the category of fetal growth restriction. Many 
similarities were found in the placental phenotype in the 
mice and human pregnancy models, including increased 
placental weight, decreased placental efficiency, and al-
tered vascular function (Lean et al., 2017b).  
All of these support the hypothesis that maternal aging 
is associated with placental dysfunction, which may result 
in higher rates of fetal growth restriction and stillbirths 
in AMA pregnancies. Abnormal cell turnover, abnormal 
nutrient transport, and increased relaxation of placen-
tal arteries all helped contribute to the less than ideal 
functioning of the placenta in AMA mothers (Lean et al., 
2017b).  
Another study was done to determine whether ad-
vanced maternal age in mice has a bearing on their 
pregnancy outcomes. The purpose of this study was to 
evaluate whether negative reproductive outcomes in 
aged female mice are a result of a dysregulation of meth-
ylation, and thus expression, of imprinted genes in their 
reproductive tissues. Tissues from the fetus, placenta, and 
ovaries were collected from young pregnant mice (4-5 
weeks old) and aged mice (15 months old) and compared 
to matured oocyte and uterine tissue from non-pregnant 
ones (Paczkowski et al., 2015).  
Results showed fetal growth restriction and over-
growth of the placenta in the older pregnant mice. 
Placental tissue showed aberration in methylation and 
transcript abundance of imprinted genes. Methylation and 
gene expression were severely dysregulated in the ova-
ries and in the uterus, including nutrient transport genes. 
There was also increased transcript abundance in oo-
cytes obtained from older females, compared to younger 
ones (Paczkowski et al., 2015). 
Major alterations in methylation and gene expression 
in the older ovary suggests that the environment in the 
follicle may not be optimal. This affects oocyte growth 
and quality, leading to compromised embryonic and fetal 
development. Aberrant methylation and expression of im-
printed genes in the uterus obtained from aged mice may 
cause reduced implantation. Even though AMA mothers 
have an equal chance of becoming pregnant after ART 
cycles when using donor eggs, this study shows that the 
environment in the uterus may be compromised. If using 
their own eggs, the environment of the follicles may be 
compromised, indirectly effecting the development of the 
oocyte (Paczkowski et al., 2015). 
Overall, AMA in mice changes methylation patterns of 
imprinted genes in reproductive tissue, which results in 
dysregulated gene expression associated with poor re-
productive outcomes. This study is significant in that it 
suggests a possibility that the same factors in aged human 
females might cause negative outcomes in their pregnan-
cies as well (Paczkowski et al., 2015).  
A study was done where associations of maternal age 
at childbearing with gestational age (number of weeks 
fetus was in the womb) and fetal growth (birthweight 
adjusted for gestational age) were examined. Those fea-
tures are important to study because these problems 
predict mortality and morbidity across the lifespan of 
the human, including psychological, health, academic, so-
cial, and economic difficulties. Preterm birth is associated 
with decreased cognitive functioning in childhood and the 
use of psychiatric medications in adults. Poor fetal growth 
has been found to be linked to psychiatric diagnoses in 
childhood (autism and ADHD) and adult health problems 
(cardiovascular disease and diabetes). Given these major 
health concerns, it is imperative to obtain a better under-
standing of the possible causes of these adverse perinatal 
outcomes (Sujan et al., 2016).
The study was designed in such a way as to rule out 
genetic and environmental factors that might contribute 
to the results. To assess potential familial confounding, 
two genetically informed designs were used comparing 
cousins and siblings. To be able to generalize results, data 
was taken from two samples with different cultures, races, 
ethnicities, economic backgrounds, and healthcare cov-
erage. Some covariates were offspring birth order, and 
parental characteristics such as levels of education, his-
tory of severe psychiatric problems, history of substance 
abuse, household income, maternal race, and maternal 
age at first childbirth (Sujan et al., 2016).
There was strong evidence that AMA at childbirth was 
associated with a shorter gestational age. The gestational 
age of offspring born to 30-34 year old mothers, 35-39 
year old mothers, and mothers of 40 years and above, 
were all less than the gestational age of offspring born to 
25-29 year old mothers. Even after accounting for shared 
familial factors, the data pointed to a strong link between 
mothers who are older at childbirth with shorter gesta-
tional age. This did not hold true for lower fetal growth. 
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Results from the study supported a causal association 
between AMA at childbearing and shorter gestational age 
(Sujan et al., 2016).
Further research is needed to explore specific factors 
that might account for the findings. Some possibilities 
might be maternal diseases, such as hypertension, diabe-
tes, and the quantity of oxygen and nutrients received 
during the prenatal period (Sujan et al., 2016). 
Another study tested the hypothesis that reduced fetal 
weight and lower success of pregnancy outcomes in AMA 
rats may be attributed to sex-specific changes in the mor-
phological development of the placenta and in its nutrient 
transport function. It was found that the sex of the fetus 
did indeed influence the placenta and offspring outcome 
in response to the adverse environment in the uterus 
during gestation (Napso et al., 2019).
Young (3-4 months old) and aged (9.5-10 months old) 
Sprague Dawley female rats were mated with young male 
Sprague Dawley rats (3-5 months old) and were evalu-
ated on gestational day 20. The study demonstrated that 
advanced maternal age caused modifications in the phe-
notype of the placenta and in this way, altered its ability 
to support the growth of a fetus. In particular, it modified 
the expression of genes and proteins that are crucially 
important in placental growth, transfer of nutrients, en-
docrine control of maternal physiology, and control of 
exposure of the fetus to glucocorticoids. AMA causes ox-
idative stress and cell death in the placenta, in a manner 
that is partially dependent on the sex of the fetus. The 
study also indicated that gene expression changes in the 
placenta of female fetuses were mostly beneficial, with 
an up-regulation of genes that support the function of 
the placenta. Gene expression changes in the placenta of 
male fetuses, though, were mostly detrimental for placen-
tal growth and functional phenotype in older rats. There 
was similar growth restriction in both male and female 
fetuses, although the absolute weight of male fetal heart, 
brain, and liver were more reduced in fetuses of aged rats 
than younger ones (Napso et al., 2019). There were pre-
vious studies that demonstrated poorer cardiovascular 
outcomes for adult male rats born from aged mothers 
(Shah et al., 2018 as cited in Napso et al., 2019). 
The sex-dependent changes in glucocorticoid handling 
in the placenta of AMA mothers affects health outcomes 
of offspring later in life. Elevated prenatal exposure to 
glucocorticoids affects development of the fetus and per-
manently alters the structure and functions of its organs, 
predisposing the offspring to certain diseases later in life 
such as hypertension (Napso et al., 2019). Even though 
the fetal weight for male and female fetuses of aged rats 
was compromised similarly, studies showed that adult 
male offspring of aged rats have a greater chance of devel-
oping cardiovascular dysfunction as adults, as compared 
to female offspring (Shah et al., 2018 as cited in Napso 
et al., 2019). 
In summary, AMA affects the phenotype of the rat pla-
centa in a sex-dependent manner. In female fetuses from 
aged rats, there were larger beneficial changes in structure 
and/or expression of genes related to placental transport 
of nutrients from mother to fetus and improved handling 
of glucocorticoids. In male fetuses of aged rats, there 
were no beneficial changes in the transport system and 
there was less protection from glucocorticoids, greater 
oxidative stress, and elevated levels of apoptosis. These 
sex-dependent changes in placental response to the envi-
ronment in the uterus of the aged mother play a role in 
the future health of female and male offspring. The results 
of this study have implications for managing human preg-
nancies, especially in developed countries where women 
are becoming pregnant at an older age. Targeted inter-
ventions can be developed to improve placental develop-
ment and function which, in turn, will aid fetal growth and 
development for mothers of AMA (Napso et al., 2019). 
Although women of AMA are a growing population 
in all developed countries with greater obstetric risks, 
women who live in the Mediterranean have specific char-
acteristics that are different than other areas. A study 
was done to establish an AMA cut-off age in a selected 
Mediterranean population in Barcelona. Although most 
studies define AMA as being above 35 years, this study 
defined AMA in Spain as being above 40 years. The aver-
age age of women delivering their first baby rose from 
25.2 years in 1975 to 30.7 years in 2016. Models predict 
that by 2050, the average age of a first pregnancy will 
be 33 years. In 2016, 38.7% of deliveries in Spain were 
to mothers over 35 years, and 8.39% were to mothers 
over 40 years. The average age of women at childbirth in 
2017 was 32.5. The scientific community is interested in 
gaining information about the impact of AMA on obstet-
rical outcomes so that they can better assess risks in this 
increasing population (Nieto et al., 2019).  
The cohort in this study were women who gave birth 
between January 2007 to June 2017. A total of 25,054 
pregnancies were included. The average maternal age was 
34.7 +/- 4.2 years. In this study, 2,807 patients were be-
tween 40-44 years and 280 patients were >45 years. Of 
the total pregnancies, women above the age of 40 account-
ed for 12.3% of the deliveries. Confounding factors were 
considered, which included chronic hypertension, preges-
tational diabetes types I/II, use of ART, obesity, smoking, 
previous C-sections, and multiparity (having more than 
one child). Over 97% of the women were Caucasian and 
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99.8% were from the Mediterranean area. After adjusting 
for confounding factors, age proved to be a significant 
risk factor in developing gestational diabetes, especially in 
women >40. The risk of placenta previa increased as well 
in women >40 years. Preeclampsia and prolonged hospi-
talization were only associated with women >45 years. 
The risk of these negative outcomes increased as the age 
of the women increased (Nieto et al., 2019).  
It was suggested that the reason for the increased risk 
of gestational diabetes in women >40 might be endotheli-
al damage. Age is known to be a cardiovascular risk factor 
that produces structural and functional changes in the 
vascular system. Dysfunctional endothelium increases the 
risk of developing insulin resistance, which then increases 
the risk of hypertension, type II diabetes, and other met-
abolic syndromes (Nieto et al., 2019).  
In summary, in this study, women >40 were the most 
positively associated with complications of gestational di-
abetes, placental previa, caesarian delivery, and prolonged 
hospitalization. They were the ones with the highest clin-
ical risks. These patients were also at greatest risk for 
iatrogenia (effects from medical interventions) since they 
have high elective C-section rates. Future investigations 
should therefore address medical interventions and preg-
nancy surveillance to improve outcomes in AMA patients 
(Nieto et al., 2019).  
Another cross-sectional study tested the hypothesis 
that there is an association between AMA and maternal 
and neonatal morbidity. The study was based on data 
obtained from 3,315 births. It compared the births of 
women who were 35 years and older, with a reference 
group of women between the ages 24-27 (Casteleiro et 
al., 2019).
Results of the study confirmed the hypothesis. Repeated 
spontaneous abortions were 2.2 times more frequent 
in the older age group compared to the younger refer-
ence group. There was a greater incidence of gestation-
al diabetes in AMA women, particularly in primiparous 
women where the risk was eight times more prevalent. 
The possibility of giving birth with the help of instruments 
was multiplied by 1.6 and the possibility of a cesarean 
delivery was multiplied by 1.5 in both primiparous and 
multiparous AMA women. Lastly, there were correlations 
between preeclampsia, preterm birth (<37 weeks) and 
low birthweight in the older age group, although the num-
bers were not high enough to have statistical significance 
(Casteleiro et al., 2019).
The cause of repeated abortions in AMA women may 
be attributed to alterations in the chromosomes, which 
increase along with increasing maternal age. The cause 
of gestational diabetes is being continually researched. 
One theory is that diabetogenic hormones, such as the 
growth hormone that releases corticotropin, produce an 
increased insulin resistance which AMA women are not 
able to overcome (Casteleiro et al., 2019).
A study was done to ascertain the effect of advanced 
maternal age on singleton pregnancies in nulliparous 
women. Records of obstetric patients were reviewed 
from routine fetal ultrasonograms that were taken in 
the middle trimester of pregnancy. Three groups were 
included in this study: a control group of ages 18-34 years 
old, advanced maternal age women of 35-39 years, and 
very advanced maternal age women over 40 years of age. 
Altogether, 957 women met the criteria to be included in 
the study (Kahveci et al., 2018).
The study clearly demonstrated that AMA nulliparous 
women with no previous chronic diseases (including obesi-
ty) had higher rates of adverse perinatal and neonatal out-
comes such as gestational diabetes, gestational hyperten-
sion, preeclampsia, small for gestational age, spontaneous 
late preterm delivery (between 34-37 weeks of gestation) 
and cesarean delivery. Gestational diabetes, gestational hy-
pertension and cesarean delivery rates were more com-
mon in the VAMA group compared to the AMA and young 
age group. No increased risk was found for spontaneous 
preterm delivery before 34 weeks, prolonged rupture of 
membranes, placenta previa, large for gestational age, and 
operative vaginal delivery (Kahveci et al., 2018).
It has been suggested that poor oxygen exchange may be 
a factor in the association between AMA and small for ges-
tational age. This stands to reason because when an unborn 
baby doesn’t get enough oxygen during pregnancy, its organs 
don’t grow as much as they should (Kahveci et al., 2018).
Concerning neonatal outcomes, admission to a NICU 
was more likely to occur in the AMA groups, but there 
was no major difference in APGAR scores, occurrences 
of low birth weight, and neonatal morbidity between the 
groups (Kahveci et al., 2018).  
During the last few decades, there has been a significant 
increase in the amount of pregnancies involving multiple 
fetuses due to the use of ART. Even in singleton pregnan-
cies, AMA poses a risk for more maternal and neonatal 
complications. Multiple gestation drives this risk up even 
more (Gluck et al., 2018).
A study was done with the goal of comparing obstet-
rical and neonatal outcomes between women older than 
35 years and women younger than 35 with the same type 
of twin pregnancy. Records were reviewed of all dicho-
rionic-diamniotic pregnancies (in which each fetus has 
its own placenta and amniotic sac) between 2009-2016 
where the babies were delivered after 24 weeks gesta-
tion. Pregnancies with abnormalities in the chromosomes 
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and those with fetal malformations were excluded. The 
older women were divided into two groups: age 35-39, 
and those >40. The control group consisted of women 
younger than 35. Altogether, 716 women were studied. 
The rate of in-vitro fertilization for conception was high-
er in the study groups (older women) than in the control 
group (Gluck et al., 2018).
AMA was found to be independently associated with 
cesarean section after adjustments were made for nul-
liparity, in-vitro fertilization, and hypertensive disorders. 
The rate of hypertensive disorders was significantly high-
er in women over the age of 35 (Gluck et al., 2018).
Twins born to women over 35 also tended to stay lon-
ger in the NICU than those born to the younger women. 
Other neonatal outcomes in women age 35 or older 
who were carrying twins were similar to the younger 
group (Gluck et al., 2018). 
A retrospective cohort study was done to evaluate 
whether AMA was independently associated with an in-
creased risk of childhood cancer in the offspring. There 
were three maternal age groups studied: 35-39, 40-50, 
and a control group of 20-34. A comparison was made 
between the three age groups for incidences of malignant 
morbidity in the offspring. Pregnancies lacking prenatal 
care, gestations of multiple fetuses, pregnancies originat-
ing with fertility treatments, and pregnancies with fetuses 
displaying congenital malformations were not included in 
this study. The offspring were followed up to the age of 
18 years. The three most common malignant forms of 
childhood cancer which were traced included leukemia, 
brain tumors, and lymphomas (Imterat et al., 2018).  
Theoretically, advanced maternal age might correlate 
with childhood cancers due to DNA damage and de-
creased repair pathways in oocytes of older mothers. 
Several previous studies (Ross et al., 2005 as cited in 
Imterat et al., 2018) showed a connection between AMA 
and meiosis errors leading to trisomies (particularly tri-
somy 21 or Down’s Syndrome) which are known to pre-
dispose for malignancies in childhood. Additionally, ART, 
which is increasingly used to offset infertility disorders 
in older women, is suggested as increasing the risk of 
childhood cancers such as retinoblastoma, by altering 
gene expression. Finally, changes in maternal hormones 
during pregnancy that are age-related, such as higher in-
trauterine exposure to endogenous estrogen and insulin 
growth factor-1, have been shown to help initiate cancers. 
Considering all the above hypothetical effects of AMA on 
childhood cancers, this study was important to conduct 
(Imterat et al., 2018).  
In the study, 201,738 deliveries were included. Results 
showed that advanced maternal age did not increase the 
risk of future malignancies in the offspring up to 18 years 
old. There was some association, though, between mater-
nal age and leukemia of the offspring which warrants fur-
ther investigation (Imterat et al., 2018).  However, overall, 
childhood cancer of offspring does not seem to be a 
major concern for AMA women planning to conceive. 
A study was done to investigate what effect AMA has 
separately in nulliparous and multiparous women on ob-
stetric and neonatal outcomes in singleton pregnancies. 
The study was a hospital-based analysis of 6,619 births 
between January 2004 and May 2007. AMA was defined 
as 35 years and older. Nulliparity was defined as women 
who had not delivered a viable fetus (greater than 24 
weeks of gestation in the past) and multiparity was de-
fined as women who had at least one pregnancy in the 
past that progressed beyond 24 weeks of gestation. The 
actual parity number wasn’t considered. Of the study 
participants, 42.7% were nulliparous and 57.3% were 
multiparous. Of the nulliparous, 21.8% were of advanced 
maternal age and of the multiparous, 42.1% were of ad-
vanced maternal age (Wang et al., 2011).
Among nulliparous women, AMA was associated with 
higher rates of cesarean sections both before and during 
labor, as well as vaginal deliveries assisted by instruments. 
Among multiparous women, however, AMA was only as-
sociated with a higher rate of cesarean sections before 
labor. This might be due to a greater percentage of mul-
tiparous women requesting cesareans (Wang et al., 2011).
A study was done in order to assess how pre-pregnancy 
weight (or body mass index) and gestational weight gain 
affect pregnancy outcomes in AMA women. This retro-
spective analysis was conducted on postpartum and hos-
pital delivery data in China. A total of 1,015 women were 
included in the study who gave birth from January-June 
2017. In China, 60% of all pregnancies are in women great-
er than 35 years of age and half of these women are above 
40 years of age. AMA women are often overweight before 
pregnancy and are more likely to have internal diseases. 
They are also more likely to be multiparas having had at 
least one previous child. Age is also an independent risk 
factor for adverse pregnancy outcomes (Lin et al., 2019).
The women were divided into an advanced age group 
(35-40 years) and a super advanced age group (>40 
years). Body mass indices prior to pregnancy were di-
vided into underweight, normal weight, overweight and 
obese groups. Gestational weight gain was subdivided 
into three groups (Lin et al., 2019).
Results showed that being overweight prior to preg-
nancy increases gestational diabetes mellitus, hyperten-
sive disorders complicating pregnancy, and fetal macroso-
mia where a newborn is significantly larger than average. 
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Poor weight gain during pregnancy increased the risk of 
preterm births, but excessive weight gain during pregnan-
cy increased macrosomia in the babies of AMA women 
(Lin et al., 2019).
The women in the super advanced maternal age group 
had higher incidences of both being overweight and 
obese than those in the AMA group. The super advanced 
maternal age group had more incidences as well of gesta-
tional diabetes mellitus, hypertensive disorders, and mac-
rosomia than in the advanced age group (Lin et al., 2019).
Overall, controlling weight gain both prior to and 
during pregnancy reduced adverse pregnancy outcomes 
in AMA women (Lin et al., 2019). It is good advice for 
older women who are planning to conceive to get their 
weight under control beforehand. 
A study was conducted with the objective of determin-
ing whether there was an association between AMA and 
race on pathology of the placenta in very low birthweight 
infants. A retrospective cohort analysis was done on pla-
cental pathology on very low birthweight singleton in-
fants born between July 2002 and June 2009. There were 
739 cases included in this study (de Jongh et al., 2015).  
The placenta is the area where maternal-fetal oxygen 
and nutrients get exchanged and so it has an important 
influence on birthweight and is necessary for a successful 
outcome to a pregnancy. Placental growth, which can be 
measured in terms of placental weight, is a good indica-
tor of how well the placenta is functioning. The placenta 
weight/birthweight ratio is used to indicate neonatal out-
comes (de Jongh et al., 2015). Both high and low ratios 
have been associated with an increased risk for stillborn 
and other negative neonatal outcomes (McNamara et al., 
1998 as cited in de Jongh et al., 2015). 
The subjects of the study were divided into two groups: 
maternal age <35 and maternal age >35. Mean placental 
weights, mean birthweights, and placental weight/birth-
weight ratios were calculated for each age group (de 
Jongh et al., 2015).  
In the final analysis, AMA was seen to be associated 
with a decrease in placental weight and placental weight/
birthweight ratio. AMA, and not race or ethnicity, re-
mained independently associated with placental weight/
birthweight ratio. It could not be determined, however, 
if older maternal age directly causes reduced placental 
weight/birthweight or whether it represents confounding 
variables not tested for. Further research is necessary to 
discover possible causal mechanisms that can explain the 
relationship between AMA and lower placental weights in 
very low birthweight babies (de Jongh et al., 2015).  
In Denmark, the rate of cesarean sections increased by 
49% between the years 1998-2015 and occurred in 21% 
of all births. This is a cause for concern since cesarean sec-
tions can have short and long term consequences for the 
mother and child and can present risks in future pregnancy. 
A possible cause of the increase may be the delaying of 
pregnancy until advanced maternal age. AMA at childbirth 
has been found to be linked to pre-pregnancy morbidity 
that might account for the increased risk of cesarean sec-
tion. The goal of this study that included one million Danish 
women was to examine the relationship between AMA 
and cesarean section, taking demographics, health and 
obstetric factors into the equation. There were three age 
groups (30-34, 35-39, >40 years) with a reference group of 
maternal age less than 30 (Rydahl et al., 2019).  
A positive association was found between AMA and 
cesarean section. When adjusting for confounders, there 
were only minor changes in the risk factor. When com-
pared to the reference group, nulliparous women aged 
35-39 had twice the risk of cesarean section, while women 
of 40 and above had three times the risk. For multiparous 
women, the risk was more moderate (Rydahl et al., 2019). 
Cesarean sections are one of the most intrusive 
obstetric interventions and is becoming much more 
common in industrialized countries. The increase in ce-
sarean sections is mainly a result of AMA, especially in 
nulliparous women. Morbidity tends to increase as age 
increases, so AMA women will include more individuals 
with prenatal risk factors such as hypertension, diabe-
tes mellitus, and higher body mass index than younger 
pregnant women. More women of advanced age will also 
develop pregnancy related complications, including gesta-
tional diabetes, preeclampsia and placenta previa. There is 
also evidence that there is a decline in the physical ability 
to maintain uterine contractions which can cause labor 
dystocia. Future studies on the possibility of advanced age 
affecting the ability to maintain progression of labor is 
recommended. Placenta previa in AMA women, as well as 
non-vertex fetal presentations might also necessitate a 
cesarean delivery (Rydahl et al., 2019).  
The higher cesarean section rate may be a result of 
these comorbidities related to AMA. It is possible, though, 
that the lower threshold for cesareans may be influenced 
by the attitudes of the healthcare professionals treating 
AMA women who may view them as high-risk patients or 
by the mothers themselves who choose a cesarean birth 
because they are more anxious about the health of the 
fetus (Rydahl et al., 2019).  
A study was done regarding the association between 
maternal age and offspring adult health. There is increas-
ing documentation associating AMA with negative health 
outcomes in their offspring. This association is considered 
to be a reflection of aging physiological processes of the 
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mother, such as the decreasing quality of her placenta or 
eggs (Myrskyla & Fenelon, 2012).   
In this study, the role of socioeconomic selection and 
lifespan overlap between the generations is examined, 
as they are related to the association between maternal 
age and offspring adult health. It was found that offspring 
born to mothers younger than 25 or older than 35 have 
the worst outcomes regarding health, height, obesity, 
and even mortality. The reason for the young maternal 
age-offspring health link may be due to the physiological 
immaturity and socioeconomic disadvantage of young 
parenthood. Regarding the older age group, the results of 
the study showed that negative outcomes are not due to 
the mother leaving a physiological imprint in the offspring 
that causes a predisposition to diseases in adulthood. 
Rather, maternal education (which is strongly connected 
to socioeconomic status) and the age at which the child 
loses the parent are two important factors that affect 
the correlation between AMA and offspring adult health 
(Myrskyla & Fenelon, 2012).  
Mothers of advanced age have generally had the oppor-
tunity to obtain a higher level of education which trans-
lates into greater affluence. Childhood socioeconomic 
status has been found to be strongly connected to adult 
health and mortality (Myrskyla & Fenelon, 2012).  
The age at which a child loses a parent is directly re-
lated to maternal age. If all other factors are held con-
stant, a child born to a younger mother will have many 
more years of lifespan overlap with the mother than a 
child born to an older mother. The psychological shock 
of losing a parent at a younger age is one factor that may 
affect the adult child’s health. Another factor might be the 
loss of parental involvement with the offspring. Thirdly, a 
shorter lifespan overlap might indicate a genetic frailty 
that runs in the family (Myrskyla & Fenelon, 2012).  
Maternal age, therefore, is related to the mother’s ed-
ucation, socioeconomic status, and lifespan overlap with 
the offspring, all of which were found to be confounders 
in the maternal age-offspring health association. These 
factors all help explain the mechanism behind the asso-
ciation of AMA and negative health outcomes in the off-
spring and challenge the standard interpretation for that 
association. The reason this study is important is because 
today’s parents, even if they reproduce at an older age, 
will likely live longer due to medical advances and there-
fore have a longer lifespan overlap with their offspring. 
If biological aging is indeed not the factor to influence 
the adult health of offspring but rather lifespan overlap is, 
AMA women can be reassured going forward that their 
late childbearing will not adversely affect their offspring 
(Myrskyla & Fenelon, 2012).  
In the latter half of the last century, the delay of child-
bearing in Western cultures has affected the biology of 
the mother-fetus relationship. Data obtained from exper-
iments, as well as clinical observations, have ascertained 
this change. As an example, there has been an increase in 
type 1 diabetes in developed countries during this time. 
This trend parallels the tendency to give birth at a later 
age which might suggest a causal relationship between 
the two events. Delayed childbearing might therefore 
have a detrimental effect not only on the development 
of the fetus in the uterus but may possibly be causing a 
predisposition to certain severe disorders. The change to 
the reproductive organs due to age, along with changes 
in hormone activity, may be the causes of this negative 
relationship (Gloria-Bottini et al., 2005). 
A study done in Italy might also suggest that delayed 
childbearing is causing a change in the genetic compo-
sition of the population. Gene frequency refers to the 
proportion of a population that carries one type of allele, 
or gene variation, at a particular point on a chromosome. 
Certain phenotypes either increase or decrease with ma-
ternal age. These changes in the genetic composition of 
AMA women were found to be similar in the mothers 
and newborns studied (Gloria-Bottini et al., 2005). 
The hypothesis of the study, which included over 600 
women giving birth, was that advanced maternal age may 
influence intrauterine selection by favoring genotypes that 
are best able to adapt to the intrauterine environment of 
the older mothers. Zygotes that are more resistant to the 
changes in the maternal environment of older women will 
be the ones to survive. Maternal and neonatal genotypes 
were found to be similar in the AMA women studied. 
Maternal age was, therefore, having an effect on the gene 
frequency in the offspring (Gloria-Bottini et al., 2005).
Very Advanced Maternal Age (VAMA)
In Australia, as in most other high-income countries, child-
bearing age has been rising to 35 years and above. A new 
trend is emerging of pregnancies in women even 45 years 
and older which comprise 0.1% of all births in the coun-
try and is continually rising. This is driven partly by assist-
ed reproductive technologies such as oocyte donation. 
There were few studies examining perinatal outcomes in 
this age group. A state-wide population-based study was 
done in Victoria, Australia covering the years 2005-2006 
to determine maternal health and the outcomes of preg-
nancies of women in this age group compared to women 
aged 30-34 years (Carolan et al., 2013).   
The study revealed prenatal complications of at least 
one of the following: gestational diabetes, antepartum 
hemorrhage (bleeding from or in the genital tract), 
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placenta previa, and multiple births. There was weak ev-
idence for increased risk for preeclampsia. Women >45 
were also more likely to have caesarian sections. They 
were not found to be more likely of having a postpartum 
hemorrhage (Carolan et al., 2013).   
Pre-existing medical conditions of the mothers, as well 
as parity and use of ART, were taken into account. Women 
aged 45 and older were most likely to have pre-existing 
hypertension, but there was weak evidence of pre-exist-
ing diabetes. Women in the group were 12 times more 
likely to have used ART (Carolan et al., 2013).   
Babies born to these VAMA (very advanced maternal 
age) mothers were at a higher risk for preterm birth 
(between 32-36 weeks gestation) regardless of parity, 
low birth weight (less than 2,500 grams) for primiparous 
women and had higher odds of being small for gestational 
age. Rates of preterm birth were very high for multiple 
births and for those who used ART (Carolan et al., 2013). 
The findings in this study have ramifications for 
the women as well as for their healthcare providers. 
Although results displayed higher rates of pregnancy 
and perinatal negative outcomes for the women aged 
45 and older in Victoria, Australia, nevertheless, the 
findings were reassuring as the vast majority of these 
women of very advanced age gave birth to healthy ba-
bies. The rate of perinatal death was low (less than 10 
per 1,000 births). This suggests that with good prenatal 
care, most women in this group can achieve a live birth. 
Future studies should include investigations into the fu-
ture health of these children who were preterm birth 
or were of low birth weight or small for gestational age 
(Carolan et al., 2013).   
A study was done to investigate the interplay between 
very advanced maternal age (>43 years) and assisted re-
productive technology on adverse perinatal outcomes. 
Data was taken from a cohort of women who deliv-
ered babies in Ontario, Canada between 2012-2015. In 
Canada, the number of births in women over 40 years of 
age tripled from 2005-2014. Even though fertility declines 
as a women ages, ART has allowed many more women 
of VAMA the chance to become pregnant. ART, though, 
has been considered a risk factor for adverse pregnancy 
outcomes as compared to spontaneous conceptions. This 
particular study aimed to assess the pregnancy outcomes 
of women who were both of very advanced age and who 
used ART to conceive. Singleton pregnancies of women 
>20 years who delivered at 20 weeks of gestation and 
above and whose offspring’s birthweight exceeded 500 
grams were included. The women were put into three 
categories of age: 20-34 years, 35-42 years, and >43 years 
of age. VAMA was defined as >43. All the subjects used 
were noted as either having used ART or having sponta-
neously conceived (Wu et al., 2019).  
The mothers age was the independent variable. The 
type of conception (ART or spontaneous conception) 
was the main covariate. ART conceptions included intra-
uterine insemination, intrauterine insemination with ovu-
lation induction but without in-vitro fertilization, in-vitro 
fertilization, and vaginal insemination. Many potential con-
founders for adverse maternal and neonatal outcomes 
were included, such as parity, income, education, body-
mass index, drug/alcohol use, and maternal preexisting 
health issues (Wu et al., 2019).  
Women at VAMA had a higher risk of a composite out-
come which included preeclampsia, intrauterine growth re-
tardation, stillbirth, and placental abruption than the moth-
ers in a younger age bracket. The fact that ART was used did 
not add to the adverse effect of VAMA, even though ART 
may play an independent role for adverse perinatal out-
comes. These outcomes were found in 10.41% of women 
under 35 and in 13.35% in women of VAMA. Regardless 
of the conception method, women of VAMA had a higher 
incidence of adverse outcomes (Wu et al., 2019).  
Another study was done to evaluate if the adverse preg-
nancy outcomes in women of very advanced age differed 
by parity and by conception method. According to a na-
tional perinatal database in Japan, women of VAMA giving 
birth rose to 28.1% of all births. A total of 365,417 women 
over the age of 30 were included. The women were di-
vided into four age groups: 30-34, 35-39,40-44, and >45. 
Pregnancies involving multiples, as well as fetuses with con-
genital abnormalities, were excluded (Ogawa et al., 2017).
Compared with the 30-34 year reference group, 
women aged 45 or older showed a higher risk for cesar-
ean sections, preeclampsia, placenta previa and preterm 
birth. Placental abruption, very preterm birth, low 
APGAR score and perinatal death were not seen as being 
of increased risk in VAMA. The effects of older age on the 
negative outcomes were significantly higher among those 
women who conceived naturally, compared to those who 
used ART to conceive. However, the possibility that ab-
normal embryos were removed during ART could have 
skewed the results. The effect of advanced age on cesar-
ean deliveries was stronger among primiparous women, 
but the risk for preeclampsia was significantly stronger 
among multiparous women (Ogawa et al., 2017).
The effects of advanced age on preterm birth were sig-
nificantly greater among women who conceived without 
ART than among those who used ART to conceive. To 
clarify, while the risk of preterm birth generally increased 
with age in women who conceived without ART, it de-
creased in women who conceived with ART. Therefore, 
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younger women who conceived through ART, may have a 
greater risk of preterm birth than women who are older 
and conceive through ART (Ogawa et al., 2017).
The greater risk of cesareans in primiparous women of 
advanced age may be due to higher rates of elective cesare-
an sections requested by primiparous older women. It might 
also be due to prolonged labor or compromised fetal status 
requiring emergency cesarean section with increasing age, 
but these hypotheses were not tested (Ogawa et al., 2017).
While the greater risk of preeclampsia in multiparous 
older women in this study contrasted to a previous study 
(Bianco et al., 1996 as cited in Ogawa et., 2017) which found 
no change in risk of preeclampsia in both primiparous and 
multiparous women of age, this might be explained by the 
recent use of low dose aspirin in women with a higher 
risk of preeclampsia. Since both primiparity and advanced 
age are both strong risk factors for preeclampsia, these 
women may be more likely to receive the medication than 
multiparous women (Ogawa et al., 2017).
Regardless of the way VAMA women conceive, the 
need for preconception counselling, and greater prenatal 
care in these women should be a priority. Regular pre-
natal visits and testing can help address potential con-
cerns early on and reduce the risk of pregnancy and birth 
complications which can be even more devastating, both 
emotionally and financially. 
Conclusion
Many studies have been done in various developed coun-
tries investigating what impact AMA has on perinatal 
and neonatal outcomes. The consensus is that advanced 
maternal age increases the mother’s risk for developing 
medical conditions such as cancer, diabetes, hypertension, 
and arthritis. The probability of pregnancy complications 
increases as well. Among these complications are chro-
mosome anomalies, placenta previa, placental abruption, 
caesarean birth, preterm labor and low birthweight. 
Abnormal functioning of the placenta and impairment in 
oocyte development potential, both due to aging, can re-
sult in fetal growth restriction and even stillbirth. Women 
who are of very advanced maternal age (over 40 and es-
pecially over 45 years of age) seem to be at even greater 
risk of pregnancy and perinatal difficulties, although risks 
differ by parity and conception method. 
Results of studies have been conflicting at times. The 
reason for this might be differences in homogeneity in 
study groups or failure to adjust for potential confound-
ers such as maternal diseases, obesity, assisted concep-
tion, pregnancies of multiples, and parity. Differences in 
definitions of pregnancy outcomes might also be a reason 
for incompatible conclusions. It is vital to determine if age 
effects are direct and have a causal relationship with ad-
verse outcomes or if they are indirect since other factors 
are at play. In order to accomplish this, future studies need 
to have control groups for age-dependent confounders. 
Inconclusive results concerning the ramifications of 
delayed childbirth must be resolved so that women of 
advanced age can make informed choices when deciding 
whether to bear children. 
Information regarding chromosome anomalies and 
the availability of prenatal screening tests are vital for 
any women over the age of 35 who are planning to be-
come pregnant. Those who receive positive results for a 
screening test can be sent for genetic counselling. Other 
emotionally supportive forms of help might come in the 
form of bereavement counselors, adoption services, or 
information on support groups for parents of multiples 
or for those who suffered a perinatal loss. 
Preconception care is especially important for women 
of advanced age planning a pregnancy.  Fertility concerns, 
pre-existing health conditions and risks for chromosome 
anomalies can be discussed. The importance of folic acid 
during pregnancy to decrease the risk of neural tube 
defects, reducing workplace risk and avoiding alcohol 
use and medications are all important topics to address. 
Older first-time mothers may need counselling regarding 
their transition into parenthood which may be more dif-
ficult for them as opposed to younger, first-time mothers. 
Most importantly, pregnancy surveillance in this older age 
group must be stressed in order to improve outcomes 
for both mother and baby. 
The trend of increased advanced maternal age is 
expected to continue and thus the effects of AMA on 
maternal and fetal morbidity and mortality is, and will 
be, of great concern. The unique needs of this popula-
tion must be addressed not only to benefit the mothers 
and babies themselves but for the implications that it 
has for the healthcare system and for service providers. 
Promoting the health of these women and their offspring 
and preventing negative outcomes reduces healthcare 
costs overall and will have an impact, going forward, on 
employment policies which will, hopefully, become more 
pregnancy-friendly. 
Overall, older women who are in generally good health 
can hope to have favorable outcomes to their pregnan-
cies with good prenatal care. Advanced technologies in 
perinatology have improved their chances of giving birth 
to a healthy child. If the needs for preconception counsel-
ling, targeted surveillance and early medical intervention 
are met, then there is no definite medical reason for ex-
cluding AMA women from attempting a pregnancy on the 
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Organ and limb regeneration might seem like something out of science fiction, but research has been ongoing since the late 1960s 
and has greatly increased at the turn of the century . It is an understatement to say that this has the potential to be life changing . The 
need for donor transplant organs and transplant waiting lists can become obsolete and the use of immunosuppressants post-trans-
plant will become unnecessary (leading to higher survival rates) . Should this happen, trauma patients will be able to achieve complete 
recoveries and the reign of some congenital disorders will come to an end . Nature has provided several opportunities for us to study 
this subject . Many species have a natural ability to regenerate complete organs . Human fetuses display a tremendous power of 
regeneration and healing in utero . The struggle has been in determining how and why this ability disappears after birth as well as 
applying the lessons we have learned from other species to humans . (However, great progress has been made and this paper will 
discuss where science is holding in terms of being able to give a human the ability to regenerate complete organs and limbs .) This 
paper will discuss whether science has been able to determine which lessons to learn from nature and how and when to apply it .
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Introduction
In 2008, nearly 2 million amputees have been reported 
in the United States and its prevalence is estimated to 
escalate more than 3‐fold by 2050 (Ziegler-Graham, et 
al., 2008). Although great strides have been made in treat-
ments for amputees which have in turn greatly increased 
their ability to lead productive lives, there are many side 
effects and frequent compromises that affect the quality 
of life (i.e. the adverse effects of long‐term immunosup-
pression) need to be accepted. In addition, current ther-
apeutic approaches, such as allogeneic hand transplanta-
tion, suffer from a limited donor supply (Schneeberger, 
et al., 2007). Besides for injuries and congenital diseases, 
regenerative medicine therapies have the potential to 
allow us the ability to treat (or even replace) failing or-
gans which have begun to decline due to age (Heidary 
Rouchi, Mahdavi-Mazdeh, 2015; Ranjeet Singh, 2016). This 
will allow for a great increase the general quality of life, 
especially for the elderly. Regenerative medicine has the 
potential to provide treatment for a tremendous variety 
of currently intractable diseases and ailments (Upadhyay, 
2015).
Methods
Data was collected using Google and PubMed databas-
es through Touro College’s online library. Among the 
key-phrases used were “regeneration”, “limb regenera-
tion”, “human regeneration”, and “regenerative medicine.”
Discussion
To begin the discussion of regeneration we must first 
gain a clear understanding of the conditions and pro-
cesses that are required for it to occur. There are a few 
species that have a natural ability to regenerate organs 
and limbs. All known livings things can be classified into 
three groups concerning their natural ability to regen-
erate. This paper will refer to the three groups as “com-
plete”, “partial”, and “minimal”. “Complete” refers to a 
lifelong, absolute ability to regenerate complete organs 
and limbs. Examples include urodeles such as newts and 
axolotls such as salamanders (Bensoussan-Trigano, et 
al., 2011; Dinsmore, 1996; Brockes, Kumar, 2002; Roy, 
Lévesque, 2006). “Partial” refers to an absolute ability to 
regenerate but only for a portion of the lifespan, after 
which the capacity is lost. For example, anurans such as 
frogs and toads can completely regenerate a limb in the 
larval stage, however, once passed metamorphosis they 
lose this ability (Satoh, et al., 2005; Suzuki, et al., 2006). 
“Minimal” refers to a very limited capacity for regener-
ation (only very simple organs and/or simple portions 
of complex organs) and only for a small portion of the 
lifespan. Neonatal mammals for example, have been 
shown to be able to regenerate the tips of digits, howev-
er, this ability fades with aging (Sánchez Alvarado, Tsonis, 
2006; Farah, et al., 2016).
Differences
Wound healing is a necessary component of regen-
eration and is comprised of four stages (a) hemosta-
sis (blood clotting), (b) inflammation, (c) proliferation 
(growth of new tissue including the formation of wound 
epidermis (WE)), and (d) maturation (remodeling) 
(Fernando, et al., 2011; Simkin, et al., 2013; Yokoyama, 
2008). Wound healing occurs in all groups, regardless 
of their ability to regenerate (Raz, Mahabaleshwar, 
2009). However, there are important variances within 
the exact mechanisms for each of the groups (Borgens, 
1982; Han, et al., 2008; Takeo, et al., 2013). Variances in-
clude the duration of wound closure (Mu, et al., 2013; 
Stocum, 2011), inflammatory response (Ferguson, et al., 
1996; Wulff, et al., 2012), and wound maturation (remod-
eling) (Bellayr, et al., 2009; Ravanti, Kähäri, 2000; Xue, 
et al., 2006). Understanding these variances is essential 
for developing regenerative capacity in humans (Mu, et 
al., 2013). The differences will be highlighted here, for a 
more thorough review of the mechanism for limb re-
generation refer to “New Insight into Functional Limb 
Regeneration: A to Z Approaches” (Taghiyar, et al., 2018)
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Wound Closure
Unlike adult anurans and mammals (postnatal) who form 
scar tissue during wound healing, urodeles, embryonic 
and fetal anurans, and neonatal mammals do not (Dang, et 
al., 2003). One difference is the length of time it takes for 
wound closure in each of these groups. In adult mammals, 
epidermal closure takes between 8- and 12-days post am-
putation (DPA) (Reginelli, et al., 1995; Simkin, et al., 2013). 
Embryonic mammals, however, take much shorter time. A 
study found it takes only up to 24 hours for an embryonic 
mouse (McCluskey, Martin, 1995). In addition, urodeles 
take only between 10 and 24 hours (Campbell, Crews, 
2007; Murawala, et al., 2012) and a study conducted on 
early post-metamorphic anurans found the wound clo-
sure time to be between 2 and 3 days (Goode, 1967). 
Last, a study on embryonic tadpoles (which are anurans) 
found wound closure took only 30 mins though the paper 
does admit that this rate seems “extremely high” (Yoshii, 
et al., 2005). It logically follows that scar tissue formation 
is related that the length of time required for complete 
wound closure (Manuel, Gawronska-Kozak, 2006; Wilgus, 
2007). Though it seems the differences between those 
with scar formation and those without must manifest 
sometime after 24 hours, this is not the case. The first 24 
hours of each of the groups are not the same. In fact, in 
(adult) mammals, it can take more than 24 hours for the 
first migration of epithelia to begin to cover the wound. 
There seems to be a fundamental difference in the wound 
healing process that must be explored..
Immune System
One such fundamental difference seems to be the im-
mune system. Urodeles have a weak immune system 
compared to anurans and mammals (G. Chen, Robert, 
2011; Kaufman, et al., 1995) who seem to share the same 
immune system in terms of complexity, specificity, and 
memory (du Pasquier, et al., 1989; Mescher, Neff, 2005). 
This isn’t the only place where anurans and mammals are 
grouped together. Interestingly, the changes that occur in 
mammals as they mature and shift from fetal scar-free 
repair to adult scar-based repair have a close resem-
blance to the changes that occur in anurans as they begin 
metamorphosize and lose their regenerative ability and 
in both cases immune signaling has been identified as a 
key regulator. In mammals specifically, scar-free healing is 
associated with an immature immune system. (Kishi, et 
al., 2012; Wilgus, 2007). Also, note that although most of 
what we know about urodeles immunity has been ob-
tained from studies on axolotls specifically, it appears it 
can be inferred to the many different species and genre 
of salamanders (Cohen, 1971).
Past research indicates that there is a correlation be-
tween the level of maturity of an immune system and the 
regenerative capacity. As an anuran undergoes metamor-
phosis (a developmental period referred to as “refrac-
tory period”), we find an inverse relationship between 
the maturation of their immune system and the loss of 
scarless healing (Bertolotti, et al., 2013; Godwin, Brockes, 
2006; Mescher, Neff, 2005). In fact, the suppression of 
the more potent immune response that develops during 
the refractory period restores a metamorphosizing anu-
ran’s regenerative ability (Fukazawa, et al., 2009). This is 
backed up by another study that found that the decrease 
in regenerative capacity that an anuran experiences as it 
matures is negatively correlated with the intensity of the 
inflammatory response as well as structural modifications 
in the thymus (Franchini, Bertolotti, 2012).
Comparison of Systems
The immune system of adult anurans and mammals is in-
tricate with a wide range of adaptive immune responses 
in addition to a complete innate immune response. By 
comparison, urodeles are considered immunodeficient 
relative to adult anurans and mammals though they have 
a strong innate immune system (G. Chen, Robert, 2011). 
This is because, despite their reasonable B-cell and siz-
able T-cell reserves, their humoral response is extremely 
slow (60 days), not able to facilitate anamnestic respons-
es, and only has one unique IgM class (Kaufman, et al., 
1995; Tournefier, et al., 1998). In addition, immunization 
with soluble antigens gives negative results and its B cells 
are not triggered by T-helper cells; in fact, thymectomy, 
X-ray irradiation or corticosteroid treatment has shown 
to improve the humoral response (Charlemagne, 1979; 
1981; Tournefier, 1982).
A urodeles cytotoxic immune response is very slow 
as well (21 days) and shows weak mixed lymphocyte 
reactions (MLRs) (Kaufman, et al., 1990; Koniski, Cohen, 
1992) causing there to be no acute xenograft rejection 
reactions. However, since they have reasonable B-cell and 
sizable T-cell reserves they have a large diversity of B and 
T cell antigen receptors which, over time, causes rejec-
tion to ultimately occur. Therefore, xenograft rejection 
appears to be dependent on the thymus (Tournefier, et 
al., 1998). Due to the weak adaptive immune response 
of urodeles they are extremely susceptible to viral infec-
tions relative to anurans. Although they display a complex 
immune response, they fail to generate adequate T cell 
proliferation in the spleen early on. By comparison, an-
urans are able to generate adequate T cell proliferation 
in the spleen early on and therefore are capable to clear 
viral infections (Cotter, et al., 2008).
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There are further differences, specifically in terms of 
innate vs. adaptive immunities (Godwin, Rosenthal, 2014) 
that are beyond the scope of this paper. However, clearly 
there are differences that seem to correlate with the abil-
ity for regeneration. The specific aspect(s) of the immune 
system that is/are responsible is still not known, but it 
appears that the more sophisticated the immune system 
is, the less of a regenerative ability there is. Perhaps this 
is the way species have evolved; prioritizing survival (by 
prevention of infection) over function and aesthetics of 
damaged organs and limbs. However, now that we have 
antibiotics, perhaps both can be achieved.
Wound Maturation
Analogous to the cytoskeleton in cells the extracellular 
matrix (ECM) allows for individual cells to come together 
and create tissues and eventually organs by providing a 
non-cellular structural platform upon which the cells ad-
here to. It is made up of macromolecular network com-
posed of collagens, proteoglycans/glycosaminoglycans, 
elastin, fibronectin, laminins, and several other glycopro-
teins (Bonnans, et al., 2014; Michel, et al., 2010; Theocharis, 
et al., 2016). For organ or limb regeneration to occur, the 
proper ECM form must be created for the cells to have a 
place to go. In addition, the interaction between the cells 
and the ECM allows for the control of growth by provid-
ing negative feedback when a sufficient number of cells 
have been produced preventing an overgrowth.
Matrix Metalloproteinase (MMP)
During regeneration, for the proper structure to be 
formed the use of matrix metalloproteinases (MMPs) 
are employed. The main function of these molecules is 
to degrade the matrix strategically and help sculp the 
proper structure needed. There are other functions that 
have been discovered but they are beyond the scope of 
this paper. To keep things in control, tissue inhibitors of 
metalloproteinases (TIMPs) keep the protease activity 
of MMPs in check and therefore are the regulators of 
wound closure, tissue regeneration and scar formation 
(Mu, et al., 2013).
In adult mammals a severe inflammatory response and 
high fibroblast activity results in collagen fiber accumu-
lation between the epidermal layer and the transected 
bone (Satoh, et al., 2012; Seifert, et al., 2012). The collagen 
deposition hinders a reciprocal interaction between the 
surface layer and most underlying mesenchymal tissues 
preventing normal skin restoration and causing scar for-
mation to occur (Satoh, et al., 2008). The discrepancy 
between scar formation and epimorphic regeneration 
is most probably attributed to the histolysis phase of 
regeneration in which MMPs are absent for ECM remod-
eling (W. Chen, et al., 2007). 
In urodeles, pre-morphologic anurans, and fetal mam-
mals, higher ratios of MMPs/TIMP have been observed 
relative to those who do not have a regenerative capacity 
(Parks, 1999; Ravanti, Kähäri, 2000). Studies have shown 
that MMP1 specifically has a beneficial impact on muscle 
healing (note: these studies were completed on those 
that do not have a natural regenerative capacity) (Bedair, 
et al., 2007; X. Chen, Li, 2009; Kaar, et al., 2008; Wang, 
et al., 2009). In fetal mice, who are not able to regener-
ate complete limbs, introduction of MMP1 has been able 
to cause complete regeneration (Muneoka, et al., 2008). 
There have been many additional benefits observed 
when the use of exogenous MMP1 has been employed. 
Building on the results of the study by Chen et. al. (2007) 
stated above, results of a study from 2013 showed that 
in adult mice who underwent MMP1 treatment achieve 
an increase in the formation of capillary blood vessels, 
peripheral nerve fibers and neuromuscular junctions, as 
well as a decrease in the formation of fibrotic scar tissues 
in the amputated digits. However, the healing of skeletal 
tissue and digit elongation was not significantly improved 
(Mu, et al., 2013). A possible solution may be stem cells 
which are able to form the segmented pattern of bone 
and cartilage crucial needed for regeneration (more on 
this later on) (Masaki, Ide, 2007).
Additional Hypotheses 
Land vs. Sea
An anuran loses its regenerative ability as it transitions 
from living in the water to living, at least partially, on land. 
As noted above the changes to the immune system of an-
urans as they metamorphosize and transition from water 
to land leave it with a much more powerful weapon, which 
makes sense as terrestrial conditions require a more ef-
fective immune system (Alibardi, 2018). However, a study 
on Xenopus laevis (anuran) embryos found that the 
rate of wound closure tends to decrease as the osmotic 
pressure approaches isotonicity (Yoshii, et al., 2005). The 
authors suggest that perhaps the extremely rapid rate of 
wound closure is a result of the stimulation of the osmot-
ic pressure regulation system, something which amniote 
embryos do not require and therefore why they have a 
much slower rate of wound closure. This begs the ques-
tion; why do urodeles have an increased wound closure 
rate if they are terrestrial organisms? While it may be true 
that osmotic pressure can affect an organism’s ability to 
regenerate, it is unlikely for urodeles and pre-metamor-
phic anurans to have developed two completely distinct 
methods of regeneration, especially since anurans and 
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urodeles are part of the monophyletic Lissamphibians. 
In addition, of the three orders included, anurans and 
urodeles are more closely related to each other than to 
the third order (the legless caecilians) (Elinson, del Pino, 
2012). More likely, once an organism has the ability to 
regenerate, the increased wound closure rate due to 
osmotic pressure helps speed up the process. However, 
research into this is unnecessary since we are looking for 
a way to replicate the mechanism of regeneration in hu-
mans and since humans do not have an osmotic pressure 
regulation system, increasing osmotic pressure to induce 
regeneration would be futile. Though, perhaps once we 
are able to regenerate maybe we can use the principles of 
osmotic pressure to help speed up the process without 
compromising on the regenerative ability.
Intrinsic and Extrinsic Cellular Properties
If there are fundamental cellular differences between 
those with the ability to regenerate and those without, 
then the potential for humans to achieve this capacity will 
be considerably more challenging. In that case it would 
require edits to the genetic code which we are a long way 
from being able to do at this point. Fortunately, although 
some evidence indicates that regenerative capacity stems 
from intrinsic cellular properties, it is not much. For ex-
ample, transplantation of limb blastemas from post-met-
amorphic (regeneration incompetent) to larval (regener-
ation competent) stages failed to regenerate despite the 
conducive host environment. This seems to indicate that 
there may be an intrinsic property of those post-meta-
morphic cells that prevents regeneration from occurring 
(Sessions, Bryant, 1988). However, this conclusion is only 
theoretical and evidence for manipulation of extrinsic 
(specifically immunological) properties have yielded some 
interesting results in mammals (Leavitt, et al., 2016; Satish, 
Kathju, 2010). Genetic deletion of the anti-inflammatory 
cytokine IL-10 induces scar tissue formation in fetal mice 
(recall embryonic mammals heal scarlessly) (Liechty, et al., 
2000). Though, in all fairness, these results were achieved 
by genetic manipulation. In order to be certain that there 
is no intrinsic cellular property that is responsible for 
regeneration, this study must be performed without any 
manipulation of any intrinsic cellular properties (i.e. no 
genetic deletion). For all we know, the deletion IL-10 
caused some other effect, and which may very well be the 
actual reason for the results that were achieved.
Treatment Proposals
With the above in mind we will now explore some of 
the therapeutic approaches that been hypothesized to 
enable humans to be able to regenerate organs and limbs. 
These hypotheses include modulating the host environ-
ment, manipulation of the host immune system, and gene 
manipulation. However, we must keep in mind that the 
best possible solution might be to combine multiple ap-
proaches simultaneously. We will try to determine which 
discoveries discussed above form the basis for the pro-
posed treatments to build upon.
Cell-Based Approaches
Many of the concepts discussed above describe differenc-
es that develop because species are inherently different 
down to the cellular level. This is true for all living things 
on an individual level as well. For example, the liver con-
tains two types of epithelial cells named hepatocytes 
and cholangiocytes. However, both those cells originate 
from a single cell type called hepatoblasts (which are 
fetal liver stem/progenitor cells) during development 
(Oertel, et al., 2003; Tanimizu, et al., 2003). To overcome 
the lack of regenerative capacity of differentiated tissues, 
many have hypothesized harnessing the power of stem 
cells. Since stem cells are inherently able to develop into 
multiple cell types, we can theoretically achieve an en-
vironment that is similar to a fetus (recall that mammal 
fetuses do possess an ability to regenerate to some ex-
tent). However, due to ethical concerns related to the 
use of embryonic stem (ES) cells as well as the desire to 
move away from the use of immunosuppressant drugs 
commonly used nowadays post allogeneic or even xe-
nogeneic transplantations due to rejection, many have 
turned to the use of the patients own cells and then 
“reprogramming” them into a stem cell that behaves 
like an embryonic one. ES cells are pluripotent, meaning 
they can form tissues from all three primary germ layers 
(ectoderm, endoderm, and mesoderm). Somatic cells 
that have been reprogrammed to behave like ES cells 
are called induced pluripotent (iPS) cells. This is achieved 
through a number of techniques which artificially turn 
on expression of specific pluripotency genes (Hackett, 
Fortier, 2011). Last year, a study to trace the origin of 
adult intestinal stem cells provided a direct link between 
the observed plasticity and cellular reprogramming of 
differentiating cells in adult tissues following damage 
(Tetteh, et al., 2016; van Es, et al., 2012; Buczacki, et al., 
2013; Yui, et al., 2018; Nusse, et al., 2018). This indicates 
that stem-cell identity is an induced rather than a hard-
wired property (Guiu, et al., 2019).
Amongst the various candidates for reprogramming, 
mesenchymal stem (MS) cells are of central importance 
for several reasons. MS cells are found in a majority of 
adult tissues including, bone marrow, adipose, cartilage, 
and dental pulp (Eslaminejad, et al., 2006; Karamzadeh, et 
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al., 2012; Zomorodian, Baghaban Eslaminejad, 2012). The 
benefit of being able to use cells that are derived from a 
patient’s own body is that transplantation will not elic-
it a host immune response. In addition, several studies 
suggest that MS cells induce immunomodulatory effects, 
which suggests that even allogeneic transplantation of 
these cells would not trigger the host immune response 
(Shi, et al., 2011).
In the past MSC transplantation has been performed 
for different diseased tissues (Emadedin, et al., 2012; 
R. Fekrazad, et al., 2015; Reza Fekrazad, et al., 2016). 
However, in 2007 Masaki et al. experimented with neona-
tal mice and compared the application of bone marrow 
mesenchymal stem cells (BM-MSCs) and limb bud trans-
plantation into amputated limbs. They demonstrated that 
both BM-MSCs and limb bud transplantation form the 
segmented pattern of bone and cartilage which is crucial 
to regeneration (Masaki, Ide, 2007).
One issue with the stem cell approach is that stem cells 
lack the positional information needed for regeneration 
to occur. It doesn’t help to just have the cells grow; they 
need to know where to grow. Without going into too 
much detail, there have been a few studies that attempted 
to help guide the stem cells to where they belong through 
introducing different factors into the mix. One such study 
showed they can induce the formation of multi-digit frog 
limbs in post-metamorphic specimens (Lin, et al., 2013). 
Another study attempted to replicate the in-vivo niche 
of a multifaceted limb through genetic modification of 
BM-MSCs to produce blastemal-like cells. After injecting 
the blastemal-like cells they noticed the presence of digit 
patterning and they achieved complete regeneration of 
an amputated digit tip (Taghiyar, et al., 2017). According to 
this author that cell sources with BC qualities are able to 
provide a the highly complex signals required for regen-
eration (Taghiyar, et al., 2018).
Immune-Based Approach
Immune cells such as monocytes and tissue resident 
macrophages seem to be an important element in the 
regulation of tissue repair, regeneration, and fibrosis. 
Post injury, these cells begin to function significantly dif-
ferent. They begin to produce inflammatory mediators 
and growth factors that enable the regeneration pro-
cess (Taghiyar, et al., 2018). In 2013 a study showed the 
important part that macrophages play in the successful 
development of new limbs in amphibians (Godwin, et 
al., 2013).
Although we noted above that it seems the more so-
phisticated the immune system is the less of a regenera-
tive ability there will be, there still seems to be a role for 
at least some immune cells to play. Systemic macrophage 
depletion has been shown to prevent limb regeneration 
in axolotls during the first 24 hours after amputation. A 
study found that the depletion of macrophages caused 
an increase in inflammatory factors and a decrease in 
anti-inflammatory cytokines. In addition, certain growth 
factor levels decreased significantly causing dedifferen-
tiation markers to become dysregulated and disrupted 
blastema formation (Godwin, Rosenthal, 2014). Another 
study found that a wide arity of proinflammatory and 
anti-inflammatory chemokines and cytokines can be 
found immediately after an injury in axolotl limb tissue 
(Godwin, Rosenthal, 2014). In addition, similar to mam-
malian wounds, various leukocytes travel to the site of an 
injury and many of them persist throughout the begin-
ning of blastema formation. Despite this we do know that 
a severe inflammatory response promotes fibrosis and 
therefore obstructs the successful patterning needed to 
regenerate a new organ (Eming, et al., 2009) so it seems a 
proper balance needs to be achieved.
While immune-based approaches will not be able to 
induce a regenerative capacity in humans they may help 
improve other approaches when used simultaneously. To 
achieve the proper balance mentioned above we need 
to be able to distinguish subpopulations of immune cells. 
However, due to the lack of reliable markers we have 
not been able to make good progress thus far.
Genetic-Based Approach
Although there has been a “proof-of-concept” studies 
that indicates there is a link between  genes and cell 
therapy in terms of regeneration as well as tremendous 
progress in gene-based strategies, I have not been able 
to find any clinical trials that have used this approach. 
The general idea of this approach is to genetically mod-
ify specific cells so that the cell can then regulate cell 
differentiation. It could be the reason why we have not 
seen any clinical trial is because of the lack of safe and 
efficient methods of doing so. On one hand, viral vectors 
achieve high transfection rate, but they have significant 
safety concerns. On the other hand, although non-viral 
vectors are relatively safe, they do not achieve efficient 
transfection rates (Taghiyar, et al., 2018). However, as 
new technological innovations, specifically CRISPR/Cas9, 
begin to show promise they may allow for clinical trials 
to begin. A review of gene-based therapies noted the op-
portunities that CRISPR/Cas9 holds because of its widely 
acclaimed abilities and relative ease of use (Janssen, et al., 
2016). Today the vast majority of CRISPR/Cas9’s use case 
has been in basic research (i.e. knockout mice) but that is 
slowly starting to change.
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Conclusion
It seems probable that the future will see regeneration 
of complete organs and limbs. Perhaps it will be in vitro 
at first but eventually in vivo as well. New breakthroughs 
have been able to apply many of the techniques employed 
by species that have a natural ability to regenerate to 
ourselves. Whether it is the biodome or the 3D printing 
or tissue engineering, it seems that whatever final solu-
tion we come up with will require us to employ multiple 
tactics. It also seems that different organs and limbs will 
require different approaches a well.
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Integrin α6β4 is a membrane protein which is expressed in both normal and cancerous epithelia . In normal cells, it is involved 
in adhesion to the basal membrane . In carcinomas, however, it takes on cell signaling roles related to survival and migration . Due 
to its key role in cancer progression, it is now being considered as a therapeutic target . This paper examines how we can affect 
integrins, with a specific focus on integrin α6β4, to reinforce their ability to prevent migration of cancer cells and progress toward 
metastasis .
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Methods
Data was collected using ProQuest, PubMed databases, 
and the National Library of Medicine. The images and di-
agrams can be found in the research articles referenced.
Introduction
Integrin α6β4 is a membrane protein found on the basal 
side of epithelial cells. It is a member of the integrin fam-
ily of proteins. Integrins are heterodimers which are im-
bedded in cell membranes and signal allosterically; ligand 
binding to extracellular binding sites causes conforma-
tional changes in the integrin which ultimately affect their 
cytoplasmic domains. These domains link to the cell’s 
cytoskeleton and thereby perform signal transduction. 
As much as their signaling works outward-inward, their 
signaling also works inward-outward. Integrins’ position 
in the cell makes them a key component in signaling, cell 
migration, and cell adhesions. Each integrin has a distinct, 
specific function, and, therefore, they have diverse ligands. 
Many integrins, including α6β4, can be turned on or off 
and need to be activated by tyrosine kinases or growth 
factors in order to bind to their ligands. 
Integrin α6β4 is different from other integrins because 
it has a unique β subunit, with an atypically long cytoplas-
mic domain which connects to the keratin intermediate 
filament system, as opposed to the microfilament system. 
The α subunit binds to its ligand, laminin 332, in the extra-
cellular matrix. Through mediating the interactions with 
laminin and keratin, integrin α6β4 is the core component 
of the hemidesmosome, a protein complex which attach-
es basal epithelial cells to the basement membrane.
Normally, integrin α6β4 is involved in hemidesmo-
somes and contributes to tissue stability. Cancerous cells, 
however, lack hemidesmosomes and integrin α6β4 is lo-
calized at the leading edges of metastasized carcinoma 
cells. Integrin α6β4 interacts with many cancer-related 
growth factors such as epidermal growth factor receptor 
(EGFR). Significantly, integrin α6β4 activates phospho-
inositide 3-OH kinase (PI3K), a key signaling molecule for 
carcinoma invasions. 
Because of integrins’ unique positioning in the cell and 
in cell signaling, they are highly involved in development 
of cancers. At times, integrins can inhibit pathways, and 
at times they can activate pathways instead. Therefore, 
integrins should be considered as a possible target for 
treating cancers. Integrin α6β4 can be considered as a 
model, as it attaches cells to the basement membrane and 
can contribute to invasion and metastasis of carcinomas. 
However, before examining cancerous cells, it is neces-
sary to understand the behavior of integrins in normal 
epithelial tissue.
Integrin α6β4 in Regular Cells
In healthy epithelial cells, integrin α6β4 occupies a central 
place in the hemidesmosome, a protein complex which 
connects epithelial cells to the basement membrane. 
There are two kinds of hemidesmosomes: type 1, which 
is found in stratified and pseudostratified epithelia (such 
as in the epidermis) and type 2, which is found in simple 
epithelia (such as in the intestine). In the more complex 
type 1 hemidesmosomes, integrin α6β4 facilitates the in-
teractions with most of the proteins involved, including 
the intracellular proteins plectin and BP180, the trans-
membrane proteins BP230 and tetraspanin CD151, and 
the extracellular protein laminin 332, which is part of the 
basal lamina (Walko et al, 2015). In the simpler type 2 
hemidesmosomes, the only components are plectin, lami-
nin, and integrin α6β4, which mediates the interactions 
between the other two. Integrin α6β4’s presence even in 
these simplified hemidesmosome proves that it is essen-
tial for the adhesion of epithelial cells to the basement 
membrane below (de Pereda et al, 2009). Additionally, 
mice missing β4 exhibited pathology similar to junctional 
epidermolysis bullosa, a human disease characterized by 
fragile skin that blisters quickly due to the basal layer’s 
separation from the basement membrane. The epitheli-
al tissues of the mice, both simple and stratified, lacked 
hemidesmosomes and did not adhere normally (Dowling 
et al, 1996).
The α6 subunit is homologous to other integrin α sub-
units. α6, like many other integrin protomers, associates 
with more than one β subunit. For instance, α6β1 is an 
integrin found in the retina and cortex, and is linked to 
disorders of those tissues (Hynes, 2002). When it is found 
in epithelial cells, however, it is exclusively associated with 
β4 and binds to laminin as its ligand. α6 is made up of 
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1,055 amino acids, with the first 1,011 outside the cell, 
36 in the transmembrane region, and 19 in the cytoplasm. 
(Tamura et al, 1990). The amino domain has 7 homolo-
gous repeats, which were found to make up a 7-bladed 
β propeller (Kamata et al, 2001). It is made up of two 
polypeptides, a heavy chain and a light chain, which origi-
nated from one polypeptide but which were cleaved using 
post-translational modification.  They are joined by a di-
sulfide bridge, similar to α5, αv, α11b, and αP52. However, 
it does not contain the insert domain near the amino ter-
minus that other α subunits possess (Tamura et al, 1990). 
β4 has 710 amino acids in its extracellular region, with 
cysteine conservation of that region the same as that of 
other β subunits. It has a 23 amino acids in its transmem-
brane region and has 1089 amino acids in its cytoplasmic 
region (Tamura et al, 1990). The cytoplasmic domain is 
made up of 5 globular domains. From the membrane to-
ward the inside of the cell, they are: a Na+- Ca+ Calx-β 
exchange motif, a pair of fibronectin type III domains 
(FnIII-1,2), and another pair of fibronectin domains (FnIII-
3,4). Between the two pairs of FnIII domains, there is a 
flexible connecting segment (CS), and after the second 
set, there is a c-terminal tail (Walko et al, 2015). There 
are 5 possible N-glycosylation sites, all of which are gly-
cosylated (Tamura et al, 1990).
Over time, a clearer picture of α6β4 has been formed. 
Scanning electron microscopy revealed that both sub-
units have a large globular head and a stalk portion which 
then traverses the cell membrane. The two protomers 
complex by binding their heads together (Luo, 2007). α6’s 
amino domain contains a 7-bladed β propeller domain, 
which is made up of 7 four-strand β sheets similar to 
those found in other integrins, which is topped by a ligand 
binding site. However, it lacks the “insert” domain, other-
wise known as a Von Willebrand Factor A domain, which 
has a MIDAS (a cation coordination site), that is found 
imbedded in the propeller of the majority of integrins 
(Kamata et al, 2001). This makes sense because only integ-
rins that are exclusive to chordates have this domain, and 
α6β4 is homologous to that of more primitive species. 
When an integrin has this insert domain, cation coordina-
tion to the MIDAS site causes a conformational change in 
the protein, pulling part of the α6 head further down and 
allowing the ligand to bind to its binding site. 
Ligand binding occurs differently in integrins lacking this 
insert domain like α6β4. In this integrin, β4 has its own 
insert domain with a MIDAS motif, which, when inactive, 
is in contact with α6’s propeller. When the C-terminus 
of β4 moves downward, or when a cation binds to the 
MIDAS, it pulls the rest of the protein, exposing more of 
the propeller surface to allow for a greater affinity for 
ligand binding (Hynes, 2002). When priming and ligand 
binding occur, a large-scale conformational change over-
comes both subunits. In their resting, low-affinity phase, 
both subunits’ stalks are bent downward in the middle 
in a genuflected position, with their intracellular domains 
touching. When ligand binds, the subunits straighten in a 
switchblade-like motion and the legs separate, exposing 
binding surfaces. This is one instance of allosteric signaling 
in integrins (Luo, 2007).
The majority of connections in the hemidesmosome 
occur with the large intracellular domain of β4. The four 
FnIII domains have a conserved hydrophobic core, with 
9 out of 11 identical residues, but their outer surfaces, 
which are exposed to solvent, are entirely different, so 
they can bind to different groups (Alonso-Garcia et al, 
2015). The critical interaction within the hemidesmo-
some is between β4 and plectin. Plectin binds to the IFs 
in the cell, while α6’s interaction with β4 allows it bind 
to its ligand, laminin. The two proteins join at β4’s second 
Fn-III domain and at plectin’s actin-binding domain (ABD). 
This complex is formed by three sets of ionic interac-
tions: between R1225 of β4 and D151 of plectin, between 
R1281 of β4 and E95 of plectin, and between E1242 of 
β4 and R98 of plectin. Missense mutations in one of the 
residues involved in these salt bridges disturbs the inter-
action with plectin. The first 7 residues of the connecting 
segment also play a part in this interaction by extending 
the binding surface of the Fn-III domain. The first FnIII 
domain also contributes to the interaction through a hy-
drophobic pocket made up of I1163, Y1187 and C1190, 
which interacts with an R-side chain in plectin. When β4 
binds to plectin, a conformational change is triggered in 
β4; in unbound β4, part of the CS is folded over FnIII-2 
and engages in antiparallel H-bonding with it. In bound β4, 
that part of the CS is unbent and may reveal binding sites 
for other proteins in the hemidesmosome, like BP230 
and BP180 (de Pereda et al, 2009). 
Integrin α6β4 in Wounded Cells
Although integrin α6β4 is associated with cell adhesion, 
it is also involved in signaling pathways associated with 
cell migration, differentiation, and proliferation. These 
processes assist in healing wounds. This is indicated by 
its localization to the front edge of cells migrating into a 
wound.  Additional proof can be seen in an experiment 
involving A549 (adenocarcinomic human alveolar basal 
epithelial) cells. When the β4 gene was knocked down, 
the cells migrated less processively than the controls. 
When the α6 gene was knocked down, the cells migrated 
both less processively and more slowly. Examination of 
keratinocytes has revealed that wild-type keratinocytes 
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move on a straight line along their matrix of laminin, while 
β4-deficient keratinocytes move in a circular fashion. All 
of this shows that integrin α6β4 plays an essential role in 
healing wounds (Colburn, Jones, 2017).
In order for cells to migrate toward a wound bed, the 
hemidesmosomes need to disassemble, a process that 
begins from the cytoplasmic domain and then contin-
ues in the extracellular domain. β4 serine residues are 
first phosphorylated by tyrosine kinases to separate β4 
from its binding partner, plectin; this is stimulated by 
epidermal growth factor (EGF) (Mainero et al, 1996), as 
well as protein kinase C (Rabinovitz, et. al. 1999). After 
β4’s phosphorylation, the rest of the connections in the 
hemidesmosome are then severed (Walko et al, 2015). At 
this point, α6β4 detaches from the intermediate filament 
(keratin) cytoskeleton and instead associates with the 
actin cytoskeleton. It becomes involved in the formation 
of lamellae and filopodia, which are protrusions of the cell 
membrane that give the cell motility.
Epithelial cells involved in wound healing are similar to 
metastasizing carcinoma cells, allowing comparisons to be 
drawn between them. In both cases, there is a lack of 
polarization in the cells and an induction of migration. 
(Rabinovitz et al, 2015). Importantly, many of the same 
mechanisms are involved, including the coordination with 
growth factors, the disassociation from the hemidesmo-
some, and the formation of lamellae and filopodia.
Integrin α6β4 in Carcinoma
In many types of carcinomas, high levels of integrin α6β4 
correlate with the invasiveness of the cancer, as well as 
the patient prognosis. For example, in basal-type breast 
cancer, which is a highly aggressive form of breast can-
cer, a β4 “gene signature” was associated with decreased 
time to tumor recurrance and a smaller chance of pa-
tient survival (Lu, 2008). Other research shows similar 
correlation with elevated β4 expression in other invasive 
phenotypes of squamous cell carcinomas, including some 
kinds of bladder (Grossman et al, 2000), cervical (Jeffers 
et al, 1997), head and neck (Kurokawa et al, 2008), lung 
(Stewart et al, 2016), and pancreatic (Cruz-Montseratte 
et al, 2007) carcinomas. Interestingly, although thyroid 
cells do not normally express α6β4, it has been found 
in thyroid carcinomas (Kitajiri et al, 2002). In addition to 
overexpression of α6β4, it is also located throughout 
multiple layers of cells in tumors, as opposed to its nor-
mal concentration of the basal side of the epithelial cells 
(van Waes et al, 1995).
However, in some varieties of cancer, integrin α6β4 
expression is correlated with tumor suppression. For 
example, in prostate carcinomas, α6β4 is downregulated 
(Nagle et al, 1995). Also, when α6β4 was added to cells 
from the RKO cell line, a colon carcinoma cell line which 
is missing β4, the result was partial G1 arrest and apopto-
sis (Clarke et al, 1995). Because this integrin is associated 
with both growth and migration, but with suppression as 
well, it may be hard to target as a treatment for cancer. In 
order to examine treatment options, an in-depth look at 
the mechanism of action of integrin-implicated signalling 
pathways must take place.
Integrin α6β4 Signalling Mechanism
When integrin α6β4 is released from hemidesmosomes, 
it leads to altered signals promoting tumor cell growth, 
invasion and metastasis (Lipscomb, Mercurio, 2005). Once 
free from the hemidesmosome interaction, integrin α6β4 
can bind or cooperate with many different molecules or 
growth factor receptors to activate various cell signal-
ling pathways. Integrin α6β4 can bind directly to its reg-
ular ligand, laminin, activating both phosphatidylinositol 
3-kinases (PI3K) and RhoA small GTPases. Alternatively, 
it can cooperate with various growth factor receptors, 
including those in the EGFR (epidermal growth factor 
receptor) family, such as ErbB-1,2, and 3 (Guo et al, 
2006), as well as c-Met (Chung et al, 2004), Ron, LPA1 
and LPA2 (O’Connor et al, 2012). This leads to intensifi-
cation of signaling through PI3K, AKT, MAPK and the Rho 
small GTPases, as depicted in Figure 1. Integrin α6β4 can 
also promote tumor progression through transcriptional 
regulation. It has been shown to increase the expression 
of invasive and metastatic proteins such as the epithe-
lial to mesenchymal transition (EMT)-associated protein 
S100A4 (Stewart, O’Connor, 2015).
Figure 1 (Stewart, O’Connor, 2015)
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Integrin α6β4 is involved in the PI3K pathway, a signal-
ing pathway known for promoting carcinoma progression 
(Shaw et al, 1997). However, the cytoplasmic domain of 
the integrin β4 subunit does not have a consensus-bind-
ing motif for the regulatory subunit of PI3K , so direct ac-
tivation of the pathway does not seem possible. One pos-
sible mechanism for integrin β4-mediated activation of 
PI3K involves insulin receptor substrate-1 and −2 (IRS-1 
and IRS-2), which act as signaling intermediates facilitating 
integrin α6β4-mediated PI3K activation. Ligation of inte-
grin α6β4 promotes phosphorylation of IRS-1 and IRS-2, 
and then activation of PI3K (Shaw, 2001). Additionally, in-
tegrin α6β4 cooperates with ErbB-2 to promote PI3K-
dependent invasion (Gambaletta et al, 2000). Integrin 
α6β4 has also been shown to localize to lipid rafts in the 
membrane, allowing it to recruit other receptor tyrosine 
kinases, and thus allowing it to activate PI3K (Gagnoux-
Palacios et al, 2003).
ErbB-2 is one of the members of the EFGR family which 
signals for invasion and aggression in breast carcinoma. 
Integrin α6β4 has been shown to associate with ErbB-2 in 
multiple breast carcinoma cell lines (Falcioni et al, 1997). 
Although ErbB-2 is implicated upstream of PI3K, ErbB-2 
does not have a binding site for the regulatory subunit of 
PI3K. ErbB-2, as a receptor tyrosine kinase, must dimerize 
with another receptor to function. In this case, it dimeriz-
es with an ErbB-3, a different EGFR receptor. Erb-B3 has 
a binding site for PI3K’s regulatory subunit, and this het-
erodimer is a strong activator of PI3K. There is a positive 
association between integrin α6β4 and ErbB-3 expres-
sion in patient-derived tumors (Folgiero et al, 2008).
Other receptor tyrosine kinases that cooperate with 
integrin α6β4 include c-Met, which is activated by HGF 
(hepatocyte growth factor); a complex of α6β4 and 
c-Met was shown to promote HGF dependent invasion 
(Trusolino et al, 2001). Ron, a tyrosine kinase receptor 
closely related to c-Met, has been shown to form a com-
plex with integrin α6β4 that induces hemidesmosome 
disassembly and the relocation of integrin α6β4 to mo-
tility structures. Ron activation is important in pancreatic 
carcinoma progression, and it interacts with the integrin 
β4 subunit in this setting to disrupt the association be-
tween integrin β4 and plectin (Yu et al, 2012).
Integrin α6β4 also upregulates the Rho family of small 
GTPases. The Rho family of small GTPases control the 
reorganization of the actin cytoskeleton required for cell 
motility (Machacek, et. al. 2009). The activation of RhoA 
leads to lamellae formation, as well as the generation of 
contraction forces that enable cell migration (O’Connor 
et al, 2000). Significantly, RhoA generally controls the gen-
eration of stress fibers rather than lamellae formation, 
suggesting that integrin α6β4 changes RhoA’s function to 
facilitate tumor invasion (Stewart, O’Connor, 2015).
Integrin α6β4 can also stimulate angiogenesis by en-
hancing signaling through the protein kinase ERK and 
transcription factor NF-κB. Studies using knockout mice 
carrying a deletion in the signaling domain of the integ-
rin β4 subunit displayed reduced angiogenesis in a retinal 
neovascularization model, and developed smaller and less 
vascularized tumors after subcutaneous implantation. The 
same study demonstrated that the integrin β4 subunit 
could promote both bFGF (basic fibroblast growth fac-
tor)- and VEGF (vascular endothelial growth factor)-in-
duced angiogenesis by enhancing signaling through ERK 
and NF-κB (Nikolopoulos et al, 2004).
Cell Survival and Tumor Suppression
Returning to the paradox above, integrin α6β4 promotes 
either cell survival or apoptosis, depending on context. 
For instance, in normal epithelial cells, integrins promote 
survival when in contact with the extracellular matrix. 
However, once separated, the loss of integrin signaling can 
inhibit cell growth and promote anoikis, a form of apop-
tosis (Ruoslahti, Reed, 1994). Similarly, in cancer, at times 
integrin α6β4 acts as a promoter of cell survival, while at 
times it acts as a tumor suppressant.
To discover why these two different scenarios exist, 
a group studied two cell lines. In the RKO cell line, β4 
led to increased apoptosis, while in the MDA-MB-435 
cell line, β4 did not induce apoptosis. They discovered 
that the difference lay in the cells’ p53, a protein which is 
often implicated in cancer when mutated. RKO cells have 
wild-type p53, while MDA-MB-435 cells have mutant p53 
(Bachelder et al, 1999). Integrin α6β4 can trigger apop-
tosis through p53 activation in cells harboring wild-type 
p53; however, in carcinoma cells deficient in p53, integrin 
α6β4 promotes cell survival by activating the PI3K path-
way and through growth factors such as VEGF (vascular 
endothelial growth factor). This discovery suggests that 
tumors expressing high levels of integrin α6β4 in con-
junction with mutated p53 are resistant to apoptosis and 
will therefore display a more aggressive clinical course. 
Interestingly, an association between p53 mutations and 
integrin α6β4 overexpression is present in a number of 
aggressive human malignancies, including basal-like breast 
cancer, head and neck squamous cell carcinoma, and 
pancreatic ductal adenocarcinoma (Stewart, O’Connor, 
2015).
Treating Carcinomas Through Integrin 
Modification
Since integrins were discovered as molecules involved in 
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cancer, there has been a move to target them in cancer 
treatment. However, drugs developed to impact integrins 
have largely been unsuccessful. It’s possible that it is be-
cause the integrin-targeting drugs may only have moder-
ate affinity in vivo for integrin receptors, as shown by the 
doses used in clinical trials. Another reason may be that 
integrin antagonists work best when inhibiting early met-
astatic spread and not in advanced cancer stages, when 
cancer cells are already widespread (Paolillo, Schinelli, 
2017)
Another issue may be that the wrong integrins have 
been targeted. Not all integrins have been thoroughly 
explored as therapeutic targets, including integrin α6β4. 
That said, a common issue for all the integrins is that 
cells express multiple integrins at the same time, and if 
one would be targeted in treatment, the others might 
compensate for it. That explains why the drugs given were 
well tolerated with few ill effects, but also did not im-
pact the cancer. The solution would be to try and impact 
multiple integrins at once, but that might be difficult to 
achieve in a patient (Alday-Parejo et al, 2019).
The issue may also not be the stage or affinity, but the 
drug target itself. Most drugs designed for integrins target 
the integrin-ligand interaction; in this case, they would 
try to competitively inhibit the interaction between the 
integrin’s extracellular side and laminin 332. This could be 
a problem because integrins signal allosterically, so if an 
inhibitor would bind to the integrin’s ligand binding pock-
et, it could actually turn on the integrin and the signalling 
cascades could begin. The cytoplasmic domain may be a 
better option (Alday-Parejo et al, 2019).
Thus far, one group has worked on an inhibitor tar-
geting the cytoplasmic side of integrin α6β4. They found 
that curcumin, a yellow pigment derived from turmeric, 
inhibited the interaction between the cytoplasmic tail and 
EGFR, which is implicated in the PI3K pathway related 
to survival, invasion, and metastasis. EGFR is activated 
when the residues Y1068 and Y1045 are phosphorylated; 
when α6β4 was knocked out, there was significantly less 
phosphorylation, showing a connection between the two 
structures. They added curcumin to other cells and found 
that it had a similar effect on EGFR phosphorylation as 
knocking down α6β4. The hemidesmosomes in cells with 
curcumin remained stable upon stimulation with EGF 
(Soung, Chung, 2011).
Discussion/Conclusion
Integrin α6β4 plays an essential part in both regular and 
cancerous cells. Significantly, it contributes to the PI3K 
pathway, related to cancer aggression and survival. Integrin 
α6β4 should definitely be studied, both as a diagnostic 
tool and as a target for therapeutic intervention. As dis-
cussed above, it is a predictor of the cancer’s severity and 
can be used in a diagnostic setting. More research should 
be put into targeting its intracellular interaction with 
growth factors so that these pathways can be inhibited.
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Abstract
Those who suffer from infertility, either due to a congenital or acquired cause and cannot or are opposed to other means, such as sur-
rogacy or adoption, to have a child, are potential candidates for uterine transplantation .  Uterine transplantation is a form of allograft 
transplantation, meaning that it is a transplant of tissue from a donor who is genetically different from the recipient .  Additionally, it 
is a vascularized transplant, including donor blood vessels that will be sutured to the vasculature of the recipient (Testa et al . 2017) . 
This procedure has been attempted around the globe with varying levels of success ranging from delivery of a healthy child to 
necrosis of the graft and rejection of the transplanted tissue.  While there does not seem to be one specific reason that can account 
for the rejection of a uterus transplant, the main factor responsible for failure is problems with arterial inflow or venous outflow in 
the recipient . Other potential factors that may contribute include cervix-vaginal size differences between donor uterus and recipient, 
pathology of the donated uterus, immunosuppressants, and wait time from transplant to embryo transfer .  Advancements in robotic 
assisted hysterectomy to procure the donor uterus, using ovarian veins instead of uterine veins for venous outflow, and deceased 
donor uteri instead of living donor uteri are all promising ways that can streamline the transplant process and help transition the 
experimental procedure of uterine transplantation to an accepted clinical one .
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Factors that Account for the Success or Failure of this 
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Introduction
Uterine transplantation is a procedure where a uterus 
from either a live or deceased donor is surgically implant-
ed temporarily in a recipient, in order that the recipi-
ent can carry her own child in the transplanted uterus. 
The transplanted uterus is subsequently removed, either 
when a baby is born, if the pregnancy is terminated due 
to complications, or due to rejection of the transplant. 
Uterine Transplantation is an innovative treatment for 
those who are unable to carry a fetus in their own re-
spective uteri, either due to a congenital disorder, such 
as the absence of or an underdeveloped uterus, hyster-
ectomy, due to disease, cancer, endometriosis,  elective 
hysterectomy, or for transgender individuals who do not 
have a uterus (Testa et al., 2017).  Since uterine transplan-
tation is not considered a life-saving procedure, many are 
ethically opposed to the promotion and investment into 
such an experimental and costly surgery.
In this paper we will try to determine if the uterus 
can be transplanted successfully with childbearing results, 
and which factors are responsible for the rejection of a 
uterus transplant.
Materials and Methods
The Information contained in this review was found by 
searching the Touro online library general search, Ebsco, 
and Proquest databases using key terms such as “uterine 
transplantation.”  Pubmed and Google Scholar were also 
searched utilizing similar key words and phrases.
Candidates for Uterine Transplantation
People who express interest in uterus transplants gener-
ally suffer from what is known as uterine factor infertility, 
UFI (Arian et al., 2017), also known as absolute uterine 
factor infertility, AUI (Branstrom et al., 2020),  This can be 
due to a congenital cause, such as a condition known as 
Mayer-Rokitansky-Kuster-Hauser syndrome (MRKH), or 
Mullerian agenesis, which is caused by the “underdevel-
opment of the Mullerian duct, with resultant agenesis or 
atresia of the vagina, uterus, or both” (Oelschlager, 2018). 
Agenesis refers to the failure during embryological devel-
opment of an organ and atresia is where there is either 
an obstruction to the lumen, or an opening is abnormally 
narrowed. Since the Mullerian duct in utero is responsible 
for the development of the uterus, fallopian tubes, cervix, 
and the upper part of the vagina, when it fails to devel-
op in MRKH, all those structures, aside from the ovaries, 
are affected, and this often results in infertility.  Patients 
with MRKH are good candidates for uterine transplan-
tation because they have functioning ovaries, which are 
not included in the uterus transplant. Their oocytes can 
be extracted for in vitro fertilization, and they can have 
a biological child of their own genetics. Another class of 
those who are interested in uterine transplants include 
those who have absolute uterine factor infertility due to 
an acquired cause which resulted in hysterectomy, such 
as fibroid tumors, endometriosis, chronic pain, abnormal 
bleeding, malignancy, and obstetric complications.  In one 
study, out of the 239 people screened, one third sought 
treatment due to congenital UFI, while the other two 
thirds had acquired UFI.  Of the acquired group, half were 
due to benign conditions, 25.3% were due to gynecologic 
malignancies, and 24.7% had had prior obstetric compli-
cations that resulted in hysterectomy.  Although there 
were five transgender and one intersex individual, they 
were not included because they did not fit the inclusion 
criteria of the screening (Arian et al., 2017).  In anoth-
er 2017 study, candidates similarly included those with 
MRKH, acquired conditions such as irreversible intra-
uterine adhesions, fibromas that could not be operated 
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on, and those who had lost their uterus from either be-
nign or malignant pathologies or postpartum complica-
tions (Testa et al., 2017).
Donor Eligibility
Different studies had varied qualifications included in their 
inclusion criteria.  Firstly, age was a consideration. In one 
study, age was determined to be from 40-60, though those 
under the age of forty were considered if a candidate had 
successful pregnancies in the past and did not want to have 
another pregnancy in the future (Testa et al., 2017).  Similarly, 
in other studies, with successful live-birth outcomes, a 32 
year old uterus was used, having borne 2 children prior to 
transplantation (Testa et al., 2018), and a 24 year old nul-
ligravid uterus was also used in successful transplantation 
(Chmel et al., 2019). However, in the first successful trans-
plant in 2014 that resulted in childbirth, a 62 year old uterus 
was used, and another a successful live birth resulted from 
a 63 year-old uterus at the time of birth, indicating that al-
though older uteri are not necessarily considered ideal, they 
have yielded live births.  (Brannstrom et al., 2020).  Since 
often enough recipient’s mothers want to be donors for 
their daughters, in some studies an older upper limit is given 
at 55-65 years of age (Kisu et al., 2018).
Additional donor requirements in some studies includ-
ed criteria such as testing negative for gonorrhea, chla-
mydia, syphilis and HPV, or previous vaccination against 
HPV.  Previous history of HSV-2 was considered if there 
were no current symptoms, and previous HPV was con-
sidered as long as a negative history was shown since 
the case of HPV. Last, one prior full-term live birth was a 
qualification (Testa et al., 2017).
Other requirements included normal-shaped uteri, 
proper perfusion through uterine vasculature, and the ab-
sence of uterine damage or disease  (Chmel et al., 2019). 
Nulliparous, Nulligravid, or Multiparous Donor Uterus
In choosing between a nulligravid uterus, one that has 
never carried a fetus, a nulliparous uterus, a uterus that has 
never born offspring, and a multiparous uterus, one that 
has born offspring, different studies included multiparity in 
the inclusion criteria while others did not.  According to a 
2019 study using a nulliparous deceased donor, nulliparity 
was considered an advantage in terms of graft recovery be-
cause the uterine veins and arteries were straight and not 
varicose, as opposed to what they noted with multiparous 
donors (Chmel et al., 2019).  However, that was an ob-
servation made using few subjects, and would need to be 
further investigated to determine if a significant difference 
between the straightness of vasculature exists between 
nulliparous and multiparous uteri.
Live vs. Deceased Donor
Before investigating the differences between a living as 
opposed to a deceased donor, it is important to define 
who is considered “deceased.”  In this paper, deceased is 
used to mean brain-dead.
There are certain advantages to using a deceased 
donor over a live donor.  Firstly, using a live donor to 
procure a graft includes certain risks associated with any 
surgical procedure, such as the use of anesthesia, and sur-
gery, and specifically possible urological, psychological or 
sexual dysfunction that may result, which are not consid-
erations that need to be taken with a deceased donor. 
Secondly more radical surgical dissection can be done 
using a deceased donor than a live donor, which enables 
surgeons to procure larger vessels, decreasing the risk 
of graft thrombosis. Additionally, a longer vaginal cuff can 
be procured from a deceased donor, allowing a better 
vaginal–vaginal anastomosis between the donated uterus 
and the recipient’s vagina (Chmel et al., 2019).
A clear disadvantage of using a deceased donor is the 
practicality; the nature by which deceased donor uteri 
become available is unpredictable.  Also, multidisciplinary 
teams and the recipient must go to the location of the 
donor.  Moreover, in many countries, physicians have less 
access to deceased vascularized composite allografts, and 
there is more restricted access to deceased donor uteri 
due to the complicated nature of surrogate consent if the 
deceased has not expressly stated the desire to donate 
before death (Chmel et al., 2019).
However, new innovations in procurement of the donor 
uterus, such as using robotically-assisted minimally invasive 
procedures, can likely decrease risks to live donors by min-
imizing tissue trauma and bleeding compared to open sur-
gery, which would favor using live donor uteri (Brannstrom 
et al., 2020).  In one minimally invasive, robotic surgery, the 
estimated blood loss of the donor was 400 mL, compared 
to the researchers previous surgeries using laparotomy in 
nine cases, which ranged from estimated blood loss val-
ues between 300-2400 mL, with an average of 920 mL 
(Brannstrom et al., 2020).   Using robotic technology can 
also provide more dexterity and seven degrees of free-
dom for the surgeon, not to mention micro-suturing can 
be done more efficiently through laparoscopic ports (Wei 
et al., 2017).  Also, minimally invasive robotic procedures 
can minimize both surgery and recovery time for the 
donor (Carbonnel et al., 2020).  Surgery time in one ro-
botic assisted surgery took 6 hours, which is the shortest 
surgery duration time recorded for uterus procurement 
for transplant.  That may be partially due to the choice of 
vasculature that the researchers procured with the graft, 
but nonetheless they were able to drastically reduce 
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surgical time (Wei et al., 2017).  In addition to a reduction 
in bleeding and trauma, minimally invasive surgery yields 
better cosmetic results, which may influence a candidate’s 
readiness to donate (Carbonnel et al.,  2020).
Steps involved in Uterine Transplantation
The process of uterine transplantation can be summa-
rized briefly, according to Testa, et al., as follows.  First, 
the successful transplantation of the graft, including per-
fusion, or blood flow through the grafted vasculature, 
and the assessment of vital tissue present on the cervix 
in cervical biopsy to determine if the tissue is accepted 
by the recipient.  Next, a normal menstrual cycle should 
result, which means that the grafted uterus is responding 
to the recipient’s hormones.  Stable immunosuppression, 
suppression of the recipient’s immune system toward the 
foreign uterus should be maintained.  Once immunosup-
pression is achieved, a fertilized ovum is implanted.  After 
implantation that results in pregnancy, the last step is the 
successful delivery of a hopefully healthy child.  At any of 
these steps, complications can occur that would result in 
the failure of the uterine transplant (Testa et al., 2017).
 Removing the donor uterus can be done through either 
laparotomy or laparoscopy.  In a 2017 clinical trial on five 
individuals, the laparotomic removal of the donor uterus 
is detailed.  The hysterectomy performed on the donor, 
however, is more complicated than a regular hysterecto-
my, due to the vasculature that needs to be connected 
to the recipient to allow graft inflow and outflow in the 
recipient. To allow that, the vascular pedicles, tissues con-
taining the arteries and veins of the donor uterus, were 
dissected completely.  The arterial vascular pedicle of the 
graft included the uterine artery, which supplies blood 
flow to the uterus, and a part of the internal iliac artery. 
The graft uterus was drained by the uterine and ute-
ro-ovarian veins, located between the uterus and ovary. 
A transverse cut was made below the cervix, in order to 
obtain a cuff that could sufficiently be anastomosed to the 
upper vagina of the recipient. After removal, arteries were 
reconstructed, when needed, through microvascular sur-
gery (Testa et al., 2017).
As for the recipient, the external iliac artery and the 
external iliac vein were dissected and the internal iliac ar-
tery patch of the donor was grafted to the external iliac 
artery of the recipient.  For venous outflow, the uterine or 
utero-ovarian vein, depending on which provided better 
venous outflow, was sutured to the external iliac vein of 
the recipient.  Once blood flow was reperfused, the cervix 
of the new uterus was connected to the vaginal vault of the 
recipient.  Blood flow was subsequently monitored by a 
doppler blood flow monitor to assess arterial inflow to the 
transplanted uterus.  Postoperatively, for the first five days 
Doppler ultrasounds were performed, cervical biopsy was 
done on the fifth day, MRI of the uterus was performed to 
evaluate blood flow, and cervical examination under anes-
thesia was done to determine if rejection of the transplant 
tissue occurred. To suppress the immune response of the 
host to the allograft, immunosuppressive drugs such as thy-
moglobulin, tacrolimus, mycophenolic acid, and a steroid 
taper were administered (Testa et al., 2017). 
Vasculature Involved
The common iliac artery bifurcates into the internal and 
external iliac arteries.  A branch of the internal iliac artery 
is the uterine artery, which supplies blood flow to the 
uterus.  Blood flow from the uterus is via the uterine 
veins, internal iliac veins, inferior vena cava, and to the 
heart.  Figure 1 shows a diagram of the vasculature where 
blood vessels attached to the allograft are connected 
slightly differently in the recipient than expected. At point 
A, the uterine artery, with a branch of the internal iliac 
from the donor is anastomosed to the external iliac ar-
tery, instead of the recipient’s own internal iliac artery.  At 
point B, the uterine vein of the donor uterus is attached 
to the external iliac vein of the recipient, instead of the 
internal iliac vein. 
One of the most difficult parts of uterus transplanta-
tion is securing a good venous outflow.  In most cases, 
the uterine veins are used, which often have thin walls, 
can vary in number, and often are not shown sufficiently 
in preoperative imaging.  During surgery, their dissection 
can be tedious, can increase the risk of bleeding, and in-
creases surgery time (Testa et al., 2018).  Moreover, the 
uterine vein has multiple branches and is close to the 
Figure 1 . This schematic diagram portrays the blood vessels 
supplying and draining the allograft uterus . Point A is the 
anastomosis of the uterine artery to the external iliac artery . Point 
B is the anastomosis of the donor uterine vein to the external iliac 
vein (Testa et al ., 2017) .
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ureter, which could result in accidental bleeding or in-
jury to the ureter (Carbonnel et al., 2020).  In one 2018 
successful trial, researchers sustained an allograft through 
the utero-ovarian veins alone, without uterine veins.  The 
researchers recommended using the utero-ovarian veins 
instead of the uterine veins, which are easier to identify, 
dissect, and provide for safer surgery on the part of the 
donor.  In another clinical trial, the proximal portions of 
the utero-ovarian veins were dissected as potential extra 
venous outflow, and ended up being used along with the 
uterine veins as well, due to the thinness of the uterine 
veins of the donor (Brannstrom et al., 2020).  Further, by 
using the utero-ovarian veins instead of uterine veins, a 
robotic laparoscopic approach is more feasible, which will 
again increase the safety and ease for the donor (Testa et 
al., 2018).  Also, the ovarian veins are more distant from 
the ureter, so surgeons will not be concerned about inad-
vertent damage to them (Carbonnel et al., 2020).  There 
can, though, be negative repercussions for the donor as-
sociated with using the ovarian veins as venous outflow. 
In transplant procedures done in both India and China, 
removal of the ovarian veins required bilateral oophorec-
tomy, removal of the ovaries.  The donor women were 
premenopausal, which increases their risk of morbidity 
and mortality (Brannstrom et al., 2020).  However, using 
ovarian veins for venous outflow still need to be further 
researched in the future to determine whether uterus 
outflow can in all cases be sufficiently maintained using 
the ovarian veins alone (Carbonnel et al., 2020).
Wait Time Between Transplant and Surgery
Common convention for many of the different uter-
us transplant trials has been to wait one year between 
transplantation and attempt at pregnancy, similar to 
other solid organ transplants.  In a 2019 study, for ex-
ample, embryo transfers were done starting at least 12 
months post-transplant, and were done in months 13, 
16, 19, and 23, until the last transfer resulted in clinical 
pregnancy  (Chmel et al., 2019).  This convention arose 
out of a recommendation from the American Society of 
Transplantation which suggested that recipients of organ 
transplants wait one year between the transplant and 
conception to decrease any risks that may result, such as 
acute rejection to the recipient, infection that could harm 
the fetus, immunotherapy that could potentially be toxic 
to the fetus, and to be sure that the allograft is functioning 
properly (Johanesson et al., 2019).
However, women who receive uterus transplants 
are generally healthy individuals whose surgical recov-
ery should resemble that of any surgical intervention. 
There is no reason to believe that tissue healing would 
be impaired, and immunosuppression does not seem to 
hinder tissue healing (Testa et al., 2018). Further, a uterine 
transplant, unlike other organ transplants, is not meant to 
be a long-term functioning transplant.  Its longevity is for 
about five years and for a maximum of two pregnancies 
(Johanesson et al., 2019). Some suggest that there is no 
scientific basis for waiting a year between transplant and 
embryo transfer, especially because immunosuppression 
must be terminated as soon as possible, to avoid renal 
failure, which could be a risk of long-term immunosup-
pression.  Decreased time on immunosuppressants also 
reduces costs and decreases waiting time for the recipi-
ent to give birth to her baby.  In their clinical trial, embryo 
transfer was done before the six month post surgery 
mark, and yielded successful results (Testa et al., 2018).  
To provide a groundwork for the amount of time to be 
waited, researchers laid down conditions to be met in the 
recipient, which if achieved, should be a signal to begin 
embryo transfer, as opposed to giving a generalized time 
recommendation for all uterine transplant procedures. 
The patient criteria are given in order as follows.  First, 
graft function should be stable.  An indication of graft sta-
bility would be menstruation, as it is a sign that the foreign 
uterus is responding to the recipient’s hormones.  Next, 
the absence of any acute rejection, which is determined 
via cervical biopsy.  Finally, stable immunosuppression 
achieved with low teratogenic, or carcinogenic, risk, and 
the recipient is at low risk for opportunistic infection, 
which is generally associated with those who undergo 
transplantation.  Once these conditions are met, embryo 
transfer should begin as soon as possible, even as early 
as three months post-transplant if the recipient is ready 
(Johanesson et al., 2019).
Complications in Pregnancy and Post-Operatively
Generally, pregnancies resulting from uterine transplanta-
tion do not reach full-term.  However, many studies have 
been successful in which participants have carried close 
to term.  In the first successful clinical study in Sweden, 
mean delivery for the six patients was at 35 weeks ges-
tation.  Besides the difficulty in reaching full term, there 
are some other pregnancy complications that have aris-
en.  Some patients from the previously mentioned study 
experienced preeclampsia.  It is possible though, that the 
preeclampsia, preterm delivery, and delivery by cesarean 
section may be related to the original infertility; MRKH 
sometimes presents with renal defects, such as having 
a solitary kidney, which could cause extra stress to the 
recipient during pregnancy, and has been generally associ-
ated with higher risk for preterm delivery, preeclampsia, 
and cesarean section (Kisu et al., 2018).
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Other major complications that have arisen post-oper-
atively in recipients include urinary tract infections, throm-
bosis, and hematoma.  The risk of thrombosis is because 
the vessels that are anastomosed are generally narrower 
and can get obstructed more easily than vessels attached in 
other organ transplants.  Hematoma could be the result of 
inadequate hemostatic processing, or cessation of bleed-
ing.  Care must be taken with re-bleeding from capillaries 
that are unligated or bleeding from the vaginal cuff (Kisu 
et al., 2018).  Also, in one particular clinical study, vaginal 
stenosis, vesicovaginal fistula, herpes, and cytomegalovirus 
were complications experienced by some of the recipients. 
Vesicovaginal fistulae can occur more frequently in patients 
with MRKH who have a neovagina, which is constructed 
due to an underdeveloped or absent vagina, and which 
needs to be separated from the bladder during surgery. 
This could lead to a fistula, or an opening between the 
bladder and vagina (Kisu et al., 2018).
Immunosuppressants During Pregnancy
Since the transplanted uterus is from a foreign donor, 
the recipient needs to be on immunosuppressive drugs 
to prevent her own immune system from mounting a 
response against the uterus.  There have been different 
recommendations as to the type of drug, based on trials 
from both pregnant women on immunosuppressants due 
to uterus transplants and other organ transplants.  The 
importance here is that the immunosuppressive drug 
should not be toxic to the developing fetus.  Therefore 
care must be taken to either prescribe immunosuppres-
sants that are not fetotoxic, or at least halt fetotoxic 
immunosuppressants when the uterus recipient begins 
embryo transfer. One immunosuppressive drug that has 
been implicated in spontaneous abortion in the first 
trimester and congenital abnormalities of the fetus is 
mycophenolate salts, which come in two different prod-
rugs, mycophenolate mofetil and mycophenolate sodium, 
that release the compound mycophenolic acid. The FDA 
classifies this drug as a Category D drug, meaning that 
there is evidence that it can cause risk to the fetus during 
pregnancy (Ponticelli et al., 2018). Therefore, if it is used 
following the transplant, there must be a waiting period 
afterward before embryo transplant begins.  In one uter-
ine transplant trial, mycophenolate mofetil was taken out 
entirely from the maintenance immunosuppression to 
decrease the time exposed to toxic medications for the 
fetus.  They were thus able to expedite the waiting time 
before embryo transfer.  Another drug, thymoglobulin, 
is considered a category C drug, meaning it is current-
ly unknown if risk exists to the fetus. Therefore, there 
should also be a wait time between pregnancy and usage 
of thymoglobulin in immunosuppressive therapy.  Other 
common immunosuppressants such as corticosteroids, 
azathioprine, and calcineurin inhibitors appear to be safe 
in doses prescribed for transplant recipients and are 
not associated with increased risk of congenital defects 
(Johanesson et al., 2019).
Reasons for Rejection of Transplanted Uterus
Although in some cases there is not a clear reason why 
the graft failed and rejection occurred, different studies 
have hypothesized reasons for the difference in outcome. 
A conclusion was that uterus pathology and venous out-
flow were largely responsible for three graft failures that 
occurred. The authors explained that assessment of vas-
culature preoperatively could be improved. Thus, imaging 
could be used to eliminate uteri with vasculature that is 
unsuitable for a uterus transplant. They explain that using 
a CT angiogram, while helpful in showing arterial blood 
flow, was not sufficient in their study to tell the length and 
diameter of veins. This was significant because a large part 
of the donor hysterectomy surgery time was spent in dis-
section of the uterine vein, which can taper into thinner 
tributaries where it joins with the internal iliac vein, even 
though it may appear satisfactory near the uterine body. 
The researchers concluded that MRI with venous phase 
would have been a better choice in imaging to view the 
uterine veins (Testa et al., 2017). Similarly, the research-
ers explained that the arterial vasculature was not of the 
expected quality; in some patients arterial pathology was 
present. In the preoperative imaging, the vessels appeared 
patent, however; in the three grafts that failed in their 
study, there was severe arterial disease present.  In one 
donor specifically there was thickening that resulted in 
over a fifty percent decrease in luminal size. Additionally, 
the researchers noted that in the first two of the five 
patients studied there was a downward kinking of the 
vein if the anastomosis was to the superior aspect of the 
host external iliac vein. In the other three patients they 
switched the venotomy position of the external iliac vein 
to the medial aspect to avoid kinking.  Further, the re-
searchers observed that procuring a patch of the internal 
iliac with the uterine vein provided a vessel with thicker 
and stronger walls.
Another potential reason that contributed to the failure 
of one of the transplants was the variation in size between 
the large cervix size of the donor and small size of the vag-
inal vault of the recipient, which made it difficult for vagi-
nal anastomosis. The researchers believed that the limited 
space, due to the larger cervix size contributed to the graft 
congestion, poor venous outflow, and pathologies present 
ultimately resulted in transplant rejection (Testa et al., 2017).
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As far as immune-system induced rejection, ostensibly, 
since the uterus carries a non-self, it would appear that 
pregnant uterus should have some immune tolerance. 
However, cervical biopsies have shown rejection in some 
cases post-operatively.  In one transplant study, 13 out of 
163 cervical samples taken from seven patients showed 
mild rejection after transplantation.  Steroid therapy helped 
patients reach remission, yet some developed rejection 
complications again during pregnancy, which is more dif-
ficult to manage and measures need to be developed for 
the future for treatment-resistant rejection.  Some suggest 
that the contact that the uterus has with the external en-
vironment, through the vagina, is responsible for the pros-
pect of rejection of the allograft (Kisu et al., 2018).
Ethical Implications
The practice of uterine transplantation is a subject of 
great ethical controversy.  As a non-life-saving procedure, 
it differs from other forms of organ transplantation, which 
are considered essential.  However, there are those who 
categorize it similarly to face, hand, or other vascularized 
transplants, which though not life-saving transplants, are 
nonetheless justifiable organ transplants for improving 
the quality of life of recipients.  Additionally, although 
uterine transplantation is considered an elective treat-
ment, it stands as the only medical treatment for abso-
lute uterine factor infertility.  Surrogacy and adoption are 
options for women with infertility, but for some women 
they are not adequate substitutes for the experience of 
pregnancy (Bayefsky and Berkman, 2016).
Once uterine transplantation transitions from an ex-
perimental procedure to a common clinical one, there 
are multiple points that will need to be taken into con-
sideration.  There will likely be a shortage of uteri for 
donation. While there are those who argue that uteri 
from women who have had hysterectomies should be 
used to supply organs for uterine transplants, often hys-
terectomies are done to remove unhealthy uteri, and 
are done in a way that does not leave the organ fit for 
transplantation, so those would not be feasible sources of 
uteri. Uterine transplants must also come with sufficient 
vasculature, which is generally not removed in an average 
hysterectomy.  Given that there will likely be a greater de-
mand than the supply of uteri, there will need to be a way 
to prioritize some individuals over others.  As far as for 
other organ transplants, such as heart, kidneys, or lungs, 
pediatric or younger individuals are generally prioritized 
over older adults, because adults have experienced child-
hood, and pediatric patients, if not given the transplant, 
may never have that experience.  In the same vein, it is 
sensible to say that when prioritizing women for uterine 
transplants, women who are of childbearing age should 
be given precedence over both women who are older 
and beyond reproductive age and adolescents who have 
not yet reached childbearing age.  However, in choosing 
between younger and older individuals within the span of 
child-bearing, women who are nearing the end of their 
childearing years should be given priority over younger 
individuals so that they can have their chance to have 
children before they age out of their childbearing years, 
while the younger individuals still have time.  “Normal 
childbearing age” is considered between the ages of 
15-49 according to the World Health Organization, and 
a standard for recipients should be within those limits.  A 
national standard, in limiting the age of recipients, should 
reflect medical assessment of the surgical and obstetric 
risks incurred to women of different ages, the risk to the 
fetus, and the probability of successful pregnancy.
Further, there must also be some sort of child-rearing 
capacity standard created that potential candidates will 
demonstrate before allocating a uterus, similar to how 
women who wish to adopt must meet certain criteria.
In differentiating between women with uterine infertil-
ity, different candidates have different needs with regard 
to treatment.  Some need only a transplant, while others 
may need IVF, egg donation, or sperm donation.  It is rea-
sonable to suggest that those with the least interventions 
necessary to achieve pregnancy should be given priority, 
in the same vein as choosing candidates for transplanta-
tion who are more likely to have successful transplanta-
tion (Bayefsky and Berkman, 2016).
Putting aside the controversy associated with can-
didates for treatment, there is also dispute about the 
source for donor uteri.  Procuring a uterus from a live 
donor can incur risk to the individual.  While there are 
innovations to the process of securing a uterus, through 
laparoscopic robotic procedures, as opposed to open lap-
arotomy, advancements will need to be made to decrease 
the risks for the donor.  Also, the advancement of using 
cadaveric or nonliving donor uteri will be important in 
fueling the future of uterine transplantation, though it will 
be a source of contention as to whether a person who 
has lost all brain function and is considered “brain dead,” 
will be categorized as deceased along with those whose 
circulatory and respiratory systems have failed.
Conclusion
Uterine Transplantation is a possible radical and innova-
tive surgical option for those who suffer from absolute 
uterine factor infertility.  Many studies have been done 
world-wide, which have contributed to the available data 
on the risks and ways to improve the process. While 
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there is no one factor that contributes to the rejection 
or success of a uterine transplant, certain factors have 
been implicated in the reasons for transplant failure or 
success.  Vasculature problems can account for some 
reasons for rejection, such as sclerotic vessels, or using 
thin-walled uterine veins that are difficult to dissect and 
may not provide adequate venous outflow.  Adequate im-
aging should be done to identify vessel pathology and the 
acceptability of the donor vasculature.   The possibility 
of using the utero-ovarian veins might be a good alter-
native to the uterine veins, though it can cause the onset 
of menopause and may increase morbidity in premeno-
pausal women, due to oophorectomy.  Also, mismatch in 
vaginal-cervix size between the donor and recipient may 
be problematic. Wait time between transplant and em-
bryo transfer and immunosuppressants are other factors 
to take into account. Advances in using deceased donor 
uteri, which allows harvesting longer length of vessels, or 
using live donor uteri procured through laparoscopic ro-
botic assisted hysterectomy can streamline the process. 
Although a promising treatment for those with absolute 
infertility, more research needs to be conducted to en-
sure its safety and to standardize the procedure.
References
Arian, S. E., Flyckt, R. L., Farrell, R. M., Falcone, T., & Tzakis, 
A. G. (2017). Characterizing women with interest in 
uterine transplant clinical trials in the United States: 
who seeks information on this experimental treatment? 
American Journal of Obstetrics and Gynecology, 216(2), 
190–191. doi: 10.1016/j.ajog.2016.11.1028
Bayefsky, M. J., & Berkman, B. E. (2016). The Ethics of 
Allocating Uterine Transplants. Cambridge Quarterly 
of Healthcare Ethics, 25(3), 350–365. doi: 10.1017/
s0963180115000687
Brännström, M., Dahm-Kähler, P., Kvarnström, N., Akouri, 
R., Rova, K., Olausson, M., … Bokström, H. (2020). Live 
birth after robotic-assisted live donor uterus transplanta-
tion. Acta Obstetricia Et Gynecologica Scandinavica. doi: 
10.1111/aogs.13853
Carbonnel, M., Dahm-Kähler, P., Revaux, A., Brännström, 
M., & Ayoubi, J.-M. (2020). Adapting surgical skills from 
robotic-assisted radical hysterectomy in cervical 
cancer to uterine transplantation: a look to an opti-
mistic future! Journal of Robotic Surgery. doi: 10.1007/
s11701-020-01058-7
Chmel, R., Pastor, Z., Novackova, M., Matecha, J., Cekal, 
M., & Fronek, J. (2019). Clinical pregnancy after deceased 
donor uterus transplantation: Lessons learned and future 
perspectives. Journal of Obstetrics and Gynaecology 
Research, 45(8), 1458–1465. doi: 10.1111/jog.13992
Johannesson, L., Wall, A., Putman, J. M., Zhang, L., Testa, G., 
& Diaz-Garcia, C. (2019). Rethinking the time interval to 
embryo transfer after uterus transplantation – DUETS 
(Dallas UtErus Transplant Study). BJOG: An International 
Journal of Obstetrics & Gynaecology, 126(11), 1305–1309. 
doi: 10.1111/1471-0528.15860
Kisu, I., Kato, Y., Obara, H., Matsubara, K., Matoba, Y., 
Banno, K., & Aoki, D. (2018). Emerging problems in 
uterus transplantation. BJOG: An International Journal 
of Obstetrics & Gynaecology, 125(11), 1352–1356. doi: 
10.1111/1471-0528.15230
Oelschlager, A.-M. E. A., Committee on Adolescent 
Health Care, North American Society for Pediatric 
and Adolescent Gynecology, & American College 
of Obstetricians and Gynecologists’ Committee on 
Adolescent Health Care. (n.d.). ACOG Committee 
Opinion No. 728: Müllerian Agenesis:... : Obstetrics & 
Gynecology. Retrieved January 2018, from https://journals.
lww.com/greenjournal/Fulltext/2018/01000/ACOG_
Committee_Opinion_No__728__M_llerian.41.aspx
Ponticelli, C., & Moroni, G. (2018). Fetal Toxicity of 
Immunosuppressive Drugs in Pregnancy. Journal of Clinical 
Medicine, 7(12), 552. doi:10.3390/jcm7120552
Testa, G., Koon, E. C., Johannesson, L., Mckenna, G. J., 
Anthony, T., Klintmalm, G. B., … Olausson, M. (2017). 
Living Donor Uterus Transplantation: A Single Centers 
Observations and Lessons Learned From Early Setbacks 
to Technical Success. American Journal of Transplantation, 
17(11), 2901–2910. doi: 10.1111/ajt.14326
Testa, G., Mckenna, G. J., Gunby, R. T., Anthony, T., Koon, 
E. C., Warren, A. M., … Johannesson, L. (2018). First live 
birth after uterus transplantation in the United States. 
American Journal of Transplantation, 18(5), 1270–1274. 
doi: 10.1111/ajt.14737
Wei, L., Xue, T., Tao, K.-S., Zhang, G., Zhao, G.-Y., Yu, S.-Q., 
… Chen, B.-L. (2017). Modified human uterus transplan-
tation using ovarian veins for venous drainage: the first 
report of surgically successful robotic-assisted uterus 
procurement and follow-up for 12 months. Fertility and 
Sterility, 108(2). doi: 10.1016/j.fertnstert.2017.05.039
59
Abstract
The term organoid refers to a miniature version of any organ of the body. An organoid is artificially produced in vitro from stem 
cells or tissue that possess the ability to recapitulate and form the three-dimensional structure of the organ they were once a part 
of . Scientists have learned to create a culture for the organoid that mimics its original micro cellular environment, allowing the 
3-D structure to self-organize and develop into miniature organs . The purpose of this paper is to explore the many advancements 
of organoid technology, and how this progress has benefited the medical field. Organoid technology allows for the observation of 
human organ development and disease, while also providing scientists with the opportunity to test drug interactions with these 
“mini-organs” (Barbuzano, 2017). Organoids also shed light on the future of artificial transplantation, providing replacements 
for dysfunctional organs and tissue. The advancements of organoid technology can potentially revolutionize the field of medicine, 
contributing to the progress of modern biology .
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Introduction
The human body is composed of a variety of tissue-specific 
adult stem cell populations. Adult stem cells of each organ in 
the body possess the ability to self-renew and generate all 
the different cell types present in that specific organ. Recent 
studies allow scientists to apply this knowledge of stem 
cells by culturing them in vitro. Through growing these cells 
under the right conditions, the cells can assemble miniature 
versions of the organs they were once a part of (Drost & 
Clevers, 2017). Through the development of new 3-D tech-
nologies and these ideas, scientists were successful in pro-
ducing artificial organs like the liver, placenta, stomach, lymph 
nodes, and brain. (John D. Loike and Robert Pollack, 2019).
These miniaturized models that mimic real organs have 
been termed ‘organoids’ (Huch, Knoblich, Lutolf, & Martinez-
Arias, 2017). Cells of an organoid can be derived from tissue 
stem cells, embryonic stem cells or induced pluripotent 
stem cells (iPSCs). These cells possess the ability to regener-
ate, allowing the tissue to perform its original function (Prior, 
Inacio , & Huch, 2019).
The ability to create and develop human tissue in a lab 
offers a major breakthrough in modern biology. The ad-
vancement of organoid formation provides scientists with 
the ability to study human development and disease and 
test therapeutic medicine through a personal approach. 
Organoids also offer hope for transplantation of function-
ing organs, eliminating the need for organ donations (Huch, 
Knoblich, Lutolf, & Martinez-Arias, 2017). Organoid research 
can also provide improvement when it comes to animal ex-
perimentation, bioethics, and gene therapy (Xinaris, 2019).
Method
This study was written by researching peer reviewed 
scholarly articles and medical journals to obtain the most 
accurate information on the advancements of organoid 
technology. The data was analyzed and evaluated from 
many different angles, using Touro College’s access to on-
line publications. Additional searches were done through 
Google Scholar, PubMed, and the Science Journal to accu-
mulate relevant information for the study.
Discussion
In 1998, the first successful organoid culture system de-
rived from adult stem cells was the small intestinal organ-
oids of a mouse. This development in organoid research 
led to many discoveries, among them the knowledge 
that Wnt signaling is crucial for maintaining the stem 
cell compartment of the mouse small intestine. Further 
observation brought about the awareness that ectopic 
expression of R-spondin, which communicates with Wnt 
and acts as a Lgr5 ligand, is necessary to include in a cul-
ture of intestinal stem cells as well, for ultimate function 
of the organoid (Drost & Clevers, 2017).
Following these observations and through his own re-
search, Toshiro Sato of Keio University confirmed that the 
artificial inclusion of growth factors present in the organ’s 
original stem cell niche is crucial for optimum efficiency and 
function of the organoid. Sato too researched and studied 
intestine stem cells. He observed that the 3D organoid 
forms from single Lgr5-positive Intestine Stem Cells. He re-
tained the architecture of the authentic intestine, and includ-
ed Wnt/R-spondin, epidermal growth factor (EGF), noggin 
(BMP inhibitor) and an artificial laminin-rich extracellular 
matrix in his in vitro culture. (Drost & Clevers, 2017).
In the body, cells are exposed to intricate and complex 
surroundings where they are involved in many chemical 
interactions (Prior, Inacio, & Huch, 2019). When creating 
an organoid derived from adult stem cells in vitro, the 
stem cell niche of the specific tissue must be duplicat-
ed. Common niche factors necessary when dealing with 
healthy human tissue include, but are not limited to, Wnt, 
R-spondin, noggin and EGF (Drost & Clevers, 2017). 
Inclusion of the precise concentrations of growth factors 
within the culture, and maintaining identical micro-archi-
tecture, allows stem cells to mature into organized tis-
sues, healthy or diseased (Dumont, Heremans, Jan et.al. 
2019). Incorporating these factors in the culture will 
ensure natural interactions among stem cells. It is cru-
cial to mimic these interactions when creating in vitro 
phenotypes to maintain the functions of the cells. This is 




To begin creating an organoid, stem cells must be isolat-
ed from embryonic stages or adult tissues and placed into 
a media with these natural growth factors. Development 
begins from a totipotent cell undergoing rapid cell divi-
sion. The divided cells become more restricted as they 
evolve. At the blastocyst stage, the outer cells mature 
into extraembryonic cells, while the inner cell mass of the 
blastocyst (ICM) is composed of pluripotent cells which 
possess the ability to evolve into tissue of the embryo 
proper. These pluripotent cells are isolated to form the 
embryonic stem cells. The next step in the developmental 
process is gastrulation. During this period, cells of the 
ICM mix together and perform morphogenetic move-
ments that are controlled by signaling factors like Wnt, 
fibroblast growth factor (FGF) and transforming growth 
factor-beta ligands. These signaling factors activate tran-
scription and differentiation into the three germ layers: 
endoderm, mesoderm and ectoderm. After forming the 
three germ layers, the progenitor cells become more 
specific and form the primitive structures of organs, thus 
developing into any tissues and organs of the body (Prior, 
Inacio, & Huch, 2019).
Transplantation and Xenotransplantation
The development of organ transplantation (OT) is “one 
of the most successful advances in modern medicine.” 
For struggling patients with end stage disease, transplan-
tation is usually their last hope to survive. One major 
problem we face today regarding OT is the lack of organ 
availability. We are unable to meet the exceptionally high 
organ demand (Bezinover & Saner, 2019). Arthur Caplan 
of NYU Langone Medical Center reports that the space 
between supply and demand of transplanted organs is 
“worse than it appears to be” (Caplan, 2014).
The phenomenon of creating human 3D cultures that 
duplicate authentic organs allows for extensive use of 
these organoids for many cell therapies, and as a poten-
tial substitute for whole-organ transplantation (Huch, 
Knoblich, Lutolf, & Martinez-Arias, 2017). Organoids have 
been successfully transplanted both orthotopically, in the 
organs, in vivo location, and ectopically, outside of the 
organ’s natural environment. Through both methods of 
transplantation, organoids were successful in undergoing 
cell maturation. These advancements show that organoid 
models can effectively mature and develop when in contact 
with natural signals provided by the in vivo environment, a 
crucial understanding for developing organoid transplan-
tation. An abundance of research in the field of organoid 
transplantation is done to further advance our knowledge 
of its capabilities. The use of immunocompromised mice in 
many experiments has paved the way for great progress. 
When transplanting organoids into these mice for matura-
tion, the organoids were positioned at highly vascularized 
sites, making it easier to control organoid engraftment and 
growth. This allows the organoid to develop for several 
months, without interfering with the mouse’s required 
organ function. Some of these sites include epididymal fat 
pads and underneath kidney capsules (Holloway, Capeling, 
& Spence, 2019).
More recently, scientists were successful in orthoto-
pically transplanting colonic epithelial organoids derived 
from human primary tissue into the murine colon. This 
study was supported by the Research Center Network 
for Realization of Regenerative Medicine project from 
the Japan Agency for Medical Research and Development. 
The experiment was done by removal of epithelial tissue 
from the mice. Results were most efficient when only 
one side of the colon mucosa was removed, to prevent 
obstruction of the murine colon. Following the removal 
of the epithelial cells, human colon organoids were trans-
planted. The xenografted organoids were observed by 
fluorescent endoscopic imaging. After many trials, long-
term engraftment of the human colon organoids was 
eventually successful and was monitored and observed 
by endoscopy for over 6 months. Immunohistochemistry 
of human-specific cytokeratin (KRT8/7) confirmed the 
presence of the human donated epithelium in the colon 
of the mouse. This study broadened our understand-
ing of transplantation through organoids in general, but 
also suggested that the location of the injury must be 
significantly large to successfully create a niche for the 
transplanted organoid. Small injuries requiring engrafted 
tissue, although also allowing for engraftment, proved to 
be more complicated. The tissue did not last as long as 
the engrafted tissue of the case of the larger injury, and 
eventually disappeared over time (Sugimoto, et al., 2017).
Personalized Medicine
Of the many exciting advancements brought about 
through organoid research, the ability to model diseases 
of specific patients in vitro can be of great benefit to med-
icine (Drost & Clevers, 2017). Scientists begin to predict a 
future in which organoid cultures derived from a patient 
can provide correct and effective therapeutic options for 
that particular patient. Induced pluripotent stem cells 
(iPSCs) are skin or blood cells that have been placed back 
into an embryonic-like pluripotent state. This allows the 
cells to mature and develop into any kind of human cell 
and is commonly used for therapeutic purposes. (Huch, 
Knoblich, Lutolf, & Martinez-Arias, 2017).
In regard to oncological patients, these organoids could 
allow testing of drug response, minimizing the load of 
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therapy. Organoids created from tumor-derived cells are 
obtained from human tumor biopsies. Induced pluripo-
tent stem cells or adult stem cells are taken from the 
biopsy and develop into organoids that mimic the can-
cerous organs. These organoids display identical tumor 
heterogeneity to their in vivo counterparts (Dumont, 
Heremans, Jan et.al. 2019).
Marc van de Wetering, a senior researcher dedicated 
to pediatric oncology, created a biobank of 20 tumor 
organoids derived from patients with colorectal cancer 
(CRC). He characterized the organoids by genes and per-
formed drug testing to observe the correlation of specific 
mutations with drug responsiveness. For example, only 
one of the tumor organoid cultures reacted sensitively 
to LGK974, an inhibitor of Wnt secretion. The sensitivity 
toward this inhibitor was observed to be connected to 
a mutation that was found in the negative Wnt regula-
tor. This study indicated that characteristics of tumors, 
histological and genetic, were mimicked precisely in the 
organoid. These findings can offer a promising future in 
understanding the correlation between tumor genetics 
and drug response (Drost & Clevers, 2017).
Additional studies have also been done to create or-
ganoid models from normal and neoplastic murine and 
human pancreas tissues. Pancreatic cancer is of the most 
fatal malignancies because of its lack of improvement from 
treatment and late diagnosis. Pancreatic organoids can 
develop quickly from cells derived from resected tumors 
and biopsies. These organoids display characteristics that 
are helpful in understanding drug and therapy response of 
the pancreas. Neoplastic organoids that are transplanted 
back into the body, reperform the whole tumor devel-
opment. The organoids develop from early-grade neo-
plasms into “locally invasive and metastatic carcinomas.” 
Organoids are an ideal model for genetic analysis because 
of their ability to be genetically duplicated. Close obser-
vation of murine pancreatic organoids presented altered 
genes and pathways during the onset and progression 
of the disease. After confirming these characteristics in 
human tissue, organoids have been deemed as an effective 
model system for discovering the nature of this deadly 
malignancy (Boj, et al., 2015).
Gene Therapy
Incorporating organoids into gene-editing through the 
use of tools like CRISPR/Cas9 technology offers the pos-
sibility of correcting gene mutations of patients. These re-
paired and healthy genes can then be transplanted into the 
patient (Huch, Knoblich, Lutolf, & Martinez-Arias, 2017). 
CRISPR/Cas9 also allows for manipulation of genes in or-
ganoid cultures, causing drug testing for specific genes to 
be more definitive and reliable (Dumont, Heremans, Jan 
et.al. 2019). Comparing a variety of organoids that are all 
derived from the same iPSC line allows scientists to ob-
serve mutations in specific genes, and the effects on tissue 
specification and development in organs when the genes 
of a patient carry a specific congenital allele. The ability to 
create organoids from the diseased tissue offers various 
methods for clinicians to explore, like computerized drug 
screening tests, or mirroring antibiogram tests to deter-
mine antibiotic susceptibilities (Huch, Knoblich, Lutolf, & 
Martinez-Arias, 2017).
Studies were done to prove the benefits that can be 
gained from adult stem cell-derived organoids with regard 
to hereditary diseases (Drost & Clevers, 2017). Recently, 
advancements in organoids have shown that CRISPR/ 
Cas9 technology can repair cystic fibrosis gene mutations 
(Huch, Knoblich, Lutolf, & Martinez-Arias, 2017). Dr. J.M. 
Beekman of the Regenerative Medicine Center Utrecht, 
along with some colleagues, created a modeled cystic fi-
brosis (CF) in vitro culture. The model was composed of 
cells obtained from CF patients through rectal biopsies, 
creating intestinal organoids. The cystic fibrosis trans-
membrane conductance regulator (CFTR) gene is re-
sponsible for encoding an anion channel that is expressed 
on the surface of epithelial cells. CFTR maintains fluid and 
electrolyte homeostasis. Cystic fibrosis is the result of a 
mutation in the CFTR gene. As a result of this mutation, 
epithelial ion transport is weak, and a build-up of viscous 
fluid becomes present in the respiratory and gastrointes-
tinal tract. CFTR is activated by forskolin, which increases 
intracellular cyclic AMP levels. In a healthy sample of in-
testinal organoids swelling was rapid. However, organoids 
derived from cystic fibrosis patients presented minimal 
swelling in comparison. It is now possible for research-
ers to test various drugs on different CF patient-derived 
organoids, depending on specific CFTR mutations. These 
findings shed light on a future of patient-specific treat-
ment strategies (Drost & Clevers, 2017).
The Liver
There are many diseases associated with the liver, and 
over two million deaths a year worldwide are related 
to liver complications like cirrhosis, viral hepatitis and 
hepatocellular carcinoma (Asrani, Devarbhavi, Eaton, & 
Kamath, 2018). The amount of deaths associated with 
liver disease calls for the advancement of liver organoids 
as treatments for struggling patients. Researchers like 
Meritxell Huch of Gurdon Institute and Takanori Takebe 
from Yokohama City University present their progress in 
the field of liver organoids. They were successful in cre-
ating ductal structures from adult liver and went further 
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to activate these structures to differentiate into hepato-
cytes capable of producing bile acid and maintaining cyto-
chrome activity (Muthuswamy, 2017).
The creation of the liver organoid has been further 
developed through the use of co-culture systems. Many 
studies reported that liver hepatocyte-like cells derived 
from human pluripotent stem cells (hPSCs) in 2D result-
ed in the cells developing immaturely and did not perform 
all functions of mature hepatocytes. Additionally, after 
implantation of these hPSC derived hepatocyte-like cells 
into immunocompromised mice, the cells operated with 
little effectiveness. Due to these poor results, research 
has been dedicated to creating more functional hPSC-de-
rived hepatocytes, to produce a liver organoid model 
that will function more efficiently. The use of co-cultures 
is thought to be the answer to this progress. When ob-
serving mice, researchers found endothelial cells to be a 
crucial cell type in the process of
liver organogenesis. Due to this finding, a hypothesis 
was formed that placing endothelial cells and mesenchy-
mal precursors with the hepatic endoderm in a co-cul-
ture will provide an environment that closely mimics in 
vivo development of the liver. This will give rise to ef-
ficient hepatocyte differentiation, ultimately generating a 
complex human liver bud organoid (Holloway, Capeling, 
& Spence, 2019).
The liver is made up of epithelial, stromal, endothelial 
and mesenchymal cells that all work together to carry 
out its functions. Hepatoblasts are the embryonic progen-
itor cells of the liver. At the time of organogenesis, these 
cells are set aside from the posterior foregut endoderm. 
Hepatoblasts communicate with surrounding signaling 
factors found within the mesenchyme, like FGF, BMP, he-
patocyte growth factor (HGF) and Wnt. These communi-
cations cause the hepatoblasts to evolve and modify until 
they can migrate into the adjacent mesoderm to form 
the liver bud (Prior, Inacio, & Huch, 2019). After creation 
of the hPSC-liver buds, transplantation of the liver buds 
into immunocompromised mice tested the functionality 
of these artificial structures. The hepatocytes of the liver 
bud were proved to be functional due to the presence 
of high sustained levels of albumin within the liver bud 
(Holloway, Capeling, & Spence, 2019). After the liver bud 
is formed, the hepatoblasts expand and differentiate to 
form hepatocytes and biliary epithelium. Meanwhile, the 
mesenchyme generates liver fibroblasts and stellate cells. 
The structure of the liver is formed completely when the 
hepatocytes and cholangiocytes mature further and the 
endothelium and mesenchyme are integrated (Tremblay 
& Zaret , 2005).
Artificial Ovaries
Of all gynecological cancers, epithelial ovarian cancer 
(EOC) is the fifth largest cause of cancer-related deaths in 
European women. EOC patients frequently relapse, with 
an expanding resistance to chemotherapy and targeted 
therapy. Consequently, further research is crucial for the 
advancement of therapy in EOC patients, and organoid 
development seems promising. Models of EOC organoids 
can contribute a constructive platform for drug testing 
and screening, and can ultimately be utilized as a person-
alized in vitro prototype for an individual patient.
High-grade serous ovarian carcinoma (HGSOC) is a 
tumor that arises from the serous tubal intraepithelial 
carcinoma (Dumont, Heremans, Jan et.al. 2019). The fallo-
pian tube epithelium (FTE) has been observed as the site 
where HGSOC originates (Yucer, et al., 2017). Therefore, 
observation of fallopian tube tissue can be very enlighten-
ing in discovering the nature of EOC. Mirjana Kessler of 
the Department of Infectious Diseases and Respiratory 
Medicine, through experimentation, created differentiated 
ovarian organoids from a single fallopian epithelial stem 
cell. These organoid models maintained their stability for 
over several months. This experiment uncovered the ex-
istence of fallopian tube stem cells for the first time. The 
creation of an ovarian organoid requires growth factors 
and microcellular substances, particularly Wnt and Notch 
pathways. The inclusion of Notch is especially important 
because it primarily regulates and maintains the stemness 
of these fallopian epithelial cells (Dumont, et al., 2019).
The urogenital system arises from the intermediate 
mesoderm (IM) of a developing embryo. The Müllerian 
duct within the urogenital system gives rise to the entire 
female reproductive tract (Yucer, et al., 2017). Following 
Kessler’s research, Nur Yucer of the Regenerative Medicine 
Institute at Cedars-Sinai Medical Center was successful 
in constructing Fallopian tube organoids (Dumont et al., 
2019). He created an in vitro culture of the Müllerian duct 
from induced pluripotent stem cells. Yucer then generated 
IM differentiation by adding pro-Mullerian growth factors, 
causing the fallopian tube epithelium to develop. The dif-
ferentiation of the cells was monitored by the addition of 
cell-related markers such as PAX2, GATA3, OSR1, WT1, 
and OVGP1. A 3D growth platform was set up for further 
development and maturation of FTE, which successfully 
caused the tissue to self-organize into an FTE organoid 
structure. When forming the FTE organoid, the canonical 
WNT signaling pathway proved to be crucial. Sub- set of 
WNT gene family members were also included in the 
culture, like WNT3a and WNT4. These genes were nec-
essary for generating the different phases of development 
and maturation of the Müllerian duct. WNT3a and WNT4 
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are also responsible for inhibiting male differentiation 
pathways. After three days of forming the culture, epithe-
lial buds formed from the flat cell sheets. The buds then 
became spheroids, which were put in Matrigel beads with 
pro-mullerian growth factors. The intermediate meso-
derm matured most at day 4, so spheroids were observed 
on days 3 to 6. Inclusion of a weak estrogen, phenol red, in 
Matrigel caused the complete organoid structure to form 
(Yucer, et al., 2017). This finding highlights the necessity 
of estrogen for the differentiating and maturing of the 
Fallopian tube. To maintain and stabilize fully developed 
organoids, both estrogen and progesterone must be pres-
ent. (Dumont, et al., 2019) This is because estrogen alone 
did not maintain the organoids for long periods of time.
More progress has been made in regard to EOC organoid 
research. Dr. Oded Kopper of NewStem efficiently produced 
organoids with epithelial ovarian cancer characteristics. He 
obtained cells from primary tumors or metastatic lesions. 
The organoids he created successfully retained identical ge-
nomic landscapes as the tumors they were derived from. 
Histological aspects and heterogeneity of the tumors were 
also maintained. (Dumont, et al., 2019)
Ovarian cancer organoids can be utilized to observe 
various tumor responses to chemotherapy and for 
drug-screening assays. Xenografting OC organoids also 
allows clinicians to test drug susceptibility in vivo. These 
are some of the many advancements and applications of 
ovarian cancer organoids (Kopper, et al., 2019).
Another major benefit of an artificial ovary is to pre-
serve fertility in patients suffering from cancer. An artificial 
ovary can allow women to fall pregnant after the dam-
aging effects of chemotherapy. (University of Erlangen-
Nuremberg, 2019) Ovarian tissue cryopreservation is the 
process of preserving reproductive potential in oncological 
patients after being exposed to gonadotoxic therapeutic 
agents. (Liverani, et al., 2019) Ovarian tissue cryopreserva-
tion involves the removal of a section or of the complete 
tissue of an ovary. This tissue is then preserved for use 
in the future. (Ben-Aharon, et al., 2016) Cryopreservation 
can be utilized by patients with aggressive malignancies 
who must receive instant gonadotoxic treatment. These 
women do not have the time to receive ovulation induc-
tion, and cryopreservation can be a great benefit. Although 
ovarian tissue cryopreservation can be of great assistance 
for many, cancer patients with moderate-to-high risk of 
ovarian metastasis are at too high of a risk. The process 
of cryopreservation introduces the possibility of malignant 
cells being reimplanted back into the patient.
A promising approach for these high-risk patients is 
the use of artificial ovaries. Isolating follicles from a pa-
tient’s ovarian tissue and reimplanting the follicles into 
an artificial ovary can guarantee that no malignant cells 
will be reintroduced to the patient. (Liverani, et al., 2019) 
Because follicles are isolated in a basement membrane, 
there is no interaction between capillaries, follicular cells, 
white blood cells and nerves. Therefore, there is no threat 
that malignant cells will be introduced back to patients. 
Artificial ovaries make it possible to transplant primor-
dial and primary follicles that were isolated to survive 
and could mature into follicles after transplantation. This 
permits sex hormones to be secreted, regulating oocyte 
maturation to the point where they are capable of fertil-
ization. In the artificial ovary, it is essential for the follicles 
to be supplied with an environment that mimics the nat-
ural human ovary. In order for the follicles to survive and 
develop, interaction with the ovarian extracellular matrix 
(ECM), as well as surrounding ovarian cells must be pres-
ent. For example, ovarian stromal cells are required to 
activate primordial follicles, while endothelial cells are 
necessary for vascularization, providing transportation 
of oxygen and nutrients, paracrine factors, and removal 
of metabolic waste. The presence of the ovarian ECM is 
responsible for maintaining 3D follicle structure, as well 
as other important roles. Therefore, all these factors must 
be present. (Dolmans & Amorim, 2019)
Drs. Teresa Woodruff and Ramille Shah of Northwestern 
University led a team of scientists in creating artifi-
cial ovary structures. The process utilized a 3D printer 
to create the structure that would hold the follicles. A 
stainless steel nozzle was used for the printer, which was 
around the width of a strand of hair. Five layers of gelatin 
filaments were printed at various angles. Tiny cylinders 
were punched through the sheets, creating pores to hold 
mice follicles. Nine mice were involved in the study, and 
all ovaries were removed. Seven of the mice received the 
structures with the follicles, and two received the arti-
ficial structures without follicles. Following the mating 
of these mice with male mice, three mice with artificial 
ovaries produced litters. The artificial ovaries also joined 
with the blood vessels of the mice, allowing for female 
hormones involved in milk production to be made. The 
hormones successfully traveled the mouse bloodstream 
to the breast tissue where it stimulated milk production 
(Piazza, 2018). The ability of an artificial ovary to restore 
endocrine function and provide an environment for follic-
ular development can be extremely useful for oncological 
patients in the future (Cho, Kim, Noh, & Ku, 2019).
Virology
The coronavirus disease-19 (COVID-19), caused by the 
SARS-CoV-2 virus is responsible for over 250,000 deaths 
globally. (Han, et al., 2020) The COVID-19 pandemic 
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proved to the world just how threatening newly surfacing 
viruses can be. Understanding the nature of these viruses 
rests in the use of in vitro cultures capable of viral rep-
lication. The use of organoids is now demonstrating its 
practicality when experimenting the tendencies of these 
deadly viruses.
The novel coronavirus first infected humans in 
December of 2019. Various research groups have been 
experimenting with organoids to better understand the 
nature and tissue tropism of SARS-CoV-2. Josef Penninger 
of the Institute of Molecular Biotechnology, along with 
his colleagues, created capillary and kidney organoids, 
both derived from human iPSCs. Through this research, 
Penninger proved that SARS-CoV-2 can infect both sites 
in the body. These observations help explain the ability of 
the virus to spread throughout the body and the damag-
ing effects on kidney function in infected individuals.
Multiple studies were done to establish whether the 
virus can infect the gastrointestinal tract. Intestinal or-
ganoids derived from adult stem cells were examined and 
presented high levels of angiotensin converting enzyme 2 
(ACE2), a receptor for SARS. The studies displayed that 
enterocytes, the most common intestinal epithelium cell 
type, were infected with the virus. These findings verified 
that the intestine is a potential site for SARS-CoV-2 in-
fection (Clevers, 2020).
Mart Lamers of Erasmus Medical Center, along with his 
colleagues, further investigated the ability of SARS-CoV-2 
to infect the intestines. The human small intestine epithe-
lium is composed of multiple cell types. The experiment 
consisted of 3D structures that displayed all cell types, 
grown in four separate cultures. Each culture displayed 
different amounts of ACE2, proving their ability to be 
infected with SARS-CoV-2. Through the use of electron 
microscopy, Lamers and his colleagues observed that the 
virus caused infection in mature and progenitor entero-
cytes alike. This study suggests that the use of human 
organoid models can provide researchers with beneficial 
resources for examining the nature of SARS-CoV-2 and 
other coronaviruses. (Aaas, 2020)
Since the primary infection site for SARS-CoV-2 is in 
the respiratory organs, research was done to create a 
lung organoid derived from human pluripotent stem cells 
(hPSCs). Development began with the differentiation of 
the hPSCs into definitive endoderm. The cells then fur-
ther progressed into the anterior foregut endoderm 
(AFE) and formed AFE/lung progenitor cells. Further 
specification and maturation of these cells eventually 
formed the lung organoids. The ability of these lung or-
ganoids to provide a platform for modeling COVID-19 
was then put to the test. The cultures were introduced 
to the SARS-CoV-2 virus, and after 24 hours viral RNA 
was detected. The use of immunostaining proved the 
presence of SARS-S protein in the lung organoids. Based 
on this research, scientists can utilize these organoids to 
observe the effects of various drugs on the coronavirus, 
by observing any decrease in the amount of markers 
present from the injected virus. (Han, et al., 2020)
Conclusion
Organoids possess the ability to model tissue structure 
and function with great accuracy, but more research is 
required to take full advantage of organoids. Organoids 
still lack vasculature, immune cells, and other cellular 
components that tissues communicate with and depend 
on in the body (Iakobachvili & Peters, 2017). Without all 
the essential cellular components of an organ, the use 
of organoid in human transplantation will be limited. 
Studying processes where these components are neces-
sary is therefore limited. (Souza, 2018) Efforts to improve 
the vasculature of organoids will provide nutrient supply, 
excretion of toxins and signaling that is present in the 
body. This research is presently making progress, though 
it is demanding and yet to be fully incorporated into stan-
dard tissue culture facilities. (Iakobachvili & Peters, 2017) 
Organoid technology brings up many ethical questions 
as well. For example, what might happen if scientists can 
successfully create a brain organoid? Utilizing a brain or-
ganoid for drug testing would be helpful, but it may pose 
an ethical issue to transplant this organoid into a patient. 
These matters must be addressed in the future. However, 
we do know that organoid technology is adding a whole 
new dimension to the medical field.
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Abstract
Maternal-fetal cellular trafficking is the bidirectional passage of cells between the fetus and mother during pregnancy. The 
presence of fetal cells in maternal circulation, brain, and muscles is known as fetal microchimerism . During pregnancy, fetal 
cells can be obtained from the mother’s blood for prenatal diagnosis of the fetus. Furthermore, it has been confirmed that fetal 
microchimerism persists decades later in women who have been pregnant . Investigation of the long-term consequences of fetal 
microchimerism is a frontier of active study, with preliminary results pointing to both beneficial and adverse effects. This review 
will examine the relevant literary information on fetal microchimerism during pregnancy and provide current knowledge regarding 
the long-term effects of naturally acquired fetal microchimerism .
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Matti Miller
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Introduction
Microchimerism is the presence of two genetically dis-
tinct cell populations in the same individual. Foreign 
cells and DNA are found in an individual’s plasma or 
tissues that originated from a genetically different indi-
vidual. Naturally acquired microchimerism is commonly 
observed and results from the maternal-fetal exchange 
of cells and DNA during pregnancy. (Gammill & Nelson 
2010) In pregnancy, there is transplacental two-way 
trafficking of living fetal cells from the fetus into the 
maternal circulation, and cells from maternal circulation 
impart in the fetus. (Naik, Shrivastava, Suryawanshi, & 
Gupta 2019) This paper provides an overview of the 
role of fetal cell microchimerism in autoimmune and 
cancerous diseases. The mechanisms by which fetal mi-
crochimerism is believed to modulate the protection 
against cancer or tumor progression will be discussed, 
along with future research directions. 
Methods
This document was written by researching peer-reviewed 
scholarly articles and medical journals to assess the 
newest research and methods in fetal microchimerism. 
The information and data were gathered from numer-
ous sources, including databases such as Google Scholar, 
Touro Library, The National Center for Biotechnology 
Information, and The National Institute of Health. Key-
phrases searched included, “fetal microchimerism,” “the 
effects of fetal microchimerism,” and “fetal microchi-
merism in autoimmune disorders.” All the content was 
carefully selected, compared, and analyzed to assure its 
validity and determine the articles’ standpoint.
Fetal Microchimerism
Microchimerism is the fetus’s cell legacy after pregnancy. 
Fetal stem cells can leave the fetus and migrate across 
the placenta to engraft in the maternal bone marrow and 
other tissues. The transfer of fetal progenitor stem cells 
begins four or five weeks after fertilization and continues 
throughout the pregnancy. This form of microchimerism 
occurs in both male and female embryos, but the detec-
tion of male microchimerism in maternal tissue is easier 
to detect due to the unique presence of Y-chromosome 
in the women. (Miech, 2010)   
Fetal microchimerism has been reported in the periph-
eral blood of women in cellular subsets, including lym-
phoid-lineage and myeloid-lineage cells. An experiment was 
done to evaluate microchimerism in CD66b sorted gran-
ulocytes. Granulocytes were isolated from the peripheral 
blood of healthy women. CD66b+ cells were then isolated 
by fluorescence-activated cell sorting, and a panel of poly-
morphism-specific quantitative assays was employed to 
investigate the presence of fetal and maternal microchime-
rism. One-third of the women tested positive for at least 
one form of microchimerism. 40% had maternal microchi-
merism compared to 15% who had fetal microchimerism. 
The maternal and fetal origin CD66b+ cells are strong evi-
dence for an active microchimeric hematopoietic stem and 
progenitor cell niche. Higher proportions of women might 
test positive for even larger quantities of microchimerism if 
more sensitive assays were available.  (Sunku, Gadi, Lacoste, 
Guthrie, & Nelson, 2010)
Fetal DNA in Maternal Plasma During Pregnancy 
Another study was undertaken to evaluate fetal DNA 
in maternal plasma and urine. DNA was isolated from 
plasma and urine samples of 80 pregnant women, ranging 
from 7 to 40 weeks of gestation. Their DNA underwent 
amplification for Y specific chromosome DNA via a nest-
ed polymerase chain reaction. The postpartum analysis of 
fetal gender showed that 25 women carried female fe-
tuses and 55 male fetuses. Among the 55 women bearing 
male fetuses, Y chromosome‐specific signals were detect-
ed in 96% of their plasma and 38% of their urine samples. 
(Al-Yatama et al., 2001) The detection of fetal sex chro-
mosomes with Y-chromosome-PCR has a specificity of 
100% and a sensitivity of 96%, which increases along with 
gestational age. This minor lack of sensitivity explains why 
Y-chromosome signals were only located in 96% of the 
plasma of pregnant women. (Rijnders et al.) The analysis 
of their results with respect to gestational age showed no 
significant difference in the Y chromosome‐specific DNA 
detection. These results showed that fetus‐specific DNA 
was detected in the maternal plasma by nested PCR. (Al-
Yatama et al., 2001) 
Fetal DNA is present in low concentration in maternal 
plasma increasing throughout pregnancy with a 0.1% in-
crease each week from 10 to 20 weeks’ gestation, followed 
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by a 1% increase each week from the 21st week until term. 
(Taglauer et al.) Clinical tests have tried to capitalize on 
this DNA to identify the baby’s sex, determine whether 
the child and mother have Rh incompatibility, and identify 
chromosomal disorders. (LeslieDec, et al. 2017) 
Many early investigations of fetomaternal cell traffick-
ing sought to develop methods whereby noninvasive 
prenatal diagnosis of genetic disorders could be achieved. 
(Gammill & Nelson 2010) Noninvasive testing would 
ameliorate the risk of fetal miscarriage associated with 
current invasive procedures such as amniocentesis. This 
non-invasive prenatal test is a blood test, and between 
25 and 42.5 milliliters are collected.  (Bianchi, Williams, 
Pelletier, Klinger, & Shuber 1996) The main conditions for 
which prenatal diagnosis is considered are monogenic dis-
eases, when the causation of the disease results from one 
gene, and therefore, is easier to detect and obtains con-
clusive results. Fetal DNA circulates in a high background 
of maternal DNA and is isolated and amplified using poly-
merase chain reaction technology. However, even after 
that, maternally inherited fetal alleles are very difficult to 
identify from maternal plasma, therefore, scientists have 
focused on the detection of paternally inherited fetal al-
leles that are not present in the maternal genome. The 
diagnosis of autosomal dominant diseases transmitted by 
the father could be made noninvasively. Also, by detecting 
the paternally inherited fetal alleles, one can exclude the 
fetal inheritance of autosomal recessive diseases. The dis-
covery of free cellular fetal DNA in maternal plasma has 
offered new approaches for noninvasive diagnosis, and 
fetal isolation analysis is now possible. (Lun et al., 2008)  
Fetal DNA in Maternal Plasma After Pregnancy
Microchimerism occurs as a result of the fetomaternal 
transfusion of blood cells across the placenta during preg-
nancy. After delivery, once the placenta has been expelled, 
fetal-origin cells should hypothetically depart from the 
maternal circulation. Nevertheless, studies of women who 
had given birth to a male child showed a high incidence 
of male cells in their blood after delivery. Additionally, 
some women have displayed male cells in their tissues 
up to 27 years postpartum after having birthed a male 
child. This event can be interpreted to mean that fetal 
cells transferred from the fetus to the mother during 
pregnancy established permanent microchimerism in the 
maternal body. This permanency was reported in 30–50% 
of women who gave birth to a male child. (Sato, Fujimori, 
Sato, & Ohto, 2008)   
There is an increased fetal-to-maternal transfer of pro-
genitor cells during an abortion procedure as the pla-
centa is being destroyed. Maximized fetal cell trafficking 
following a medical abortion was confirmed in an in vivo 
model. Since the embryonic circulatory system is estab-
lished in the first trimester of pregnancy, there is a greater 
chance for the transfer of a larger number of progenitor 
T cells during the first-trimester termination of pregnan-
cy. Therefore, women who had an elective abortion in 
their first or second trimester have a greater tendency 
towards fetal microchimerism. (Miech, 2010)   
Male microchimerism in women without sons and the 
correlation of microchimerism to prior pregnancy history 
was researched. Y-chromosome-specific quantitative PCR 
was used to test peripheral blood mononuclear cells of 
120 women. Women were categorized into four groups 
based on their pregnancy histories. Group A was nulli-
gravid and displayed 10% male microchimerism, Group B 
had induced abortions and displayed 57%, Group C had 
spontaneous abortions and displayed 22%, and Group 
D had only daughters and displayed 8%. Male micro-
chimerism prevalence was the greatest by a significant 
amount in those with induced abortions. Other possible 
sources of male microchimerism, such as those obtained 
in Groups A and D, include unrecognized spontaneous 
abortion or a vanished male twin. (Yan et al., 2005) 
Autoimmune Effects on The Mother
It has been theorized that the persistence and abundance 
of fetal microchimerism are dependent on numerous fac-
tors, including the immunogenetic relationships between 
mother and fetus, and perhaps between and preexisting 
inhabitants of the maternal system, from her mother or 
previous children. (Gammill & Nelson 2010) 
Fetal microchimerism, a form of trans-placental stem 
cell transplant, helps to explain the etiology, diversity of 
tissue pathology, predilection for females, and increase in 
the annual incidence of autoimmune diseases in women. 
(Miech, 2010) Fetal stem cells can differentiate into 
mature and competent cells, such as lymphocytes and 
monocytes. Fetal cells in maternal circulation or tissues 
may mediate a graft vs. host disease, which can lead to the 
development of autoimmune diseases. Women comprise 
80% of people with autoimmune diseases. Researchers 
have begun investigating the association of micro-chime-
rism with autoimmune diseases that predominately affect 
women. (Naik, Shrivastava, Suryawanshi, & Gupta 2019)   
Fetal microchimeric cells in maternal tissues led to the 
discovery of a positive correlation between fetal microchi-
merism and autoimmune diseases in women. Progenitor 
cells in the fetal immune system, such as T cells, mono-
cytes, macrophages, lymphocytes, and NK cells, are among 
the many fetal cell types that can be transferred to ma-
ternal tissues. In maternal tissues, the fetal microchimeric 
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progenitor immature T cells are capable of self-renewal, 
proliferation, and differentiation. Progenitor cell activation 
can result in the production of autocrine and paracrine in-
flammatory responses in autoimmune diseases. Triggering 
agents that activate these fetal microchimeric immune cells 
to attack the maternal host cells resulting in autoimmune 
disease have not yet been identified. Suspected triggers 
include viral or bacterial agents, abnormal localized tissue 
protein, and drugs. Microchimerism in affected tissues is 
more likely to be abundant in women with autoimmune 
diseases than in women with non-autoimmune diseases. 
(Miech, 2010)  
Pregnancy alters symptoms of autoimmune diseases. 
The maternal immune system develops a tolerance to 
the fetus, and the suppression of the maternal response is 
lifted postpartum. Fetal tolerance may explain why some 
autoimmune disease symptoms decrease during pregnan-
cy in some women. (Boddy, Fortunato, Sayres, & Aktipis, 
2015) Autoimmune diseases are often repressed during 
pregnancy and exasperate postpartum. It was then hy-
pothesized that fetal cells in maternal circulation might be 
important in influencing autoimmune disease in pregnancy 
and postpartum. (Ando, Imaizumi, Graves, Unger, & Davies, 
2002) Systemic sclerosis provided the first evidence for 
the involvement of fetal microchimerism with autoim-
mune diseases. Patients frequently had fetal cells not only 
in peripheral blood, but also in skin lesions. The hyperthy-
roidism of Graves’ disease frequently abates during preg-
nancy and exacerbates after childbearing. (Ando, Imaizumi, 
Graves, Unger, & Davies, 2002) Between 43 and 75% of 
patients with rheumatoid arthritis exhibit amelioration of 
some or all their rheumatoid arthritis symptoms during 
pregnancy. Additionally, in rheumatoid arthritis patients, 
symptoms tend not only to show improvement during 
pregnancy, but an exacerbation of symptoms postpartum. 
Correspondingly, the rate of relapse declines with pregnan-
cy in women diagnosed with multiple sclerosis, with the 
lowest rate in the third trimester. Relapse rates return to 
pre-pregnancy levels postpartum. This framework suggests 
that a contributor to autoimmune disease development 
may be the maternal immune response to the presence of 
fetal cells that invade maternal tissues. (Boddy, Fortunato, 
Sayres, & Aktipis, 2015)  
The risk of developing an autoimmune disease in parous 
women is higher after the first year postpartum. Fetal cells 
in the thyroid may contribute to thyroid cancer risk or 
susceptibility to other thyroid diseases. Current research 
suggests an association with postpartum thyroid tissue 
and thyroid diseases. Fetal cells are more abundant in the 
thyroid tissue and blood of women with Graves’ disease 
and Hashimoto’s thyroiditis, compared to healthy controls. 
Also, the risk of autoimmune disease in parous women 
is significantly higher after the first year postpartum. This 
knowledge suggests that the presence of fetal cells in the 
thyroid is associated with a maternal disease rather than 
health. (Boddy, Fortunato, Sayres, & Aktipis, 2015) 
Autoimmune thyroid disease affects reproductive-aged 
women. It commonly initiates or exacerbates postpartum, 
and so the involvement of fetal microchimerism was sus-
pected. Autoimmune thyroid disease does have e a profound 
relationship with pregnancy. Autoimmune thyroid disease in-
volves autoimmune antigens, such as the TSHR, Tg, and TPO. 
Placental immune suppression during pregnancy lessens the 
activity of autoimmune thyroid disease, as seen in the re-
mission of Graves’ disease. However, exacerbation of preex-
isting autoimmune thyroid diseases or initiation of autoim-
mune thyroid disease is also common postpartum. Increased 
titers of thyroid autoantibodies have been observed in the 
postpartum. Graves’ disease has also been shown to be 
most markedly suppressed by pregnancy itself, but; however, 
up to 60% of Graves’ disease patients of childbearing age 
have been reported to develop this disease within one year 
of delivery. (Ando & Davies, 2003) 
Cancerous Effects on the Mother
During pregnancy, fetal cells enter the maternal body, 
cross the placenta, and are found frequently in the ma-
ternal lung. It was generally accepted that the fetal cells 
in the lung were passing through the mother’s pulmonary 
circulation; however, the presence of fetal cells in the lung 
shows an association with cancer. A study reported high-
er levels of male DNA and significantly more fetal cells in 
the lung and thymus tissue in the diseased lung compared 
to healthy bone marrow from the same person. (Boddy, 
Fortunato, Sayres, & Aktipis, 2015) Fetal cells have also 
been detected as clusters in lung tumors in women de-
cades after pregnancy. Their tumor frequency was higher 
in lung tumors than in the healthy surrounding lung tissue. 
The fetal cells may be recruited from the bone marrow 
to the tumor sites where they assumed their role in 
immunosurveillance and tissue repair. (Naik, Shrivastava, 
Suryawanshi, & Gupta 2019) 
Fetal cells are frequently found in normal breast tissue 
postpartum women. The research presents a complicated 
picture of fetal cell’s role in breast cancer. Fetal cells are 
found less the tissue and blood of women with breast 
cancer compared to healthy controls. (Boddy, Fortunato, 
Sayres, & Aktipis, 2015) It was reasoned that naturally 
acquired allogeneic immune cells in the form of fetal mi-
crochimerism might correlate with protection from the 
development of breast cancer. Fetal microchimerism was 
found in higher quantities in healthy women compared 
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to breast cancer patients, 43% to 14%, respectfully. This 
shows a correlation between the role of fetal allogeneic 
cells as malignant cell immune surveillance and protection 
from breast cancer. (Gadi & Nelson, 2007)  
Reduced risk of breast cancer is recognized among 
parous compared to nulliparous women. Eighty-two 
women were tested for male DNA in peripheral blood, 
presumed from a prior pregnancy with a male fetus. Forty-
seven of the subjects were healthy, and 35 had breast can-
cer. The levels of male DNA were determined by real-time 
PCR for a Y chromosome-specific gene in DNA extracted 
from peripheral blood mononuclear cells. Fetal microchi-
merism was found in 43% of healthy women and 14% in 
women with breast cancer. These findings suggest that allo-
geneic fetal microchimerism may contribute to a reduction 
in the risk of breast cancer. (Gadi & Nelson, 2007) 
Through the evolutionary history of fetal microchime-
rism in the maternal body, it is possible that it now has 
a role in normal breast tissue physiology. The maternal 
mammary gland hosts stem cells that contribute to the 
development of normal breast tissue and can be trans-
ferred to the neonate during lactation. Mouse fibroblast 
fetal cells have been shown to differentiate into mammary 
epithelioid cells when exposed to lactation hormones in 
vitro, and a functional mammary gland has been generated 
from a single stem cell in a pregnancy mouse model. This 
suggests that fetal progenitor cells play a role in breast 
morphology and maternal milk supply. (Boddy, Fortunato, 
Sayres, & Aktipis, 2015)  
Pregnancy at older ages has been linked to risk for 
ovarian cancer. Given the data that microchimeric cells in 
parous women decline overtime after pregnancy, and that 
ovarian cancer develops most commonly in postmeno-
pausal women, fetal microchimerism may play a protec-
tive role in ovarian cancer as well. (Naik, Shrivastava, 
Suryawanshi, & Gupta 2019)
Neurological Effects on the Mother 
It was unknown whether fetal cells, which are capable of 
crossing the placental barrier to enter maternal blood, 
could also cross the blood-brain barrier and enter the 
maternal brain. To determine if fetal cells could enter the 
maternal brain during pregnancy, female wild‐type mice 
were crossed with green mice. Their offspring ubiquitous-
ly expressing the enhanced green fluorescent protein. 
Green mouse fetal cells were found in the maternal brain, 
and quantitative real‐time PCR of genomic DNA for the 
enhanced green fluorescent protein gene showed that 
more fetal cells were present in the maternal brain for 
weeks postpartum than on the day of birth. After an exci-
totoxic lesion to the brain, more fetal cells were detected 
in the injured region. For weeks postpartum, enhanced 
green fluorescent protein‐positive green mouse fetal 
cells in the maternal brain were found to adopt locations, 
morphologies, and expression of immunohistochemical 
markers indicative of astrocytes, neurons, oligodendro-
cyte, and macrophage-like cell types. The expression of 
morphological and histochemical characteristics of these 
cells was confirmed on the identification of fetal cells in 
the maternal brain by Y chromosome fluorescence hy-
bridization. The characterization of these cells that allow 
them to cross both the placental and blood-brain barri-
ers and to target the injured brain may improve selection 
procedures for isolation of stem or progenitor cells for 
brain repair by infusions. (Tan et al., 2005) 
Several studies have found male DNA in human and ma-
ternal mouse brains, but the function of these cells is not 
entirely known. One study found that fetal cell DNA in nu-
merous regions of the maternal brain, even decades after 
the woman had birthed a son, suggesting that fetal micro-
chimerism in the human maternal brain may be long-lasting. 
(Boddy, Fortunato, Sayres, & Aktipis, 2015) A team led by 
autoimmunity researcher, J. Lee Nelson sought to discover 
how leftover fetal cells affect the brain. They took samples 
from autopsied brains of 59 women. Male DNA evidence 
was found in the brains of 63% of the participants. The male 
DNA was scattered across several brain regions. Studies 
have hypothesized that the risk of Alzheimer’s disease in-
creases with an increasing number of pregnancies, so the 
team also examined the brains for signs of the disease. Of 
the 59 women, 33 had Alzheimer’s disease. Compared to 
healthy controls, fetal cells were found to be less common 
in the brains of women who had Alzheimer’s disease. That 
correlation suggests that the presence of fetal cells in the 
maternal brains helps protect women against Alzheimer’s 
disease. (PhillipsSep, et al. 2017)  
Conclusion
The placenta is unique because it allows for intimate con-
tact between maternal and fetal cells at the maternal-fe-
tal interface throughout pregnancy. (Than et al.) During 
pregnancy, the semi-allogeneic fetus is protected from 
rejection by the maternal immune system. (Trowsdale and 
Betz) It was hypothesized that the semi allogeneic fetus 
could survive due to the regulation of the immunologic 
interactions between mother and fetus. Such regulation 
can be caused by functional suppression of the maternal 
immune response or a lack of fetal antigen expression. 
(Morelli et al.)   
In the human placenta, fetal trophoblast cells do not 
express MHC HLA-A and B molecules, which are re-
sponsible for allograft rejection in humans. (Chen et al.) 
71
The Effects of Fetal Microchimerism on Maternal Health
Mixed hematopoietic chimerism, the state in which bone 
marrow hematopoietic stem cells from two genetically 
different animals coexist, remains the most robust tool 
for tolerance induction. Unfortunately, bone marrow 
or hematopoietic stem cell transplantation for patients 
awaiting solid organ transplantation remains at high-
risk, due to the dangers of graft-versus-host disease. 
(Zavazava) Human embryonic stem cells express low 
levels of (MHC)-I antigens and lack expression of MHC-II 
antigens. These stem cells must engraft in the transplant 
recipient, inducing tolerance to foreign cells, and reducing 
the immune targeting of the transplant. Upon injection 
into immunocompetent mice, human embryonic stem 
cells are unable to produce an immune response. Human 
embryonic stem cells may provide a potential tool for the 
induction of immunotolerance. Further studies in human 
embryonic stem cells immunobiology are warranted and 
may reveal unique mechanisms that account for the im-
munological properties of human embryonic stem cells. 
(Menendez et al.) 
Fetal cells and DNA go beyond the womb and into 
maternal blood and tissues during pregnancy and can last 
long after birth.  In some instances, fetal microchimerism 
contributes to perturbations in maternal immunity that 
may contribute to autoimmune diseases. In other cases, 
these interactions seem to benefit long-term maternal 
health by allowing fetal microchimerism cells to act as 
allogeneic surveyors in her system. Fetal microchime-
rism has potential implications for the understanding of 
women’s health and disease pathology postpartum. The 
pregnant mother mshould never be viewed as merely an 
incubator. Rather, microchimerism expands the biological 
bonds that are established between the pregnant mother 
and her fetus. 
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As an ever-progressing field of study, vaccine development has made headway over the past decades. By doing a comparative study 
between development of the measles vaccine in the mid-20th century, and the ongoing development of the COVID-19 vaccine in 
2020, many of the insights and advancements in the field can be easily highlighted. First, the knowledge and experience gained over 
those decades has helped the vaccine developing process become more efficient. With more vaccines in production, or at least under 
study, it is more likely to have a related precedent to build upon, as opposed to relying on a successful vaccine of some unrelated 
disease . More to the point, different vaccine types have altered the way researchers attempt to formulate future vaccines . No longer 
are inactivated and attenuated vaccines the only option; subunit vaccines, as well as innovative, (though yet to be proven), nucleic acid 
vaccines are now additional approaches. These advancements have opened doors for researchers in their quest to fight diseases. This 
paper will explore the advancements and their impact on the present-day COVID-19 vaccine development .
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Advancements in Vaccine Development:  
Measles vs. COVID-19
Though the majority of successful vaccines were devel-
oped in the 1900s, the challenge to develop vaccines still 
exists today, with both known diseases, such as cancer, 
as well as with novel infections that sweep the world. 
Measles used to be a common childhood disease; one 
which everyone contracted and with the majority of 
patients recovering completely. It was practically inevi-
table until the late 1900s, when a measles vaccine was 
introduced to the public. In the mid-1950s, after weeks of 
trying, John Enders’s lab successfully isolated the measles 
virus. Eventually, through implementation of routine mea-
sles vaccine—one dose at 12-15 months, and a second at 
4-6 years—measles was successfully eradicated from the 
U.S. in 2000, and from the Americas in 2016 (The College 
of Physician of Philadelphia, n.d.). However, that milestone 
of eliminating measles was not yet to be reached, as it was 
another ten years from the isolation of the virus until the 
measles vaccine officially debuted.
Contrastingly, it took Chinese researchers weeks to 
sequence the genome of SARS-CoV-2, a feat way beyond 
the simplicity of merely isolating the virus. Even more so, 
a projected release date for a safe and effective COVID-
19 vaccine is only 12-18 months from the start of devel-
opment, and one can only hope that the vaccine will erad-
icate the virus. Normally, vaccine development with FDA 
approval can take anywhere from 5-10 years. Obviously, 
vaccine technology has critically advanced in the decades 
since the measles vaccine, thus allowing researchers to 
expedite the vaccine development process for COVID-
19 and all future pandemics. This paper will explore some 
of these advancements and their potential impact on the 
COVID-19 vaccine development.
Methods
All of the information discussed in the paper was ob-
tained through the PubMed database, as well as via 
Google searches which led to government sites, like the 
CDC and NIH, and also to known and established med-
ical sciences related sites, like CHOP and The College of 
Physicians of Philadelphia.
The majority of the amassed information pertained to the 
techniques involved in developing both the measles vaccine 
and the potential COVID-19 vaccine, so that I could com-
pare and contrast the respective availability of resources.
One study explored in the paper included vaccine trial 
studies in which the efficacy of various measles vaccines 
were tested either alone, or in a series with other forms 
of developing measles vaccines. At a designated interval 
after each trial, measles titers were measured and even-
tually, the most effective vaccine was sought out.
There are currently over one hundred biotechnology 
companies and universities developing vaccine candidates 
for COVID-19. For the  vaccine studies that are not yet 
ready  for human test trials, i.e. majority of the COVID-19 
studies, this paper analyzed selected studies which elabo-
rated on the numerous approaches towards an effective 
COVID-19 vaccine.
Discussion 
An Overview of Vaccines 
How vaccines work
The purpose of a vaccine is to trigger the immune system 
to stimulate an initial immune response and ultimately 
create a cellular memory mechanism to fight future at-
tacks by the pathogen. This way, when the body is ex-
posed to the actual disease in the future, the body will 
produce an immediate secondary immune response and 
not a primary response (Clem, 2011). Secondary immune 
responses are quicker and more specific, and are there-
fore better than a primary immune response.
Classically, vaccines are created by deactivating or atten-
uating the virulent part of the pathogen, while leaving the 
antigenic portion of the pathogen intact so that the vac-
cine can induce an immune response without causing the 
disease itself  (The College of Physicians of Philadelphia, 
2018). When the body detects a foreign antigen, the innate 
immune system goes into action first (Clem, 2011). The 
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innate system includes non-specific white blood cells (i.e., 
macrophages and natural killer cells), which can either de-
stroy the invader or process the pathogen and present its 
antigen to aid in the adaptive immune response. Both the 
humoral and cell-mediated immune responses are part 
of the adaptive immune response. The humoral response 
consists of B-cells, which detect the foreign antigen and 
then self-mutate to find the antibody that best fits the 
antigen. After that is successfully accomplished, the B-cell 
that is able to produce the most effective neutralizing 
antibodies replicates and becomes either plasma cells, 
which secrete antibodies to help fight the current infec-
tion, or it creates memory B-cells specific to that antigen, 
so that upon future infection the body will have an anti-
body that targets and destroys the specific disease patho-
gens. The cell-mediated immune response contains two 
types of cells, T-killer and T-helper cells, which are either 
activated by major histocompatibility complex I (MHC I) 
or major histocompatibility complex II (MHC II). MHC 
proteins are expressed on the surface of all bodily cells 
to signal that the cells belong in the body. However, when 
the cells become infected with a pathogen the MHC will 
take the processed antigen and present it on the surface 
of the cell, so that the T cells of the cell-mediated immune 
system can respond. T-killer cells recognize the antigen 
presented by MHC I molecules and subsequently advance 
to kill the invading cell. On the other hand, T-helper cells 
recognize the antigen presented by MHC II molecules, 
and T-helper cells aid in the activation of B cells as well 
as T-killer cells. Regardless of their function, either T cell 
can replicate and form T-memory cells in preparation of 
future infections (Clem, 2011). In all, the job of a vaccine is 
to prime the body for a future encounter with a specific 
pathogenic agent.
Stages of Vaccine Production
Before any vaccine can be mass produced for public use, 
it must go through a series of developmental phases to 
assess first and foremost its safety, in addition to the vac-
cine’s efficacy, required dosage and dose frequency, and 
screenings for any harmful side effects (The College of 
Physicians of Philadelphia, 2018). Prior to these phases 
though, researchers study the specific disease and at-
tempt to identify its immunogenic parts. Once that has 
been done, researchers can either isolate the antigenic 
portion, or inactivate the virulent part, depending on 
what type of vaccine they propose to create.
Following those preliminary steps, the candidate vaccine 
can then enter the preclinical phase of study. In this stage, 
researchers test the vaccine safety and immunogenicity 
on animals (The College of Physicians of Philadelphia, 
2018). Also during this preclinical stage, researchers may 
conduct what are known as challenge trials. In these tests, 
researchers inject their candidate vaccine into the lab an-
imals or human volunteers, wait an amount of time so 
that the vaccine can elicit an immune response and create 
memory cells, and then finally, they inject the targeted 
virus into the subjects to determine if the vaccine can 
do its job. Based on the challenge trial results, research-
ers will adjust their vaccine development accordingly. 
During this phase, there may be a bit of trial and error 
in determining a safe starting dose, i.e. how many viral 
particles are needed to elicit an immune reaction, and 
method of delivery for human subjects of the next phase 
(The College of Physicians of Philadelphia, 2018). For the 
COVID-19 mRNA vaccine trials conducted by Moderna 
and the NIAID, three trial groups have been set up each 
with a different dosage. One group is testing the low 
dose of 25mcg, a second group is receiving the midrage 
amount of 100mcg, and the third group is receiving the 
highest dose, 250mcg (National Institute for Allergy and 
Infectious Disease [NIAID], 2020).
In order to advance from the preclinical stage to the 
clinical phases, the research group must submit an inves-
tigational new drug (IND) application to the FDA for ap-
proval to further their studies (The College of Physicians 
of Philadelphia, 2018). Once the researchers receive 
authorization, they can proceed to phase I clinical trials. 
At this juncture, researchers experiment with human 
subjects once again to test safety and immunogenicity 
of the proposed vaccine. This step starts with healthy 
adult subjects and if the vaccine is intended for younger 
or older age groups, the trials gradually trend towards 
the desired group. During this phase, researchers may 
conduct human challenge trials as well (The College of 
Physicians of Philadelphia, 2018). With regard to COVID-
19, Moderna has reported that after two doses of their 
potential mRNA COVID-19 vaccine, participants in the 
low and mid groups have expressed immunity at or above 
the level in which someone who was naturally infected 
would have. This seems to be a promising result for phase 
I trials, especially since it seems that once someone con-
tracts COVID-19 they do not get it again, and so the nat-
ural amount of antibodies should be sufficient for vaccine 
induced protection (CBS News, 2020).
After successful phase I trials, the vaccine can move on 
to phase II clinical trials. Here, researchers study a larger 
test group including a control group and the main point 
of this phase is to further characterize dosage, frequency 
of immunization, and method of delivery (The College of 
Physicians of Philadelphia, 2018). In this phase, the clinical 
studies will also ascertain whether the vaccine shows any 
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efficacy. Safety of the vaccine is monitored as well.
Next, there are phase III clinical trials. This is where 
the potential vaccine is determined to be effective by 
recruiting hundreds or thousands of volunteers to help 
quantitate how effective the vaccine is in a large cohort 
(The College of Physicians of Philadelphia, 2018). The 
large subject group also allows for the detection of rare 
side effects. During this phase, vaccine safety and dosage 
are still monitored for necessary corrections. Vaccines 
are never 100% effective. Measle vaccine is thought to be 
about 85% effective. Therefore, phase III trials must assess 
vaccine effectiveness. 
Finally, after the vaccine has successfully passed through 
all phases of clinical testing, the researchers can submit 
a biologics license application to the FDA for licensure 
of their candidate vaccine (The College of Physicians of 
Philadelphia, 2018). If the FDA approves, and the CDC 
subsequently recommends this vaccine for routine ad-
ministration, the researchers will be able to manufacture 
their vaccine and enable mass population immunization.
At this point, researchers can conduct an optional phase 
IV clinical trial to further monitor the vaccine’s safety and 
efficacy (The College of Physicians of Philadelphia, 2018). 
Studies can also be done to learn if the vaccine has poten-
tial for any alternate uses (i.e. other than for protection of 
the targeted pathogen).
Post licensure, the FDA and CDC continue to monitor 
the vaccine (The College of Physicians of Philadelphia, 
2018). In 1990, the FDA and CDC established the vac-
cine adverse event reporting system (VAERS). The VAERS 
allows for anyone to report adverse side effects, which 
seem to be caused by a particular vaccine. The CDC then 
analyzes all of the input data to determine several con-
clusions. Among those conclusions are whether a new 
adverse side effect has indeed been detected, and wheth-
er certain health conditions place a patient at a greater 
risk of developing an adverse side effect. Also in 1990, the 
CDC established the vaccine safety datalink (VSD). This 
system provides access to numerous databases listing 
which vaccines were given to a particular patient on the 
reported date. The VSD conducts vaccine safety studies 
based on questions raised in medical literature or reports 
from the VAERS. In addition, the VSD monitors the safety 
of new vaccines.
Advances in Vaccine Development
In the sixty years since the development of the measles 
vaccine, the technologies used have improved as well as 
increased. For example, while Enders, Hilleman, and all the 
other researchers of that time were experimenting with 
either inactivated (dead virus) or live-attenuated vaccines, 
researchers of today can work with a greater variety of 
vaccine types ranging from pathogen subunit vaccines 
to nucleic acid vaccines (NIAID, n.d.). Both forms of the 
newer vaccine methods aim at inoculating with only the 
antigenic portion of the microbe as opposed to injecting 
the whole pathogen, which is what is done with inactivat-
ed and attenuated vaccines. In an inactivated vaccine, the 
entire pathogen is killed and then subsequently adminis-
tered to the patient (Clem, 2011). Attenuated vaccines, on 
the other hand, leave the pathogen partially alive, and then 
upon administration, induce a stronger immune response 
than inactivated vaccines. However, because the attenuat-
ed vaccine is slightly live, it does present a greater risk to 
the immunocompromised community (Clem, 2011). The 
challenge in designing inactivated viruses or attenuated 
viral particles is that there is no set formula for how to 
kill or attenuate the virus. Each virus is different. That is 
why it can take months, or even years, to generate an 
effective candidate vaccine. 
Over the past decade, new innovative technologies 
have been instituted to develop effective vaccines. Subunit 
vaccines are one example where a mere pathogenic 
unit—a protein, or sugars on the microbe’s outer coat—
are administered into the patient to elicit an antibody re-
sponse, thus allowing a person to attain immunity (NIAID, 
n.d.). However, subunits vaccines are often not effective 
enough on their own and require an adjuvant to enhance 
their immune response (NIAID, n.d.). While historically 
composed of only aluminum salts, adjuvants today come 
in many more varieties like MF59 (oil in water emulsion 
composed of scalene), CpG 1018 (cytosine phosphogua-
nine, a synthetic form of DNA that mimics bacterial and 
viral genetic material), and others (Centers for Disease 
Control and Prevention [CDC], n.d.-a). All of these adju-
vants serve to aid in the immunogenicity of the vaccine, 
hopefully providing a stronger response and longer lasting 
protection. The inclusion of adjuvants in vaccine formula-
tion requires researchers to carefully assess where these 
added compounds elicit unwanted side effects. 
Contrary to the aforementioned vaccines, nucleic acid 
vaccines do not inject any physical part of the pathogen 
into the body. Rather, these vaccines inject a lab synthe-
sized DNA or mRNA sequence that codes for one or 
more antigenic proteins (NIAID, n.d.).  Once inside the 
body, the nucleic acid is taken up by the virally targeted 
cells and instructs those cells to synthesize and secrete 
the desired protein. Only then, after the protein is in the 
body, will the body generate an immune response and 
acquire antibodies to that specific disease (NIAID, n.d.). 
With this method of inoculation, the body itself is an in-
tegral part in creating the immunogenic portion of the 
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vaccine. An mRNA strand alone will do nothing. However, 
when acted upon in vivo, the body completes the last step 
in the vaccine synthesis, creating the protein to which it 
needs to attain immunity.
Nucleic acid vaccines have a quicker production time 
than traditional whole-pathogen vaccines (NIAID, n.d.). 
This is because a pathogenic specimen does not need to 
be grown for the creation of the vaccine (Park, 2020). 
Under normal circumstances, the microbe can take a few 
months to grow to the desired quantity. Thus, nucleic acid 
vaccines may be favored over whole-pathogen vaccines, 
especially in situations where time is a consideration.
Additionally, though nucleic acid vaccines can be inject-
ed directly into the body, another vaccine delivery mode 
has developed over the years. Instead of injecting the 
DNA or mRNA directly into the body, options now exist 
to use a vector for introduction of the vaccine (NIAID, 
n.d.). A vector is a small particle that acts as a vehicle for 
vaccine delivery. A viral vector, such as adeno-associated 
virus, can incorporate the vaccine’s genetic material by 
replacing some of its viral genes with the vaccine’s desired 
sequence (Robert-Guroff, 2007). Studies have proven 
that viral vector administration is both safe and effective, 
though the quantitative values vary amongst the viruses 
(Robert-Guroff, 2007). There are also non-viral vectors, 
for example, liposomes and lipid nanoparticles (LNP), 
which can be used to deliver nucleic acid vaccines as well. 
One advantage of non-viral vectors, is that they are less 
immunogenic than their viral counterparts. With both 
forms of vectors, however, the target site in the body can 
be specified with the help of specific receptor molecules. 
Like this, researchers can guide and control the vector’s 
integration and vaccine delivery within the body.
The Measles Vaccine
In 1954, just a year before the introduction of the in-
activated polio vaccine, Thomas Peebles, MD, working 
in John Enders’s lab at Boston Children’s Hospital, suc-
ceeded in isolating the measles virus from the blood of 
13-year-old David Edmonston (The College of Physicians 
of Philadelphia, n.d.). After isolating the virus, Enders’s goal 
was to formulate a vaccine. It took until 1960 to prove 
that the isolated strain could be formulated into an effec-
tive attenuated measles vaccine; it just needed addition-
al tweaking to attenuate it further (Hendriks & Blume, 
2013). Wanting other researchers to also attempt to 
create a measles vaccine, Enders shared the Edmonston 
strain. Most researchers of that time were inspired by the 
recent success of the polio vaccine, and tried to mimic 
that development in their construction of a measles vac-
cine (Hendriks & Blume, 2013). In countries where Salk’s 
inactivated polio vaccine (IPV) took credit for controlling 
the disease, like in Sweden and Netherlands, researchers 
worked at creating an effective inactivated measles vac-
cine. In other countries, such as the U.S. and U.K., where 
Sabin’s recently released oral polio vaccine (OPV) was 
used to combat polio, researchers preferred to attempt 
an attenuated version of the measles vaccine.
Regardless of the method chosen, subsequent patient 
trials proved the attenuated measles vaccine to be more 
effective than the inactive vaccine (Hendriks & Blume, 
2013). Some studies created several groups, each receiving 
a different vaccine regimen. While one group received only 
inactivated doses, another group received some inactive 
doses followed by a live dose, while  a third group received 
one dose of the attenuated vaccine. Though several studies 
tried this method, all pointed to the same results: the in-
activated vaccine initiated a lesser immune response and it 
was not known how long those antibody titers would last. 
The attenuated vaccine however, generated a substantial 
response, making it the vaccine of choice for elimination of 
measles (Hendriks & Blume, 2013).
It was in 1963 that John Enders and his associates re-
ceived FDA licensure for their live-attenuated measles 
vaccine and mass measles vaccination began (CDC, n.d.-b). 
However, the vaccine was not attenuated enough and thus 
required coadministration of gamma globulins to prevent 
children from developing fever and a rash following inocu-
lation (Hendriks & Blume, 2013). Approximately five years 
later, in 1968, Maurice Hilleman, working at Merck labs, 
developed Moraten—more attenuated Enders—which 
eliminated the need to inject the vaccine along with 
gamma globulins (Hendriks & Blume, 2013). Since licen-
sure, Moraten, a descendant of the original Edmonston 
strain, has been the only measles vaccine administered in 
the U.S. (The College of Physicians of Philadelphia, n.d.). 
Even today, when the monovalent vaccine is no longer on 
the market, the Edmonston strain is still used to create 
the measles component of the MMR vaccine routinely 
given to children (CDC, n.d.-c; The College of Physicians 
of Philadelphia, n.d.).
Potential COVID-19 Vaccines
The COVID-19 pandemic, rampant now in early 2020, and 
possibly beyond, has killed hundreds of thousands world-
wide in a matter of months (World Health Organization 
[WHO], 2020a). As of June 1, 2020, the WHO reports 
that there have been 371,166 deaths globally. Researchers 
all over the world are racing to develop a vaccine to com-
bat the virus and stop the ever-rising death toll.
Luckily, there is an extensive history of vaccine devel-
opment, allowing researchers to base their COVID-19 
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vaccine developments on the experiences and accu-
mulated information from the past. More so, unlike the 
measles vaccine development, COVID-19 vaccine devel-
opment has a related precedent. Coronaviruses SARS 
(severe acute respiratory syndrome) and MERS (Middle 
East respiratory syndrome), while claiming no marketed 
vaccine, have documented research and experimentation 
on vaccine development. Current researchers are using 
these semi-constructed vaccines and adapting them for 
further development towards the current strain of coro-
navirus, SARS-CoV-2. However, regardless of the starting 
inspiration, all potential COVID-19 vaccines will have to 
go through all phases of vaccine production before being 
offered on the market.
As of June 15, 2020, there are scores of COVID-19 
vaccine candidates starting the preclinical stage or clinical 
studies phase of vaccine development. These attempts 
include vaccine designs containing mRNA, DNA plasmid, 
protein subunit, non-replicating viral vectors, or inacti-
vated COVID-19 viral particles (WHO, 2020b). Just the 
breadth of these alone shows how many more resourc-
es and technologies are available now versus the 1960s, 
when the measles vaccine was in development.
The more recent vaccine technologies, namely nucleic 
acid vaccines, demonstrates  how the updated and in-
creased methods are truly playing a role in COVID-19 
vaccine development. In this paper, I would like to high-
light one specific mRNA candidate vaccine. (An LNP-
encapsulated mRNA vaccine, co-developed by Moderna 
and the NIAID.) As an RNA virus with RNA-dependent 
RNA polymerase, SARS-CoV-2 replicates RNA from an 
RNA template as opposed to transcribing RNA from 
a DNA template (using DNA-dependent RNA poly-
merase). This can result in high levels of RNA present 
within the virus (Wang, et al., 2020). Thus, using RNA 
as a method of priming the body towards an RNA-rich 
pathogen makes sense in the overall picture of vaccine 
development (Wang, et al., 2020).
Also, when developing this RNA vaccine, researchers 
opted to use the spike protein as the vaccine’s target 
sequence. Though there are other targetable proteins 
on SARS-CoV-2, such as the envelope, nucleocapsid, and 
membrane proteins, the spike (S) protein is the subunit 
of the virus that binds with the body’s ACE2 (angioten-
sin converting enzyme 2) receptor, and therefore the S 
protein comes across as a more effective vaccine target 
(Wang, et al., 2020; Zhang, et al., 2020). Figure 1 shows 
the location of all four proteins on the virus as well as the 
binding of the spike protein to the ACE2 receptor.
After injection of the vaccine which contains the mRNA 
sequence for the S protein, a cell in the body should 
translate the genetic code into the functional S protein that 
can be secreted to allow the immune system to respond. 
Figure 2 depicts the process by which this COVID-19 
mRNA vaccine ultimately yields memory cells in the body.
As of May 30, 2020, this candidate vaccine has advanced 
to phase 2 clinical trials (WHO, 2020b). Though mRNA 
vaccines have great theoretical potential, there are current-
ly none on the market. However, this mRNA vaccine may 
successfully proceed through all phases of vaccine develop-
ment, and should that happen, the Moderna/NIAID mRNA 
vaccine will be the first of its kind on the market
Conclusion
For the ongoing developments for a COVID-19 vaccine, 
it is unknown whether the vaccine’s immunity will be life-
long. Currently, it is unknown if natural immunity is long 
Figure 1 Proteins and Binding Site of SARS-CoV-2 Source . Zhang, et al ., 2020
Figure 2 COVID-19 mRNA Vaccine Response
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lasting, though whatever that case is, I would hypothesize 
that the artificially induced immunity would follow suit. In 
my opinion, though vaccine type does play a role in dura-
tion of immunity (as illustrated in measles vaccine devel-
opment), a larger portion depends upon the properties 
of the virus itself. Since that is yet to be determined, it 
is too soon to draw a conclusion with regards to any 
COVID-19 vaccine. Also, because all vaccines are at most 
in early phase II clinical trials, one cannot determine 
which candidate vaccine will be more effective than the 
others. Currently, the mRNA vaccine from Moderna is on 
a road to success, though results are still too incipient to 
make a final decision.
Finally, although the essence of a vaccine is unchanged—
the goal to elicit an effective immune response still drives 
development—advancements in vaccines development 
as well as accumulation of scientific knowledge have 
broadened our minds when attempting to develop a new 
vaccine. We now have more options, some of them with 
more precise targeting than ever, and it is the hope that 
with our newfound tools, we can go on to create better 
vaccines and continue saving lives.
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Kidney Stones
Nephrolithiasis is the process of the aggregation of certain 
minerals in the urine due to super saturation, thereby caus-
ing the formation of kidney stones. What complicates mat-
ters, is, that there is no single cause that can be attributed 
to Nephrolithiasis. In fact, as research progresses, an abun-
dance of causative agents are being linked. Outlined below 
is a comprehensive summary of the occurrence, recurrence, 
treatment and causative factors of kidney stones.
Kidney stones usually form in the renal pelvis and pass 
through the urine unnoticed. However, at times these stones 
can grow up to several centimeters. These large stones can 
cause blockages in different locations in the urinary system 
and can be very painful. Stones that do not obstruct passages 
cause no symptoms besides hematuria (blood in the urine). 
Passing a stone causes renal colic.  The pain intensifies as the 
stone progresses downward. Pain is felt as the stone passes 
through the ureter. When a stone reaches the uretero-ve-
sicular junction it may cause dysuria and urinary frequency. 
Unfortunately, colic is felt regardless of body position and 
motion. Stone size is a big determinant of treatment option. 
Stones smaller than five mm in diameter have a high possibil-
ity of passing. Those that are between five to seven mm have 
a 50% chance of passage. Stones that are greater than seven 
mm almost always require medical intervention (Coe, Evan 
and Worcester, 2005).
The prevalence of kidney stones is dependent on many 
different factors, including gender. About 5% of American 
women will develop a kidney stone at some point in their 
life. By contrast, about 12% of American men are likely to 
develop a stone. The peak age in men is 30 years old. In 
women stones are most common between the ages of 35 
and 55 with peaks at both 35 and 55. Previous stone formers 
have a 50% chance of forming a second stone within five to 
seven years of the first.(Malvinder,2004). 
In recent years there has been an increase in the inci-
dence of kidney stones. This has been associated with many 
different factors. For example; BMI, race, ethnicity and region 
of residence are strongly associated with stone formation. A 
seasonal disparity is also seen. Men have high urinary calcium 
oxalate saturation during the summer and women during 
the early winter. High levels of calcium oxalate in the urine 
are prone to solidify into stones. (Malvinder, 2004)
In the majority of cases, stones are passed without 
medical intervention. Even so, physicians will still pre-
scribe strong pain killers to combat the typical pain that is 
experienced. In addition, anti-nausea medications as well 
as antibiotics may also be prescribed. Medicinal treatment 
is also an option. Alpha blockers may be prescribed, which 
relax the muscles of the ureter, allowing the stone to pass 
thereby mitigating the pain. If a stone is too large to pass, 
it may require a medical procedure to either break it up 
so that it can pass, or to completely remove it. In some 
situations, although the stone is small, it still requires 
medical intervention to remove it if it has lodged itself 
somewhere between the kidney and the urethra; usually 
in the ureters (Frassetto & Kohlstadt, 2011).
One method of treatment is using sound waves to break 
up stones. This is done through a procedure known as ex-
tracorporeal shock wave Lithotripsy (ESWL). ESWL shat-
ters stones into very small pieces by use of shock (sound) 
waves that that create powerful vibrations. These stones 
can now pass more easily in the urine. This procedure is 
done under sedation or light anesthesia. It lasts around 45 
minutes to an hour. Possible side effects include bruising on 
the back or abdomen and bleeding around the kidney and 
other nearby organs (Mayo Clinic, 2020). 
Another method involves using a scope to remove 
stones. This is often done when the stones are smaller 
but have been lodged and can no longer pass on their 
own. The physician will pass a ureteroscope equipped 
with a camera through the urethra to the ureter. The 
stone will then be removed or broken into pieces. This is 
done under general anesthesia. Often a stent is placed in 
the ureter to relieve some of the swelling. The stent is left 
inside the ureter for a few days following the ureterosco-
py to allow for further healing (Mayo Clinic, 2020).
When all other therapeutic options have been exhaust-
ed, a surgical procedure will be necessary. Smaller stones 
that did not respond to the aforementioned treatments 
and larger stones require surgery. This procedure is called 
percutaneous nephrolithotomy. It is the process of re-
moving the kidney stone using small telescopes and other 
tools that are inserted through a small incision in the pa-
tient’s back. The patient will be under general anesthesia 
at the time of the surgery and will remain hospitalized for 
a few days to recover (Mayo Clinic, 2020)
The Composition of Kidney Stones
Kidney stones are composed of different minerals that are 
found in urine. Calcium oxalate and Calcium phosphate 
comprise the composition of approximately 80% of stones. 
19% are composed of struvite and uric acid. The remain-
ing one percent are composed of cystine or ammonium 
acid urate. Kidney stones arise from the unwanted phase 
change of these substances from the liquid state to the 
solid state. The substances listed above exist in the urine 
as dissolved salts. However, at times, these salts can be-
come super saturated. When a substance is super saturat-
ed no more of this solute can dissolve in solution and it 
will consequently precipitate out as a solid, forming hard 
granules. Super saturation is approximated by the ratio of 
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a substance’s concentration in the urine to its solubility. 
At super saturation levels less than one, crystals of a sub-
stance will dissolve. But at super saturation levels greater 
than one, crystals can grow and form. The composition of 
stones correlates with the super saturation values from 
the urine produced (Coe, Evan and Worcester, 2005).
Calcium Oxalate Stones: 
How/Why do they form?
The vast majority of Calcium Oxalate stone formers do 
not suffer from a systemic disease and are therefore de-
scribed as idiopathic stone formers. In other words, they 
form stones spontaneously; the cause is unknown.  The 
commonality found in many CaOx stone formers are 
disorders of calcium metabolism, resulting in abnormal 
levels of calcium. In addition, low urine citrate levels have 
been shown to permit CaOx stones. This is because urine 
citrate binds urine calcium in a soluble calcium citrate 
complex which reduces calcium super saturation (Coe, 
date unknown). However, when levels are low, calcium 
levels rise and ultimately stones may form. Furthermore, 
high urine uric acid excretion in men and women (above 
750-800mg/d) is associated with idiopathic CaOx stones 
as well. These dissolved uric acid salts appear to reduce 
the solubility of calcium oxalate thereby promoting the 
formation of stones.  
Disorders of Calcium metabolism range in severity 
and in the scope of their consequences. The most com-
mon cause of calcium metabolic irregularities is Primary 
Hyperparathyroidism, a systemic disorder in which an 
excess of Parathyroid hormone causes increased levels 
of calcium in the blood. In a healthy body, the kidneys 
lose calcium in the urine every day. In response, calci-
um receptors on the surface of the parathyroid glands 
cause the parathyroid glands to release PTH, a hormone 
that increases blood calcium levels. However, because of 
abnormalities, there is excess calcium and less reabsorp-
tion by the kidney leading to stone formation (Primary 
hyperparathyroidism).(Coe, date unknown). High calcium 
levels in the urine are also found in people with Idiopathic 
Hypercalciuria. Hypercalciuria results in increased intesti-
nal absorption of calcium. High intestinal calcium absorp-
tion raises the amount of filtered calcium presented to 
the renal tubules in the kidney. It can also result in the 
reduction of the reabsorption of the renal tubules. Both 
of these mechanisms can increase the urinary calcium 
level. In certain instances, the excess calcium may solidify.
Other diseases linked to Hypercalciuria are of genetic 
natures. Dent disease is an X-lined hypercalciuric disor-
der found almost exclusively in males. In affected indi-
viduals, kidney problems result from damage to proximal 
tubules. The disorder is due to mutations in the gene 
(CLCN5) that codes for the voltage-gated endosomal 
chloride channel 5 (Heller & Pak 2002). Another type of 
genetic disorder is Barter Syndrome – specifically types 
I and II. In this syndrome renal calcifications are found 
in the cortex and the medulla. These calcifications come 
from problems in transport that reduce the capacity of 
the thick ascending limb of the kidney tubules which 
consequently reduces salt and calcium reabsorption. This 
results in a higher salt and calcium concentration leading 
to hypercalciuria (Heller & Pak 2002).
High Oxalate concentrations also lead to the formation 
of stones. Hyperoxaluria occurs when there is too much 
oxalate in one’s urine. Hyperoxaluria can be caused by 
inherited-genetic disorders, because of intestinal disease 
or because of a diet of oxalate rich foods (Mayo Clinic, 
2019). Primary hyperoxaluria is an autosomal recessive 
disorder caused by the overproduction of oxalate. This 
overproduction leads to calcium oxalate precipitation in 
the kidney and eventually to end stage renal disease (Ther, 
2018). Enteric hyperoxaluria is caused by an increase in 
absorption of oxalate from foods. Several intestinal dis-
eases including Crohn’s disease and irritable bowel syn-
drome increase the absorption of oxalate from foods. 
This in turn increases the amount of oxalate excreted 
from the urine (Mayo Clinic, 2019). There are also many 
oxalate rich foods that can contribute to an overabun-
dance of oxalate in the urine. These foods include beans, 
beer, beets, berries, chocolate, coffee, cranberries, dark 
green vegetables, nuts, oranges, sweet potatoes and tea. 
It has been proven that avoiding high oxalate foods can 
substantially help lower oxalate levels (Thomson, Husney, 
Romito, & Vachharajani, 2019)
Treatment
A new and developing form of treatment for CaOx 
stones is using a drug called Stiripentol. Stiripoentol is 
an antieplipetic drug used to treat children affected by 
Dravet syndrome. It has been shown to inhibit neuro-
nal lactate dehydrogenase 5 enzyme. This isoenzyme is 
the last step in hepatic oxalate production and therefore 
can potentially reduce hepatic oxalate production and 
urine oxalate excretion. A young child affected by type 
1 hyperoxaluria received this drug for several weeks, and 
her urine oxalate excretion decreased 66% (Dudal…
Letavernier, 2019). Studies are still being conducted to 
ascertain the long term affects and the possibly harmful 
side effects that are accompanied by this drug.
In addition, a study was performed to see if there was an 
association between gut microbiome alterations and renal 
calcium oxalate stones. It was found that short chain fatty 
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acids may prevent stone formation. The research proposed 
that by regulating gut microbiome composition using short 
chain fatty acids, it may be possible to prevent kidney stones. 
Microbiome analysis was performed on 160 Chinese indi-
viduals some with recurring stones, some with one inci-
dence of stone formation, and some non- stone formers. 
The results identified that recurrent stone formers and 
single time stone formers both exhibited higher fecal mi-
crobial diversity than the controls. While the mechanism of 
using short chain fatty acids to regulate gut microbiome is 
still unknown, the research has shown promising signs that 
this may be a cogent method to preventing and treating 
kidney stones (Wang…Li, 2019). 
Recurrence
While there are many methods of treatment for kidney 
stones already in practice and many more in the devel-
opment stages, recurrence of kidney stones reduces the 
effectiveness of many therapeutic methods. Following an 
initial stone event, the spontaneous five-year recurrence 
rate is 35 to 50 percent. As such it is imperative to insti-
tute a treatment plan that will change the whole nature of 
the kidney’s function in order to be sure that renal calculi 
will not form yet again. 
One such method is to alter the pH of the urine. 
Recently, the administration of potassium citrate has been 
considered as a therapeutic and preventative measure 
specifically for calcium oxalate nephrolithiasis. In a study 
conducted last year patients who underwent urolithiasis 
surgery were divided into subgroups. One subgroup in 
each category were given potassium citrate 40 mEq per 
day orally. The results were conclusive. The stone recur-
rence rate for the treatment subgroup was 1.72%, while 
it was 25.86% in the control subgroup. The difference was 
statistically significant. The treatment works because ci-
trate inhibits the aggregation of calcium oxalate crystals 
by increasing the solubility by a mechanism mentioned 
above. It also inhibits urinary calcium stone formation due 
to change in urine pH.  There are many other methods 
of prevention as well (Hosseini, Alipour, Omidbakhsh, and 
Ashraf, 2019). 
Calcium Phosphate Stones: 
Why/how do they form?
Calcium phosphate stones are not as common as calcium 
oxalate stones. Calcium phosphate stones may be caused 
by hyperparathyroidism, renal tubular acidosis, and urinary 
tract infections. Calcium Phosphate is present in urinary 
stones as either apatite, or brushite. What drives the de-
velopment of brushite versus apatite stones is unknown. 
In patients of calcium phosphate stones,  plugs of apatite 
fill the lumens of the terminal collecting duct. Epithelial 
cells are damaged and destroyed and around affected tu-
bules, the interstitial area is inflamed and scarred. Besides 
for being hypercalciuric because of idiopathic hypercalci-
uria Calcium phosphate stone formers have a distinctive 
feature- their urine has a higher pH. This favors calcium 
phosphate crystallization by increasing the abundance of 
urine mono-hydrogen phosphate, the ion that combines 
with calcium. Urine pH rises progressively with increasing 
calcium phosphate percentage in stones. The mechanism of 
increased urinary pH in Calcium phosphate stone formers 
is unknown (Frassetto & Kohlstadt, 2011).  
Remarkably, Pregnant women have a double than aver-
age chance to form calcium phosphate stones compared 
with age-matched nonpregnant women. They are two to 
three times more likely to have calcium phosphate stones 
over oxalate stones.  This can be attributed to the fact 
that women have an increased glomerular filtration rate 
and have higher urinary calcium during pregnancy. In late 
pregnancy, the urine tends to have a higher pH which can 
predispose women to calcium phosphate stones. Kidney 
stones during pregnancy increase the risk of urinary tract 
infections. Also, pregnant women with renal colic have a 
50% higher risk of early delivery compared to women who 
do not have kidney stones (Frassetto & Kohlstadt, 2011).
Treatment
Thiazide diuretics such as hydrochlorothiazide can help 
the kidney absorb more calcium, leaving less of it in the 
urine where it can form stones. Thiazide diuretics are a 
type of diuretic drug. Diuretic drugs increase urine flow. 
They act directly on the kidney and promote urine flow 
by inhibiting the sodium/chloride cotransporter located 
in the distal convoluted tubule of a nephron. Thiazide de-
creases sodium reabsorption which increases fluid loss in 
urine. Potassium citrate is another medication that can 
bind to calcium and help keep calcium phosphate in the 
urine from forming stones (Mayo Clinic, 2019). 
 Brushite stones (calcium phosphate stones) are among 
the hardest to break, which, combined with the large size 
of the stones, results in poor outcomes with shock wave 
lithotripsy (SWL). In an experiment conducted, several 
shock waves were needed to break brushite stones. It 
was also discovered that pure brushite stones are hard-
er to break than brushite stones that contain a mixed 
composition. Shock wave lithotripsy is not the optimal 
treatment for brushite stones. However, invasive imaging 
is needed to determine a stones composition and so it 
remains a challenge in deciding the best treatment plan 
(Williams… McAteer, 2012). 
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Uric Acid Stones: 
Why/how do they form?
Uric acid stones form because of abnormally low-acidic 
pH of urine a pH below 5.5. low urinary volume and hy-
peruricosuria are also associated with the formation of 
uric acid stones,  (Van Hattum, de Bie, and  Somani, 2019). 
Low urine pH can be partly ascribed to low ammonia 
excretion. Low urinary pH and uric acid stones are com-
mon in patients with an assortment of disorders. Patients 
with high BMI, gout, diabetes mellitus, and the metabolic 
syndrome, may have reduced renal ammonia excretion. 
The reduced ammonia excretion may be due to insulin 
resistance which is common in these diseases. In addi-
tion, urinary pH is inversely proportional to body weight. 
As body mass increases, urinary pH falls and becomes 
more acidic. Chronic diarrhea also lowers urinary pH and 
causes uric acid stones.  Uric acid gravel can obstruct 
ureters and produce acute anuric renal failure. Uric acid 
stones can fill the entire renal collecting system. Uric acid 
pebbles and stones are often orange or red, as they have 
absorbed uricine, a pigment of bilirubin breakdown. (Van 
Hattum, de Bie, and  Somani, 2019).
Treatment/Recurrence
Prevention and even dissolution depend on the three 
main components of uric acid stone formation; an in-
crease of urinary volume, prevention of hyperuricosuria 
and increase in urinary pH. By increasing daily fluid intake 
the urinary volume increases thereby decreasing the con-
centration of uric acid. There are different medications 
that can increase the pH of the urine thereby minimizing 
the risk of supersaturation and consequently stone re-
currences. Medications such as potassium citrate, sodium 
citrate and sodium bicarbonate have been proven to in-
crease the pH of urine (Van Hattum, de Bie, and  Somani, 
2019). Allopurinol is not usually required; however it can 
be used if one of the above three medications does not 
suffice (Coe, Evan, and Worcester, 2011).
Cystine Stones: 
How/ why do they form?
Cystine stones are the most rare form of kidney stones. 
They constitute less than 1% of urinary tract stones. 
Cystine stones are often caused by Cystinuria. About 1 
in 7000 people worldwide have cystinuria. Most people 
with cystinuria get their first stones in their twenties or 
thirties, but 30% get them in their teens. According to 
some research, 8-10% of kidney stones in children are 
cystine stones.  Cystinuria is a genetic condition causing 
mutations in renal epithelial cell transporters that result 
in reduced reabsorption. This leads to an increased urine 
excretion of the dibasic amino acids, including cystine. 
Because of the high super saturation of cystine, stones 
form (Coe, Evan and Worcester, 2005).
Treatment
Cystine stones can be removed in the same manner as 
other kidney stones. They can be removed by nephroli-
thotomy, a procedure where an instrument is inserted 
through the skin and into the kidney to either take the 
stone out or break it apart. Ureteroscopy is another 
method. It involves sticking a tiny instrument into the 
bladder and then up the ureter to remove the stone. A 
third method, is Extracorporeal shock wave lithotripsy 
(ESWL). This is a procedure that uses shock waves to 
break up larger stones into smaller pieces so that they 
are passable. This method however, does not work as well 
for cystine stones as it does on other types of stones 
(Frassetto & Kohlstadt, 2011).
Recurrence
Being that Cystinuria is a lifelong condition, the recurrence 
of cystine stones is quite high. To combat this, the patient 
must be sure that the super saturation concentration of 
cystine is below one. To begin with, patients try to attain 
a urine volume of three to five liters a day which can 
dissolve the cystine that is excreted. Some also require 
a medication to raise the pH of the urine. In addition, 
reduction of sodium and protein intake reduces cystine 
excretion in the urine. It is for this reason that attention 
to diet is an essential part of the treatment process. If 
increasing fluid levels and lowering the pH of the urine 
by diet does not work, there are medications that can 
be used. D-penicillamine, α- mercaptopropionylglycine, 
or captopril, all form soluble heterodimers with cysteine 
and so they can be used. However, these medications may 
have severe side effects such as loss of taste, fever and 
proteinuria, and so the former mentioned methods are 
more desirable (National Kidney Foundation, 2016).
The Effect of the Seasons
When attempting to connect seasonal changes with occur-
rence of kidney stones a huge number of factors must be 
taken into account. There have been many studies done on 
this topic and the results have been confusing. In one study, 
research has shown no difference in urine volume from the 
summer to the winter. In another study, during the winter 
months when vitamin D intake is limited, urinary calcium 
excretion was found to be much higher. This being the case, 
it would seem that kidney stones would more likely form 
in the winter  (Attalla,  De,  Sarkissian,  and Monga, 2018) . 
Dietary patterns may fluctuate as well with the changing 
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seasons. With a reliance on packaged and processed food 
during the winter, urinary sodium may be increased. With 
an increase in urinary sodium, urinary calcium will sub-
sequently increase as well. Also, weight fluctuations may 
complicate the analysis further. With less opportunities for 
physical activity during the winter months, coupled with 
the indulgent eating during the holiday season, urinary cal-
cium may be increased. Also, lower levels of vitamin D have 
been associated with weight gain  (Attalla,  De,  Sarkissian, 
and Monga, 2018) . All these factors point to the winter 
months having a high propensity for stone formation. 
In contrast to the research above, William Haley, a Mayo 
Clinic nephrologist, has found that heat, humidity, and lack 
of proper hydration all lead to a higher prevalence of kid-
ney stones in the summer. In the summer there is a great-
er likelihood of dehydration and thereby the possibility 
of a decrease in urine volume. This would consequently 
raise the possibility of nephrolithiasis (Sparks, 2015).
Socioeconomic Status
A study was done to ascertain if socioeconomic status 
can affect nephrolithiasis. The study used the Distressed 
Communities Index (DCI) which takes into account em-
ployment status, education level, poverty rate, median 
income, and business growth. Diabetes and hyperten-
sion were more prevalent in the group of people from 
severely distressed communities. Patients from these 
communities needed more invasive treatment and 13% 
needed staged surgery versus 9% from the non-severe-
ly distressed communities. Men from the severely dis-
tressed community had a significantly larger stone size; 
12.5mm vs 9.7mm. The men also had a higher prevalence 
of stones greater than 20 mm. Interestingly, there was no 
difference in stone size between the two different groups 
of women. Socioeconomic status seems to correlate with 
stone size, but appears to have more of an effect in men 
than in women(Quarrier, Li, Best, Hedican, Penniston, and 
Nakada, 2020)
Obesity
Obesity contributes to the risk of kidney stones more 
than dietary factors. Maladaptive changes associated with 
obesity are disturbed thermogenesis and dehydration. 
This is because body fat is hydrophobic, so the propor-
tion of body water decreases with increasing obesity and 
this can lead to dehydration. Also, the decrease in body 
surface area compared to body volume complicates heat 
exchange and metabolic functions. Obesity is often as-
sociated with electrolyte imbalances and altered urine 
chemistry. All evidence points to obesity being a great risk 
factor for kidney stones.
It would seem logical and apparent that weight loss 
would be the solution to the abovementioned compli-
cations. However, it is not that simple. Weight loss has to 
be done in a healthy and reasonable fashion. A high ani-
mal protein diet, quick loss of lean tissue, or insufficient 
hydration can actually increase the likelihood of kidney 
stone formation. Diets high in acid can increase the risk 
of uric acid stones. The patient must make his or her di-
etary choices in an informed manner taking into account, 
his specific propensities to stone formation (Frasseto & 
Kohlstadt, 2011) 
Serial soda drinkers may be at an increased risk for 
kidney stones. An experiment was done with a sample 
of  males who ingested 200 grams of fructose daily for 
two weeks. Research showed that fructose intake greatly 
increases the chances of kidney stones.  This is because 
fructose affects urate metabolism, urinary pH and affects 
oxalate. Since fructose is present in so many of the foods 
that the average American consumes, it can play a major 
role in increasing the risk of forming stones. Moreover, 
a randomized trial stated that a 10% reduction in stone 
recurrence for those who could reduce their soft drink 
intake to less than 24 ounces a week (Johnson, Perez-
Pozo Lillo, 2018) 
Occupation-“You are what you do”
Studies have shown that people with certain occupations 
have a higher probability of developing kidney stones. 
Some forms of work don’t allow for proper fluid intake 
leading to a saturated urine concentration. Individuals 
who are more active when they work, especially if they 
work outdoors, perspire more, leading to more concen-
trated urine. However, those who have more sedentary 
jobs are also in danger. Since they have a higher chance 
of metabolic syndrome, they also have a higher risk of 
forming stones. Since Astronauts work in environments 
without gravity, they assemble calcium from their bones, 
leading to greater calcium levels and consequently a high-
er risk of stone disease (Malieckal & Goldfarb, 2020).  
Removal of Kidney Stones- A Wild Ride
In 2016 two physicians came up with a rather unique 
method to dislodge a kidney stone after hearing about 
this interesting phenomenon from their patients. One 
patient reported passing renal calculi after each of 3 con-
secutive rides on the roller coaster. Many other patients 
reported passing renal calculi within hours of leaving the 
amusement park, and all of them rode the same roller-
coaster during their visit. They used three renal calculi, 
based on real life measurements. The renal calculi were 
suspended in the urine model and taken for 20 rides 
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on the Big Thunder Mountain Railroad roller coaster at 
Disney World in Orlando. When the model was sitting in 
the front seat of the roller coaster, there was a passage 
rate of 4 out of 24. When sitting in the back there was 
a passage rate of 23 of 36. Sitting in the rear, different 
kidney stone location had different passage rates. An 
upper calyceal calculi passage rate of 100%, a middle ca-
lyceal passage rate of 55.6% and a lower calyceal passage 
rate of 4%. Although the data written above is encour-
aging, physicians must determine if a roller coaster ride 
is the correct form of treatment for their patients, as 
size and location may complicate the situation (Mitchell 
&Wartinger, 2016).
Corona Virus and the Kidney:
There has been emerging connections between coro-
na virus and kidney failure but why this happens is still 
unclear. Many doctors have proposed different theories. 
One theory is that the virus directly attacks the kidneys 
by its way of infiltration. A study published in March 
shows that Corona virus infiltrates the body by binding 
to the ACE2 cell receptors. The kidney contains these 
ACE2 receptors, and in this way is under direct attack. Yet 
another theory states that the kidneys are affected sec-
ondary to the virus. Because the lungs are so hard hit, the 
body is unable to deliver adequate oxygen to the body. 
In turn organs are damaged and functionality is reduced. 
The virus also effects the blood, which can lead to clots. 
The kidney, being the biggest blood filter in the body is 
not susceptible to blood clots within its thousands of 
capillaries and vessels of filtration. Also blood clotting has 
an effect on the body’s immune system possibly triggering 
a cytokine storm in which the body attacks its own cells 
and tissues. Furthering the potential damage to the kid-
neys and other essential organs (Edwards, 2020) 
Conclusion
As more research is done on kidney stones it becomes 
abundantly clear that even more research is needed. 
There are an innumerable amount of factors to take into 
account when determining the best course of treatment 
for persons with renal calculi. The patient’s occupation, 
ethnicity, BMI, family history, and region of residence are 
all contributing aspects. Stone composition may be very 
varied from case to case. Treatment that was successful 
for one may be detrimental for the other.  There is no 
one-size-fits-all solution. Each case is unique and requires 
its own analysis and diagnosis. One thing is universal 
though, sufficient hydration is essential for the prevention 
of kidney stones.
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Fecal microbiota transplantation (FMT) is a method of transferring feces from an individual with a healthy microbiome to a patient 
whose healthy gut bacteria is deficient. While this method is not a new one, it is constantly being explored and studied to determine 
if it can be an effective way to treat patients with different bowel diseases . The main target of most of these studies are patients 
with recurrent Clostridium difficile infections.  Many studies were done to determine if the method is safe, and which method is most 
effective, as well as who can be a good donor or recipient of the treatment .
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Treatment for Gastrointestinal Diseases?
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Introduction
The large intestine is comprised of the cecum, the colon, 
the rectum and the anal canal. The colon is the last step in 
the digestive tract before the feces are expelled through 
the anus in a bowel movement. It is a tube-like structure 
containing the usual four layers; the mucosa, submucosa, 
muscularis and serosa. Problems can occur if the mucosa 
becomes inflamed or infected. Bacteria colonize the large 
intestine and aid in the digestion of proteins and other 
food particles to ready them for defecation. Bacteria also 
play a role in the homeostasis of the gut (Tortora, 2014).
The colon is packed with bacteria that make up the 
human microbiome. These are symbiotic organisms that 
perform different functions in the human body. Research 
has shown that many are important for metabolism and 
epithelial cell growth, doing jobs that are similar to those of 
the endocrine system. It seems that the microbial diversity 
turns out to be significantly higher in adults than children, 
and even more so in that of the elderly.  Infants are found 
to have an extremely low diversity. (Blaut, et al., 2002)
The many commensal bacteria in the gut influence im-
mune function. There are a few different ways this could 
be true. One of these is that the bacteria can promote 
the health of the epithelial lining in the intestines. This 
strengthens the primary barrier, so that pathogens can-
not pass through the lining. In addition, some of these 
good bacteria can help produce and secrete an anti-in-
flammatory response to some inflammatory cytokines. 
Other mechanisms include the production of secondary 
bile acids, and the competition for nutrients with the 
pathogenic bacteria (Zeng et al., 2019).
In people with a healthy gut composition, there are a 
different kind of bacteria that contribute to the symbiosis 
of the gut. These bacteria serve as an anatomical barrier to 
the different pathogens that enter the intestines through 
various ways such as with food that is ingested. The four 
main phyla that are found are Firmicutes, Bacteroides, 
Proteobacteria and Actinobacteria. (Lopetuso et al., 2013). 
In a normal bacterial gut composition, there is a sym-
biosis in which the bacteria work together to perform 
different functions. Dysbiosis occurs when there is an 
imbalance of the different gut bacteria, often resulting in 
disease such as inflammatory bowel diseases (IBD), and 
other gastrointestinal disorders. One common disease 
is infectious colitis caused by C. difficile. Others include 
gastritis, peptic ulcer, irritable bowel syndrome (IBS) and 
even gastric and colon cancer.  (Lopetuso et al., 2013).
Methods
Research for this paper included using databases such as 
the Touro College Library, PubMed and Google Scholar. 
These were used to find peer reviewed articles on stud-
ies related to gastrointestinal diseases and FMT as a 
treatment.
What is C. Difficile Infection?
As a result of taking antibiotics, many patients are left 
with a decrease in gut bacteria diversity, namely of the 
commensal Bacteroidetes and Firmicutes variety. At the 
same time, there tends to be a proliferation of proteo-
bacteria which include pathogenic organisms such as C. 
difficile and shigella (Staley et al., 2016). C. difficile, an op-
portunistic organism can now cause infection because it 
is not outcompeted by good bacteria for nutrients and 
other factors that help bacteria thrive. In addition, as 
mentioned above, there is a reduction in the bacteria that 
normally prevent the proliferation of these pathogens by 
different mechanisms. In the majority of cases, C. diffi-
cile is treated with the antibiotic vancomycin or other 
similar drugs. Often, this course of antibiotic therapy is 
ineffective, resulting in recurrent C. difficile infections. 
Fecal microbiota transplantation attempts to address the 
problem by allowing the feces of the healthy donor to aid 
in replenishing the depleted gut bacteria of the patient. 
This leads to the patient’s stool bacteria becoming very 
similar to that of the healthy donor (Kelly et al., 2015).
Secondary Bile Acid Production by Bacteria
There is evidence that suggests that secondary bile acid 
production is a crucial factor in preventing C. difficile infec-
tions. There appears to be a difference in the bile acid com-
position in the colon of patients with C. difficile infections 
in comparison to those with a healthy gut composition. A 
bile acid analysis study was done on fecal extracts of both 
donors and recipients of FMT. The results demonstrated 
that the pre-FMT samples contained mainly primary bile 
acids and bile acid salts and did not contain any secondary 
bile acids. In contrast, the post-FMT samples, as well as the 
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donor samples contained a high abundance of secondary 
bile acids, indicating that the bacteria from the healthy 
donor had an effect on secondary bile acid production. 
These factors seem to indicate that it is indeed the met-
abolic function of these bacteria that aid in preventing C. 
difficile infections (Weingarden et al., 2014). 
Primary bile acids are produced in the liver. The main 
ones are cholic acid and chenodeoxycholic acid. Before 
being secreted into bile, the bile acids are chemically at-
tached to the amino acids taurine and glycine to form bile 
salts. These are then secreted into bile and then used for 
lipid digestion in the small intestines. While most of these 
are reabsorbed, about 5% of them reach the large intestine 
where they subsequently become deoxycholic and litho-
cholic acids which are secondary bile acids. As mentioned 
before, post FMT and donor samples contained mainly sec-
ondary bile acids and few primary bile acids. Some studies 
have inferred that the primary bile acid taurocholic acid 
(cholic acid combined with taurine), is actually a require-
ment for C. difficile growth and proliferation, and is used 
in growth media for this organism. It was also noted that 
the secondary bile acids lithocholic and ursodeoxycholic 
acids (from chenodeoxycholic acids), inhibit the growth of 
C. difficile (Weingarden et al., 2014). 
In a study done, it became apparent that the Clostridium 
scindens, of the firmicutes phylum, is the bacteria that is 
likely responsible for preventing infection due to its role 
in secondary bile acid production (Staley et al., 2016).
The bile acid experiment was done in conjunction with 
the bacterial diversity survey. There was a correlation be-
tween the two studies, showing that an increase of second-
ary bile acids came along with an increase in Bacteroides 
and Firmicutes. These experiments indicate that it is likely 
these commensal bacteria play a metabolic role in bile acid 
production, inhibition of the pathogenic C. difficile, and 
overall gut health (Weingarden et al., 2014). 
Who is a Good Fecal Donor?
It is not completely clear who makes a good donor for 
FMT. It is assumed that it would greatly depend on the 
donor’s lifestyle and diet. Though it was noted during one 
study that there were good outcomes from one donor 
in particular, it was hard to trace exactly what made 
that donor so effective. In addition, many FMT trials are 
done with multi-donor stools for increased diversity. 
This would cause the researchers to be unable to isolate 
which donor made it most effective (Quraishi et al, 2017). 
There is indication that relatives are beneficial as FMT 
donors because they share genetics, and are likely to have a 
similar microbiome to the patient. Others say that it is ben-
eficial for a patient to receive FMT from his or her spouse 
because they likely have been in contact with similar patho-
gens and therefore may be protected from harmful effects 
of introducing many new bacteria to the gut. Some think 
that an unrelated donor is better, because they feel that 
someone who is not related would be more honest in an-
swering questions that may rule them out from donating. 
There is not enough conclusive evidence to determine if 
any of these are indeed true (Kelly et al, 2015).
In gathering the donors, there is a list of exclusion 
factors that can rule out those who should not donate 
stool. These include those who have been on antibi-
otics in the past 3 months, have had any history of a 
disease that is normally transmitted by stool, or who 
are known to have IBD, IBS or other gastrointestinal 
complications or conditions. In addition, those who have 
had a history of autoimmune diseases, malignant diseas-
es, chronic pain or metabolic syndromes cannot donate 
feces. The reason for this is because it is assumed that 
people who have these conditions may have an altered 
microbiome which might be detrimental to introduce 
to a patient who is already compromised (Kelly et al, 
2015). In addition, someone who has an autoimmune 
disease is likely being treated with immunosuppressants 
which suppresses the body’s immune system. If this was 
introduced into the recipient, this could be especially 
harmful because there is already an infection in the pa-
tient that needs to be treated, and they must have an 
active immune system. Additionally, it is possible that 
certain DNA which causes these conditions would be 
present in the stool and it would be very risky to in-
troduce to the patient (Petrov, M. E., 2011).  Once they 
have fulfilled the above requirements, they are screened 
for infections within a month of donating and can then 
donate stool (Kelly et al, 2015).
Screening Before Donations
The specific tests done to screen a donor include those 
that play a role in metabolic function and the digestive 
system in particular. Some of these include a complete 
blood count, as well as a c-reactive protein test which 
checks for inflammation within the body. In addition, 
they are tested for levels of creatinine and liver enzymes. 
The stool itself is screened for ova and parasites and C. 
difficile in particular, among other intestinal pathogens 
(Satokari et al, 2015).
Methods of Preparing Feces for Transplantation
The transferring of feces can be done by different proce-
dures. Those include transplantation with an oral capsule, 
colonoscopy or by enema. (Kao et al, 2017). There is also 
debate about whether it makes a difference if the feces 
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were previously frozen, or if fresh stool is used. Results of 
trials show that there is little difference in effectiveness 
between these methods. Therefore, it is suggested that 
frozen samples be used simply because they are easier to 
produce and obtain (Satokari et al, 2015).
In addition to what was mentioned above, using frozen 
stool allows for universal donors. That means that when 
a potential donor is screened and found to be a good 
candidate, his feces can be used for multiple patients. This 
would also allow clinics to store the frozen feces and use 
them as needed (Satokari et al, 2015).
Fresh Stool for FMT
When using fresh stool for FMT, the stool must be used 
within a 6-hour window of time, from defecation to trans-
plantation. With this method, approximately 30 grams of 
stool is mixed with 150 ml of tap water and then admin-
istered to the patient within 15 minutes of preparation. 
This method is very limiting, and not as readily available 
as frozen stool (Satokari et al, 2015).
Preparing Fecal Slurry for Colonoscopy with 
Frozen Stool
There are slight variations in methods of preparing frozen 
stool for FMT. The following is one of them:
Fresh stool is collected and stored in units of 80-100 g. To 
each collection, 200 ml of .9% saline is added. The result-
ing mixture is filtered through a stomacher bag, designed 
to keep samples uncontaminated, yielding 180 ml of fecal 
slurry. Mixing the slurry with 20 ml of 100% glycerol al-
lows it to be frozen at -70 degrees Celsius for 2 months, 
until needed.  For use, the slurry is defrosted overnight at 
4 degrees Celsius and then reconstituted with 160 ml of 
.9% saline. (Kao et al, 2017)
In using fresh or frozen stool, one method of admin-
istering it is through a biopsy channel, a piece of flexible 
tubing in the cecum (Satokari et al, 2015).
Preparing Feces for Capsule Manufacturing
Forty ml of 100% glycerol is added to 200 ml of prepared 
fecal slurry and centrifuged for 20 minutes at room tem-
perature and 400 G (gravitational force). After decanting 
the supernatant, the sample is then centrifuged at 4-8 de-
grees Celsius and 10,000 G by high speed centrifuge. The 
remainder of the sample is mixed to yield about 12 ml of 
sample containing 10^13 microbes by estimation. This is 
then pipetted into size No. 1 gelatin capsules which are 
then encapsulated twice by size 0 and then 00, yielding 
40 capsules. These capsules are then flash frozen at -55 
degrees Celsius on dry ice to preserve them. Just like the 
fecal slurry, the capsules can remain stored at -70 degrees 
Celsius for 2 months. To administer FMT, the patient swal-
lows approximately 40 capsules within a short period of 
time (Kao et al, 2017).
Synthetic FMT
Vos W.M writes that synthetic FMT is likely a good alter-
native to the common use of donor stool. Synthetic FMT 
is a lab produced combination of the needed strains of 
bacteria, without the actual stool of the donor. The reason 
for this is because by the time the donor stool reaches the 
patient, many of the organisms are no longer viable. In ad-
dition, stool contains other wastes, mucus and pathogens. 
Vos suggests that administering synthetic microbiota which 
was cultured to get the right composition of bacteria is not 
only more effective, but less likely to have adverse effects 
as well. Synthetic FMT would not contain all the parts of 
the stool that are unnecessary as well as detrimental to the 
patient. In addition, it would allow for greater viability and 
microbial diversity as well as being able to be manufactured 
and reproduced (Vos, 2013).
Effectiveness in Treating C. difficile Infections
In order to determine effectiveness, a DNA sequencing 
test is performed to determine which bacteria were col-
onized in the gut of the patient post FMT treatment. In 
studies that were done, the patients who were treated 
with heterologous stool samples- that of a donor showed 
a greater diversity in stool microbiology than those who 
were treated with autologous samples- their own, i.e. 
the placebo group. In the heterologous stool samples, 
there was a significantly higher presence of Bacteroidetes 
and firmicutes, indicating that these are the phyla that 
should be present in healthy stool. In contrast, those who 
were treated by placebo did not contain an abundance 
of these bacteria. Instead, they presented with more of 
the Clostridium XIVa clade and Holdemania bacteria 
that were thought to take part in causing the C. difficile 
infection. Results from this study seem to imply that a 
complete engraftment- proliferation of all the bacteria, is 
not necessary so long as the needed bacteria are present. 
(Staley, et all ,2016)
In a systematic review by Cammarota, Laniro, and 
Gasbarrini, A. indicates an 87% success rate when com-
paring the data of numerous studies. The rates of diarrhea 
resolution varied depending on the site of the fecal trans-
plantation. The data indicated a rate of 81% in the stom-
ach, 86% in the duodenum-jejunum, 93% in the cecum-as-
cending colon, and 84% in the distal colon. (Cammarota, 
et al, 2014)
A randomized trial was performed on 46 patients with 
3 recurring episodes of C. difficile. All of these patients 
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were treated with vancomycin without success. During 
the study, all the patients were treated by colonoscopy. 
Some of the patients were treated with donor stool, 
while others were treated with their own autologous 
stool. Those treated with autologous stool were checked 
to determine if the donor stool was indeed more effec-
tive, or similar to the placebo effect. Of the 22 who were 
treated with donor stool, 20 had a full recovery from C. 
difficile, accounting for a 90.9% recovery rate. In contrast, 
of the 24 who were treated with their own stool, only 15 
recovered, which is a 62.5% recovery rate. The patients 
who contracted another C. difficile infection following 
FMT with autologous stool were subsequently treated 
with donor stool, with success. The outcome of this study 
seems to indicate that FMT is a safe, effective way to treat 
recurrent C. difficile infections (Kelley et al, 2016)
A study was done to determine whether transplanta-
tion by colonoscopy or by oral capsule was more efficient. 
The outcome of the study seems to indicate that neither 
one is preferable and both were effective. The factors to 
consider were those that an oral capsule is both less inva-
sive and cheaper to administer. (Kao et al, 2017) 
FMT for Ulcerative Colitis
Ulcerative colitis is a condition in which the mucosal 
layer of the colon is inflamed. Patients with this condi-
tion present with bloody stool, anemia and abdominal 
pain (Costello et al, 2019). A trial was done in 3 hospitals, 
treating 85 patients to see if FMT could work to cure ul-
cerative colitis in addition to the known effects of treating 
C. difficile infections. In this trial, patients were treated 
with stool from multiple donors to increase the biodiver-
sity. There was also a placebo group. In both groups color 
and odor was added so that the patients would not know 
if they were receiving the real transplant. The original in-
fusion was administered by colonoscopy, directly into the 
terminal ileum and caecum. The patients were monitored 
periodically for 8 weeks (Paramsothy et al., 2017).
Though there was not a significant majority, 27% of 
people who received donor FMT saw a relief of symp-
toms, while only 8% of placebo patients saw these effects. 
After the 8 weeks however, the numbers on both sides 
increased. It was observed that a particular bacterium of 
the Fusobacterium variety was present in those who did 
not have a remission of symptoms after FMT. It is import-
ant to note that majority of the patients in the placebo 
group had milder symptoms to begin with. The outcome 
of the study indicated that FMT may be a good alterna-
tive to usual steroidal therapies used for ulcerative colitis, 
though more research would need to be done to deter-
mine if that is indeed the case (Paramsothy et al., 2017).
A study was done to determine if anaerobically pre-
pared stool would be as effective as aerobically prepared 
FMT for ulcerative colitis. The purpose of the trial was to 
determine if the organisms in the stool would be more 
viable if they were prepared anaerobically. This study was 
done after the study mentioned above by Paramsothy. 
Based on data that was collected from the above study, 
researchers were hopeful that FMT could be very effec-
tive in ulcerative colitis patients. This study was a varia-
tion of the first one. The outcome of the study indicated 
that 32% of those who received donor FMT saw an initial 
relief of symptoms. Nine percent of those who received 
autologous stool saw an initial relief of symptoms as well. 
(Costello et al, 2019). This data seems to be very similar 
to that of the aerobically prepared FMT. More trials would 
be needed to determine if anaerobically prepared stool is 
actually more effective. This study adds to the research 
that FMT is helpful in some cases for ulcerative colitis. 
FMT for IBD
IBD is a general term for different inflammatory bowel dis-
eases. Included in these are ulcerative colitis and Crohn’s 
disease. As mentioned above, these diseases cause chron-
ic inflammation of the bowel. Either of these conditions 
can cause colorectal cancer, and other medical problems 
in the individual. There is evidence that suggests that it is 
the microbiome gut composition that plays a role in these 
diseases. After seeing great success in treating recurrent 
C. difficile with FMT, researchers are hopeful that it can 
work as a therapeutic treatment for other conditions as 
well (Quraishi et al., 2017).
According to studies, it seems that IBD can be an ab-
normal reaction to having microbiota in the gut. Patients 
with this condition possess genes that view these enteric 
bacteria as pathogens, even those that are considered 
symbiotic in a healthy person. Evidence to support this 
study included testing on germ-free animal models that 
were predisposed to IBD. In addition, there were stud-
ies done in which the fecal stream was diverted. In both 
of these studies, it appeared that not having any bacteria 
present in the gut led to having no inflammatory symp-
toms. The activation of innate and adaptive immunity by 
bacteria that is normally nonpathogenic can lead to an 
inflammation in the gut in the absence of pathogenic bac-
teria (Quraishi et al., 2017).
It is noted by Quraishi et al., that though it seems that 
any presence of bacteria induces IBD in those that are pre-
disposed, there are studies done that suggest that there 
is indeed a difference in microbial diversity in those with 
IBD in comparison to those with a healthy gut (Quraishi et 
al, 2017.) The composition is characterized by an increase 
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in bacteria which include Enterobacteriaceae, Pasteurella, 
Veillonella, and Fusobacteria, and also contains less Firmicutes, 
Bacteroidetes, and Clostridia (Gevers et al., 2014). It is also 
noted that there is an increase of Proteobacteria in those 
with IBD. Using FMT with IBD has been met with very lim-
ited success in the past. There has been more evidence of 
success with ulcerative colitis patients, than in those with 
Crohn’s disease (Quraishi et al, 2017).
FMT for Hepatic Myelopathy
Hepatic myelopathy is a neurological complication that 
comes from severe liver disease. Usually, it can only be 
treated by a liver transplant. There was a case study done, 
however, that indicated that FMT may indeed be a solu-
tion to this illness. The study was done on one 45-year-
old woman in china. She was admitted to the hospital 
numerous times, and underwent various procedures. The 
reasons for these included different complications such as 
splenomegaly, vomiting blood and other internal bleeding. 
The last visit was due to a weakness and stiffening in her 
legs. Interestingly, after being treated with 3 courses of 
FMT, she reported a relief of symptoms. There is no con-
clusive evidence that this can work in all cases. However, 
due to the known correlation between gut symbiosis and 
neurological health, the researchers say that FMT may be 
a good therapeutic alternative to a liver transplant as it is 
more available and less invasive (Sun et al, 2019).
Adverse Effects of FMT
In a randomized trial done, it was noted that there were 
no serious adverse effects following fecal microbiota 
transplantation. The study did not include anyone who 
was immunocompromised, or above age 75. Following 
FMT the patients were monitored periodically for 6 
months, and none exhibited any serious symptoms in re-
lation to FMT (Kelley et al, 2016).
Kao et al reports that two patients died following FMT, 
though it was not likely due to the procedure. Both had 
significant cardio-pulmonary disorders and both were el-
derly (Kao et al, 2017).
While FMT has seems to have many beneficial uses, 
as with any therapy, there are downsides as well. Dr. 
Schwartz, Gluck and Koon say that a reason for this may 
be because though fecal donors go through extensive 
screening, it is possible that they were carrying diseases 
that they were unaware of. They could have been asymp-
tomatic and not have been tested for that specific patho-
gen. There were two cases noted of norovirus in Virginia 
Mason Medical Center in Seattle. Norovirus is a common 
contagious virus that causes gastroenteritis in many peo-
ple. In those cases, the donors were asymptomatic and it 
was unknown whether the virus was transmitted through 
the feces as there was a window of time between the 
collection of the feces and the actual transplantation. The 
most significant effect of these cases was that both pa-
tients presented with a relapse of C. difficile infections. 
It was speculated that it is possible that the norovirus 
altered the bacterial community present in healthy stool 
resulting in an ineffective FMT (Brandt, L. J., 2013). 
In an FMT trial on ulcerative colitis patients, a significant 
amount reported adverse effects. Approximately 78% of 
the donor stool recipients and 83% of the placebo recipi-
ents reported gastrointestinal upset. The complaints were 
self-limiting, resolving on their own and having no long-
term effects. In addition, 2 patients who received donor 
stool, and 1 who received autologous stool as a placebo 
presented with serious adverse effects (Paramsothy et al, 
2017). The study did not mention what they were.
Quraishi et al. note that FMT should not be admin-
istered to those who have Crohn’s disease with deep 
patch ulceration in the gut. The reason for this is because 
it is likely that the bacteria may translocate. That is, the 
bacteria may cross the organ barrier and enter into the 
bloodstream where it does not belong. Administering 
FMT in those patients could cause many harmful effects. It 
is different however for ulcerative colitis because in that 
condition the inflammation is contained to the epithelium 
and risk of bacterial translocation is not high (Quraishi et 
al., 2017).
In a letter written to the editor of The American 
Journal of Gastroenterology, Dr. Brandt presents his ob-
servations that there are effects of C. difficile that are not 
yet known. He noted however that it is reasonable to as-
sume that down the line there would be adverse effects. 
Those may include short term affects like allergic reac-
tions or transmitted infections. He speculates that it is 
likely that FMT patients may suffer long term effects such 
as conditions that result from an altering the recipient’s 
microbiome to be similar to that of the donor (Brandt, L. 
J., 2013). It is interesting to note, however, that this was 
written in 2013, and articles written in later years did not 
report these predictions.
Why Not Oral Probiotics?
People think that probiotics are helpful for the gut mi-
crobiome. The reason for this assumption is that if some 
bacteria are considered good, an increase in those bac-
teria should be considered helpful to a person’s overall 
wellbeing. Research has shown, however, that this may 
not necessarily be the case. It was noticed that certain 
cancer patients were not responding to immunotherapy 
and that majority of those patients were taking probiotic 
91
Is Fecal Transplantation a Safe and Effective Treatment for Gastrointestinal Diseases?
supplements. There is evidence that taking a probiotic 
supplement reduces the biodiversity in the gut. Though it 
does cause an increase in certain essential bacteria, those 
bacteria in large quantities may be harmful to other sys-
tems. For example, an increase in Bacteroides is said to 
increase metabolism, but seems to be detrimental to the 
immune system (Hardy, L., 2019).
There is also research that indicates that taking pro-
biotics after a course of antibiotics actually slowed the 
body’s response in replenishing the gut. In this study, three 
groups of patients were given antibiotics. One group was 
not subsequently treated, another was given probiotics, 
and the third was given autologous FMT with stool col-
lected before they were given antibiotics. Evidence from 
this study indicated that those who were given probiotic 
supplements took significantly longer to recover than the 
others. This study also seems to show that FMT is indeed 
a good way to replenish the gut bacteria after treatment 
with antibiotics (Hardy, L., 2019).
Conclusion
In conclusion, there is hope that FMT can effectively treat 
dysbiosis of the gut. This is especially true for the case 
of a recurrent Clostridium difficile infection, where the 
majority of cases were cured with few or no adverse 
effects noted. There are studies that imply that other gas-
trointestinal diseases could be treated effectively as well. 
It was also noted that there is little difference in outcome 
of treatment when different methods of transplantation 
are used. Other than for recurrent C. difficile infections 
for which FMT has been deemed effective, more research 
should be done to determine if it is effective for the other 
mentioned diseases. Overall, FMT is a promising and in-
novative therapy for gastrointestinal problems.
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Nicotine dependence as a result of smoking is a chronically relapsing disorder with detrimental effects . However, fortunately for 
smokers, an armamentarium of smoking cessation aids is available in the forms of nicotine replacement therapy (NRT), non-nico-
tinic drugs (namely varenicline and bupropion), and the novel nicotine vaccines, each with their own mode of action to moderate 
nicotine addiction . This paper analyzes the mechanism of action associated with nicotine addiction and the various methods of 
combat, or at the very least, attenuation of the addiction .
Effective Treatments for Nicotine Addiction
Chaya Shor
Chaya Shor will graduate with an Honors Bachelor of Science degree in Biology in January 2021.
Introduction
Though incognito, nicotine addiction has been proven to 
be the true killer in the seemingly innocent activity of 
smoking, for it reinforces the desire to smoke. To pre-
vent the myriad adverse effects of smoking, smokers 
need to work very hard to break nicotine addiction 
through smoking cessation. Nonetheless, many smokers 
find themselves dealing with many ups and downs in the 
quitting process. It comes as no surprise that nicotine 
addiction is therefore identified as a “chronic condition” 
by The US Clinical Practice Guideline, as many smokers 
need to make several attempts before they 
successfully wean themselves off completely 
(Fagerström & Hughes, 2008). Smoking is the 
second most expensive chronic health condi-
tion in the United States, with an estimated 
economic cost of 300 billion dollars per year 
(Jordan & Xi, 2018). Yet, stopping smoking can 
reverse the biological and economical dam-
age caused by smoking (Benowitz, 2010).
Understandably, 70% of smokers admit that 
they would like to quit. Every year, about 40% 
quit for at least a day. However, due to the extreme dif-
ficulty to abstain, about 45 million Americans currently 
smoke tobacco. Moreover, the 80% who attempt to quit 
on their own return to smoking within a month. Each 
year, only 3% of smokers quit successfully and remain ab-
stinent one year later, highlighting the critical need for 
effective long-term smoking treatments (Benowitz, 2010).
Methods
This comprehensive review is based on critical analy-
ses of literature obtained using various databases avail-
able through The Touro College Library online, such 
as PubMed and ProQuest. The National Center for 
Biotechnology (NCBI) website was also useful in 
provid ing additional source material.
Nicotine Addiction
Cigarette smoking is  a  major cause of death, cardio-
vascular disease, and pulmonary disease. It also pres-
ents the risk for various infections, osteoporosis, repro-
ductive disorders, adverse postoperative events, delayed 
wound healing, duodenal and gastric ulcers, and diabetes 
(Benowitz, 2010). Although nicotine itself plays a minor 
role, if any, in causing smoking-induced diseases, the addic-
tion to nicotine, which leads to sustained smoking use, is 
the proximate cause of these diseases (Onor et al., 2017).
Nicotine (C10H14N2) is a plant alkaloid found in the 
tobacco plant (Onor et al., 2017) that consists of a pyri-
dine and pyrrolidine ring, each one possessing a tertiary 
amine (Escobar-Chávez et al., 2011). The pKa of the pyr-
idine nitrogen is 3.04 and the pKa of the pyrrolidine ni-
trogen is 7.84 under standard conditions. Based on these 
characteristics, nicotine’s distribution exists among three 
forms, depending on the pH of the solution. An increase 
in acidity of solution increases the fraction of protonated 
molecules; conversely, a more basic environment increas-
es the fraction of the unprotonated, or free base, form 
(Figure 1). Although all forms of nicotine are highly soluble 
in water and can easily dissolve in lung fluids and blood, 
the unprotonated nicotine smoke particles are volatile, 
whereas the protonated form is not. Conventionally, a 
sample of particulate matter from cigarette smoke is not 
acidic enough to cause the protonated form to dominate. 
Thus, a higher percentage of unprotonated nicotine can 
rapidly cross biological lipid membranes and be deposited 
in the respiratory tract (Centers for Disease Control and 
Prevention, 2010). Nicotine begins to reach the brain ten 
seconds after inhalation and its concentration continues 
to increase gradually (Dani et al, 2011).
Blood concentrations of nicotine rise rapidly and peak 
at the completion of smoking. The rapid absorption of 
nicotine is attributed to the broad surface area of the 
alveoli and small airways. This rapid rise allows the smok-
er to titrate and manipulate the level of nicotine during 
smoking, which makes smoking the most reinforcing and 
dependence-producing form of nicotine administration 
(Benowitz et al., 2009).




Essentially, pharmacologic feedback, learned factors, ge-
netics, and environmental factors (including tobacco prod-
uct design and marketing, stress, smoking cues, or peers 
who smoke) contribute to nicotine addiction. Other fac-
tors include sex, age, mental illness, and substance abuse. 
Although each of these features contributes, the one that 
will be discussed with percipience is the pharmacological 
interplay with nicotine addiction (Benowitz et al., 2009).
The pharmacological basis for nicotine use is enhance-
ment of mood and augmentation of mental and physical 
functions. Inhalation of smoke from a cigarette allows 
nicotine from the smoke particles to diffuse through the 
lungs, where it is rapidly absorbed into the pulmonary 
venous circulation. From there, it moves quickly to the 
left ventricle of the heart and to the systemic arterial cir-
culation and brain. Based on human autopsy samples from 
smokers, the liver, kidney, spleen, and lung have the highest 
affinity for nicotine (Benowitz et al., 2009). Subsequently, 
the nicotine enters arterial circulation to be moved from 
the lungs to the brain with high affinity, where it binds to 
nicotinic acetylcholine receptors (nAchRs), ligand-gated 
ion channels that normally bind a neurotransmitter ace-
tylcholine (Benowitz, 2010).
NAchRs are pentameric structures consisting of a com-
bination of five different subunits, including nine α sub-
units (α2 through α10) and three β subunits (β2 through 
β4), resulting in at least 12 unique nAchR subtypes that 
have been identified thus far. The α4β2 receptor, though, 
is the prime mediator of nicotine dependence. As seen 
in positron emission tomography studies in humans, 
smoking a full nicotine cigarette nearly saturated α4β2 
receptor occupancy. In fact, when disruption of the β2 
subunit gene was tested in mice, the behavioral effects of 
nicotine were eliminated. Similarly, the α4 subunit is an 
important determinant of sensitivity to nicotine. This was 
confirmed when a mutation affecting a single nucleotide 
in the pore-forming region of the receptor gene in mice 
made it hypersensitive to the effects of nicotine. These 
observations strongly implicate α4β2 nAchRs in nicotine 
addiction and illustrate the α4β2 receptor as a potentially 
attractive medicinal target for treatment of the addiction 
(Jordan & Xi, 2018).
The smoker craves nicotine to propagate dopamine 
overflow in the pleasure-seeking areas of the brain. The 
α4β2 are located on the dopamine (DA) cells of the me-
solimbic system. The system is comprised of projections 
from DA neurons in the ventral tegmental area (VTA) 
to the nucleus accumbens (NAc), the part of the brain 
responsible for reward, pleasure, laughter, aggression, and 
fear, and the prefrontal cortex. Nicotine binding to α4β2 
receptors on VTA DA cells increases neuronal excitability 
and neurotransmitter release, opening the ligand-gated 
ion channel, and allowing Ca2+ and Na+ to cascade intra-
cellularly, which stimulates DA release to NAc (Figure 2). 
This is the underlying effect of nicotine’s reward cascade, 
as dopamine serves as a pleasure signal and mood modu-
lator and is critical for reinforcing nicotinic effects (Jordan 
& Xi, 2018).
When studied under laboratory conditions, nicotine 
elicits classic addictive responses (Dani et al, 2011). In 
order to reap the rewarding feeling associated with nico-
tine and avoid withdrawal symptoms, smokers must main-
tain a certain nicotine level. Repetitive exposure to nico-
tine leads to neuroadaptation and tolerance to nicotine’s 
effects, and accumulation of nicotine in the body leads to 
a more substantial withdrawal reaction if cessation is at-
tempted. Common withdrawal symptoms include anxiety, 
difficulty concentrating, and irritability, all of which can 
last for days, weeks, or longer (Onor et al., 2017).
As neuroadaptation occurs, the number of binding 
sites on the nicotinic cholinergic receptors in the brain 
increases. This causes desensitization, wherein a ligand-in-
duced closure and unresponsiveness of the receptor 
occurs due to the profusion of ligand infiltration. Thus, 
the feelings of craving and withdrawal are exacerbated 
during periods of abstinence due to the mitigated lev-
els of dopamine and other neurotransmitters. However, 
during a smoking period, binding to the α4β2 cholinergic 
receptors alleviates the need for nicotine. To circumvent 
withdrawal symptoms, smokers will sustain sufficient lev-
els of plasma nicotine (Benowitz, 2010). 
It comes as no surprise that nicotine withdrawal is 
extremely taxing on the smoker. Such repercussions are 
powerful incentives to take up smoking again (Benowitz, 
2010). Fortunately for smokers, there is an expansive mar-
ket of nicotine treatments that promote smoking cessa-
tion, some of them in the form of nicotine replacement 
therapy (NRT), non-nicotinic drugs such as bupropion and 
varenicline, and finally, the emergence of nicotine vaccines.
Figure 2 . Schematic diagram of the mesolimbic DA projection 
pathway in the human brain . Nicotine activates a4b2 nAChRs 
located on DA neurons located in the VTA, as illustrated (Xi, 2010) .
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Nicotine Replacement Therapy (NRT)
Nicotine’s rapid rate of absorption and entry to the brain 
are key factors responsible for the high abuse potential. 
Unlike cigarettes, nicotine replacement therapy (NRT) 
products such as gums, inhalers, and transdermal patch-
es can help relieve the physical withdrawal symptoms 
by providing gradual increments of nicotine without the 
damaging chemicals found in cigarette smoke (Jordan & 
Xi, 2018). The gradual distribution of nicotine results in 
low abuse liability of NRTs. Although NRT doesn’t com-
pletely eliminate withdrawal symptoms since it does not 
provide rapid and high levels of nicotine, NRT may pro-
vide a coping mechanism, making cigarettes less enticing 
to smoke (Molyneux, 2004) and increasing the rate of 
quitting by 50 to 70% (Stead et al., 2012). NRTs are well 
tolerated and have minimal adverse effects, but are most 
effective when used in conjunction with intense behavior-
al support (Molyneux, 2004).
In 1984, transmucosally delivered nicotine polacrilex, or 
nicotine gum, was introduced as the first effective NRT to 
serve as a smoking cessation aid, as approved by the US 
Food and Drug Administration (FDA). It is not chewed like 
ordinary confectionary gum, as it must be intermittently 
chewed and held in the mouth for over 30 minutes to 
achieve optimal release of nicotine. The absolute dose of 
nicotine absorbed systemically is much less than the nico-
tine content of the gum, in part because considerable nic-
otine is swallowed with first-pass metabolism (Benowitz et 
al., 2009), where it gets metabolized in a specific location 
other than the location of interest, reducing the concen-
tration that enters systemic circulation (Herman &Santos, 
2019). The dosage is slowly decreased until it is no longer 
required (Wadgave & Nagesh, 2016).
To satisfy the behavioral hand-to-mouth ritual of smok-
ing, the nicotine oral inhaler was introduced to the NRT 
market. Contrary to its label, the inhaler is mainly delivered 
to the oral cavity, esophagus, and stomach, and negligibly to 
the lungs. Because absorption is mainly through the oral 
mucosa, a slow absorption rate of nicotine is achieved, akin 
to that of nicotine gum (Wadgave & Nagesh, 2016).
In a parallel fashion, nicotine patches deliver nicotine 
at a relatively steady rate when applied to and readily 
absorbed through the skin. In fact, the patch is the form 
that delivers nicotine at the slowest rate when compared 
to the other forms of NRT. A chief advantage of nico-
tine patches is the simplicity of user compliance, since 
the patch can be placed on the skin in the morning and 
worn for the duration of the day. The patches are available 
in a range of doses, allowing users to gradually decrease 
their nicotine intake over the span of several weeks or 
longer to ensure a proper adjustment to lower nicotine 
levels until they can attain a nicotine-free state. The rate 
of nicotine release is controlled by the permeability of 
the skin, rate of diffusion through a polymer matrix, and 
rate of passage through membranes in the various patch-
es on the market. In all cases, there is an initial lag time of 
1 hour before nicotine enters the bloodstream, followed 
by continued systemic absorption once the patch is re-
moved, the latter due to the vestiges of nicotine in the 
skin (Benowitz et al., 2009). Current evidence supports 
the safety of long-term use of nicotine patches for nico-
tine treatment (Wadgave & Nagesh, 2016).
Non-Nicotinic Drugs 
Bupropion (Wellbutrin)
The first non-nicotine drug to treat nicotine addiction 
was introduced in 1997. Bupropion (amfebutamone), 
marketed as Wellbutrin and Zyban among others (Fava, 
et al., 2005), an amphetamine-based drug, is a reuptake 
inhibitor of dopamine into neuronal synaptic vesicles 
and a blocker of nicotine’s activation of several neuro-
nal nAChRs. Bupropion undergoes metabolic transfor-
mation to an active metabolite, 4-hydroxybuproprion, 
through hepatic cytochrome CYP2B6, (Foley et al., 2006). 
Bupropion’s structure is akin to nicotine, rendering it a 
compatible competitor (Figure 3). Originally developed 
as an antidepressant, a systematic review of 44 clinical 
trials found that sole therapy with bupropion significantly 
increased long-term (≥6 months) smoking abstinence, af-
firming its efficacy as an anti-smoking agent (Onor et al., 
2017). It should be noted that the antismoking effect does 
not seem to correlate with its antidepressant effect, as 
bupropion is equally as effective for smoking cessation for 
individuals with and without depression (Roddy, 2004).
Figure 3 . The chemical structures of bupropion (left) and nicotine 
(right) (National Center for Biotechnology Information) .
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When nicotine infiltrates the blood and crosses the 
blood brain barrier, there is a release of dopamine into 
the synaptic cleft of neurons in the dopaminergic path-
ways. After nicotine levels subside, dopamine reuptake 
into the axon terminal vesicles occurs. Bupropion is 
thought to inhibit this dopamine reuptake. In vivo studies 
have also shown that bupropion antagonizes the effects 
of nicotine at the postsynaptic acetylcholine nicotinic re-
ceptor (Wilkes, 2008). During withdrawal, bupropion may 
attenuate symptoms by mimicking the effects of nicotine 
on dopamine (Warner & Shoaib, 2005). These effects may 
explain how bupropion inhibits the reinforcing effects 
of nicotine, though it is still unclear whether bupropion 
offers any long-term relapse prevention following termi-
nation of treatment. Nonetheless, both pragmatic and ob-
servational trials of bupropion have shown that approx-
imately 1 in 5 smokers will successfully remain abstinent 
for at least a year post-treatment (Wilkes, 2008).
Varenicline (CHANTIX)
Cytisine is a naturally occurring insecticide found in the 
leaves and seeds of Cytisus laburnum (golden rain tree). 
During World War II, soldiers smoked leaves of this tree 
in lieu of tobacco. Both varenicline and cytisine target 
the α4β2 receptor, where varenicline was developed to 
improve binding to the receptor to enhance efficacy of 
smoking cessation. However, the cytisine structure did 
not lead to a viable drug candidate. In due course, a series 
of efforts based on analgesic bicyclic benzazepines, one of 
which was unveiled as a potent α4β2 nAchR antagonist, 
served as a novel template that led to the development 
of varenicline, branded as CHANTIX. FDA approval was 
based on randomized clinical trials conducted in 3659 
subjects in the United States. The subjects, all of whom 
were chronic smokers, averaged 43 years of age and re-
ported smoking an average of 21 cigarettes per day for 
the previous 25 years. The primary outcome measured 
abstinence from smoking, which came in at a 44% rate, 
a significant improvement over bupropion (30%) and 
placebo (18%). Secondary outcomes, such as the urge to 
smoke and withdrawal symptoms, were likewise improved 
in varenicline-treated subjects over placebo (Jordan & Xi, 
2018). In 2006, varenicline received FDA approval, and it 
was highly touted as an aid to quit smoking (Fagerström 
& Hughes, 2008).
Like bupropion, varenicline has a somewhat paral-
lel configuration to its nicotine competitor in order to 
operate as an appropriate replacement. In fact, in vitro 
binding assays indicate that varenicline’s affinity for the 
α4β2 receptor (Ki = .15 nM) is higher than that of nic-
otine (Ki = 1.6 nM) and cytisine (Ki = 0.23 nM) (Jordan 
& Xi, 2018). Varenicline has the following chemical name: 
7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3- h]
[3]benzazepine, (2R,3R)-2,3-dihydroxybutanedioate (1:1) 
(Figure 4). Varenicline has a molecular weight of 361.35 
Daltons and is highly soluble in water (Pfizer Labs, 2016).
With varenicline, dopamine is still released, but less so 
than with nicotine. Since the α4β2 had been identified to 
have the highest sensitivity to nicotine, it had become a 
potential target for the smoking cessation drug. Varenicline 
was developed to have a high affinity for the α4β2 neu-
ronal nicotinic acetylcholine receptors in the mesolimbic 
dopamine system and stimulate receptor-mediated activity, 
but at a significantly lower level than nicotine. Varenicline’s 
highly selective nature ensures that it will bind more po-
tently to α4β2 receptors than to other common nicotinic 
or non-nicotinic receptors (Pfizer Labs, 2016).
As a result of being a partial agonist, varenicline displays 
both agonist and antagonist effects. Partial agonists have 
been reviewed thoroughly as a method of attenuating 
nicotine addiction. Partial agonists bind to nAchRs but 
do not elicit the maximum response of a full agonist, and 
instead depend on receptor occupancy by other ligands. 
For instance, in the presence of a full agonist like nicotine, 
a partial agonist would behave as an antagonist by occupy-
ing the receptor site, thereby minimizing nicotine’s effects 
at the receptor. However, in the absence of nicotine, a 
partial agonist would behave as an agonist by mitigating 
nicotine withdrawal symptoms through triggering a de-
gree of dopamine release (Jordan & Xi, 2018).
Given that continuous abstinence rates across studies 
remain low (18-30% with varenicline; 4-10% with place-
bo), novel and more effective treatments may be required. 
However, since FDA approval in 2006, incoming reports 
have been continuing to demonstrate varenicline’s effi-
cacy for smoking cessation over the alternatives. For 
example, in a randomized trial involving 376 participants 
over the span of 52 weeks, varenicline resulted in higher 
abstinence rates from smoking (55.9%) when compared 
to transdermal NRT (43.2%), highlighting varenicline’s 
progress (Jordan & Xi, 2018).
Figure 4 . The chemical structures of nicotine (left), cytisine (middle), 
and varenicline (right) (Xi, 2010) .
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Nicotine Vaccines
With the advent of the novel nicotine vaccines, smokers 
have an alternative course of action through which they 
can quit smoking. Currently undergoing clinical trials, the 
goal of the vaccine is to generate antibodies that sequester 
nicotine in the blood and hinder the pharmacological ef-
fects by preventing access into the brain. Thus, the vaccine 
brims with potential for treatment of nicotine addiction 
and relapse prevention (Goniewicz & Delijewski, 2013).
Based on the assumption that a rapid increase in brain 
nicotine levels induces feelings of reward, preventing nic-
otine from entering the brain is an intriguing idea with 
precedent in other, similar treatments. Using antibodies 
to bind a drug and thus disabling it from crossing the 
blood-brain barrier was first tested in the realm of heroin 
addiction and extended to nicotine and cocaine addiction 
(Raupach et al., 2012).
Since nicotine is too small to elicit a response from the 
immune system, nicotine is not immunogenic. In order 
to elicit an immune response, nicotine or a structurally 
similar hapten needs to be paired with a larger carrier 
protein, thus producing a conjugate vaccine (Goniewicz 
& Delijewski, 2013). Vaccination administers an immu-
nogenic substrate that activates T and B cells, leading to 
the formation of specific antibodies within the individual, 
imprinting the response in immunological memory. By 
virtue of this mechanism, this approach has been shown 
to yield longer lasting protection (Raupach et al., 2012).
When nicotine enters the body, the vaccine causes 
it to bind to the nicotine-specific antibodies, forming a 
complex too large to cross the blood-brain barrier. Thus, 
there is no nicotine-induced cerebral stimulation for 
the smoker and the impression received by the smoker 
is comparable to smoking a cigarette without nicotine 
(Escobar-Chávez et al., 2011).
The success of this immunological strategy hinges on im-
munogenicity of the vaccine, affinity of antibodies, and spec-
ificity of antibodies (Raupach et al., 2012). Immunogenicity 
refers to the antibody serum concentration. A vaccine 
must elicit and maintain a high antibody serum concen-
tration throughout the period of interest in order to be 
maximally effective (Escobar-Chávez et al., 2011).
The primary measure of antibody affinity to the target 
drug can be measured by the binding equilibrium con-
stant, Ka. The Ka is defined by Ka = [NicAb]/[Nic][Ab]. 
[NicAb] represents the plasma volume concentration of 
bound nicotine-antibody complexes, and [Nic] and [Ab] 
denote the volume concentrations of unbound drug and 
unbound antibody, respectively. Hence, in order to cal-
culate the percentage of bound nicotine, data regarding 
the amount of antibody present in circulation must be 
obtained beforehand. The Ka should be high enough to 
bind to nicotine and low enough to allow for unbound 
nicotine release and elimination (Goniewicz & Delijewski, 
2013). However, extremely high affinity may be disadvan-
tageous, as saturation of all antibodies compromises ef-
ficacy for subsequent nicotine doses (Fahim et al., 2011).
Interestingly, the interaction of antibodies with nico-
tine is reversible and each antibody binds to and releas-
es nicotine many times, much like a juggler catches and 
releases multiple sticks many times. Thus, it is observed 
that the binding capacity of the antibodies for nicotine is 
far in excess than the expected stoichiometric calculation 
(Escobar-Chávez et al., 2011).
Specificity refers to the extent to which the elicited 
antibodies bind to nicotine in preference to other mol-
ecules (Raupach et al., 2012). Greater specificity reduces 
competition from other molecules, thus improving safe-
ty and minimizing the likelihood of adverse side effects 
(Escobar-Chávez et al., 2011). This has practical applica-
tions for the design of conjugate vaccines. For example, 
one recent study showed that using longer rather than 
shorter linkers, amino acid sequences used to separate 
multiple domains in a protein (Reddy Chichili et al., 2013), 
increases antibody selectivity to nicotine. Additionally, 
linker position influences specificity. Linkers that are dis-
tant from the prime sites of metabolism (i.e. attached to 
the 6- rather than 5- position of the pyridine ring) help 
enhance antibody selectivity (Raupach et al., 2012).
In order to maintain an ideal serum antibody concen-
tration, repeated administration of the nicotine-conjugate 
system in the form of the vaccine is required. The first 
vaccination administered causes a primary immune re-
sponse, comparable to when the organism had its initial 
encounter with an infectious antigen. Each subsequent 
administration acts as a “planned infection,” which uses 
memory about the antigens during the production of an-
tibodies. Therefore, a faster and more effective response 
to the subsequent vaccinations is anticipated (Goniewicz 
& Delijewski, 2013).
Due to the prolonged effect that nicotine vac-
cines provide, they have an advantage over the ex-
isting pharmacotherapies (Shen et al., 2012, as cited 
in Goniewicz & Delijewski, 2013) and are a critical 
addition to the pharmacological smoking cessation 
aids. The relapse rate is minimal since only bimonth-
ly booster shots are required to achieve a high level 
of antibodies. Thus, patient adherence to the neces-
sary protocol can significantly improve. Nevertheless, 
early clinical trials have casted some doubts in that 
many patients may not elicit a sufficient antibody re-
sponse. To circumvent this issue, novel carriers and/
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or adjuvants with immunogenic properties can be 
introduced to stimulate a more potent immune re-
sponse (Cerny et al., 2009, as cited in Goniewicz & 
Delijewski, 2013).
For those who attain high levels of antibodies, vacci-
nation has been shown to be effective in achieving and 
maintaining abstinence (Goniewicz & Delijewski, 2013). 
Vaccines against nicotine are at an advanced stage of 
clinical trials but have not yet been approved for treat-
ment of individuals (Escobar-Chávez et al., 2011). Future 
strategies for enhanced specificity that the vaccine can 
provide in conjunction with a high affinity to nicotine 
and increased antibody level offer an effective avenue for 
smoking-cessation (Goniewicz & Delijewski, 2013).
Discussion and Conclusion:
After reviewing the various smoking cessation techniques, 
it seems that a combination of a few would be the most 
viable option. The smoker can implement preliminary ar-
rangements with the use of NRT. NRT may be useful for 
those who want to attenuate the smoking habit but do 
not want to put a halt to it completely, known as quitting 
“cold turkey.” The choice of NRT can be guided by the 
patient’s preference, though it may be wise to have a first-
line agent in conjunction with NRT; however, healthcare 
professionals must learn the benefits and potential detri-
ments of different types of NRT before guiding patients in 
its potential use (Wadgave & Nagesh, 2016).
Smokers who find that they are unsuccessful with NRT 
can choose an alternative method. Although nicotine vac-
cines have an advantage over existing pharmacotherapies 
in that they have a prolonged effect and require sub-
stantially less cooperation from patients with bimonthly 
booster shots, data from clinical trials suggest that many 
patients may not produce sufficient antibody response 
(Goniewicz & Delijewski, 2013), suggesting that it may 
not be the most pragmatic approach.
Since nicotine addiction is primarily responsible in 
impeding smoking cessation and long-term abstinence, 
it seems that the most prudent option would be a mo-
dality that targets the activity at the α4β2 receptor, the 
prime mediator of nicotine dependence. Where bupro-
pion therapy aims to alleviate the withdrawal symptoms 
experienced during the transition state to a steady state 
of neurotransmitter activity, as does NRT, varenicline was 
developed to selectively target nicotine activity at the 
receptor that leads to the addiction, a seemingly more 
robust approach. Though varenicline presents a surfeit 
of undesirable side effects, some in the forms of nau-
sea, abnormal dreams, taste perversion, and headaches 
(Burke et al., 2016), these effects may prove manageable 
and worthwhile under a cost-benefit analysis. The strong 
rationale for targeting the α4β2 receptor with a par-
tial agonist, coupled with promising findings from clini-
cal studies, reinforce varenicline’s efficacy and safety as 
a reliable smoking cessation aid. Upregulation of these 
receptors and adaptation lead to the compulsive use of 
nicotine to maintain homeostasis, both of which render 
the α4β2 receptor an effective candidate for pharma-
cologic intervention. However, patients and providers 
should determine whether to use varenicline only after 
an assessment of the potential risks and benefits. The 
efficacy of varenicline can be improved in combination 
with NRT and bupropion, especially for smokers who are 
more heavily dependent on nicotine (Burke et al., 2016). 
Greater understanding of the exact mechanisms of these 
drugs, particularly bupropion, could lead to the devel-
opment of drugs that are more effective in promoting 
smoking abstinence (Warner & Shoaib, 2005).
All things considered, nota bene that relapse is often 
prominent in a patient’s attempt to quit smoking. The av-
erage patient will quit four or five times before reaching 
complete cessation, an important point to convey to pa-
tients to prevent disillusionment and hopelessness during 
recovery (Woody et al., 2008).
Essentially, the adverse health effects associated with 
cigarette smoking are numerous and continual efforts to 
reduce the prevalence of smoking are imperative (Onor 
et al., 2017). Nevertheless, due to futile attempts to quit, 
many smokers feel demoralized and incapable of taking 
action towards quitting. However, there are options 
available to the smoker. Whether in the form of NRT, 
non-nicotinic drugs (namely varenicline and bupropion), 
or the novel nicotine vaccines, nicotine addiction can be 
mitigated to aid the journey towards recovery.
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This paper covers several pathogenic theories of Parkinson’s disease (PD); the physiology and biological pathways involved .  This 
includes a mitochondrial DNA (mtDNA) route, a nuclear DNA route, and other hypotheses about idiopathic PD .  The subsequent 
discussion of PD symptoms utilizes a neurological perspective, analyzing the neuroanatomical systems involved, and how they 
are treated .  This includes medications and surgical techniques that are employed in an effort to manage symptomatology and 
increase health-related quality of life .
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Introduction
Neurodegenerative diseases are characterized by pro-
gressive and selective loss of anatomically or physiologi-
cally related neuron systems.  The clinical syndromes as-
sociated with particular neuroanatomical patterns of cell 
loss and dysfunction are typically categorized by whether 
they initially affect cognition, movement coordination, 
sensation, vision, or autonomic control.  Typical examples 
of such neurodegenerative diseases include Alzheimer’s 
disease, Huntington’s and Parkinson’s disease (Lezi and 
Swedlow, 2012).  Cholinergic neurons are implicated in 
Alzheimer’s, and a degeneration of neurons in the do-
paminergic system is responsible for Parkinson’s disease. 
Parkinson’s disease (PD) is the second most common 
neurodegenerative disease, afflicting 1-3% of the 65+ age 
group.  It is characterized by accumulation of abnormal 
protein (Lewy bodies) in the dopaminergic neurons of 
the substantia nigra pars compacta (SNc) and their 
subsequent degeneration.  These are abnormal circular 
structures with a dense protein core and a halo of ra-
diating fibers.  They consist of aggregations of misfolded 
α-synuclein along with neurofilaments and other pro-
teins.  This neuron loss leads to a difficulty controlling 
movement.  The motor symptoms include bradykinesia, 
postural instability, muscle rigidity, and tremors.  Some 
of the non-motor symptoms (NMS) include depression, 
insomnia, anxiety, apathy, psychosis, incomplete bowel 
emptying, impulse control disorders, and dementia. 
The disease involves progressive degeneration which, 
as of now, cannot be stopped or slowed.  There are effec-
tive medications that can be used to compensate for do-
paminergic neuron loss, such as L-dopa, and other types 
of dopamine (DA) agonists.  These work by increasing the 
potency of the surviving neurons and synapses, but only 
temporarily.  Eventually, the disease will wipe out these 
pathways entirely. Furthermore, the disease spreads to 
other regions of the brain and causes other symptoms. 
For example, when neurodegeneration spreads to cho-
linergic neuronal pathways, the patient will start to show 
signs of dementia.  For now, treatment options are limited 
to symptom management.  This paper discusses some of 
those treatment options, but first it is important to con-
sider the PD pathogenesis and symptom origin. Then, this 
paper will delve into the innovations available for those 
suffering from PD, and explain how they work. 
Mitochondrial Pathogenesis of PD
Mitochondria are the site of bioenergetics and biosyn-
thesis in the cell.  Hans Krebs, for whom the tricarboxylic 
acid (TCA) cycle is named, said of his discovery “in some 
micro-organisms the cycle primarily supplies intermedi-
ates rather than energy, whilst in the animal and most 
other organisms it supplies both energy and intermedi-
ates”.  The energy supplied by the TCA cycle is in the 
form of NADH and FADH2, whose electrons are then 
fed into the electron transport chain (ETC) to pump pro-
tons into the inner membrane space of the mitochondri-
on creating a pH gradient.  This gradient is then used to 
power the conversion of ADP into ATP.  A high ATP/ADP 
ratio is required to catalyze the chemical reactions that 
comprise many of the metabolic operations of the cell. 
Additionally, many of the building blocks that a cell 
needs to form its assortment of macromolecules are 
made using the intermediates of glycolysis and the cit-
ric acid cycle.  For example, about half of the 20 amino 
acids found in human protein can be synthesized in vivo 
through the modification of Krebs Cycle intermediates 
(Reece et al., 2011). Also fatty acids are synthesized from 
acetyl CoA, which is produced by the conversion of py-
ruvate within the mitochondria.  It is important to note 
that when the mitochondria are employed in an anabolic 
capacity (the building of larger molecules and utilization 
of TCA intermediates) they are no longer producing ATP 
but consuming this molecule.
There is some evidence implicating mutations in mi-
tochondrial DNA (mtDNA) or nuclear genes coding for 
mitochondrial protein in the pathogenesis of PD.  Several 
research teams working in 1989 reported a reduction of 
activity of Complex 1 of the ETC in the substantia nigra 
in patients with idiopathic PD (Lezi and Swedlow, 2012). 
This study was based on reports of healthy individuals de-
veloping Parkinson’s like symptoms after consuming the 
compound 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP).  It was determined that the active metabolite 
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of MPTP is taken up by the cell via the dopamine trans-
porters, allowing them to cluster and wreak havoc in do-
paminergic neurons.  This particular metabolite inhibits 
Complex 1 of the electron transport chain, which was 
assumed to have led to the exhibition of Parkinson’s 
symptomatology. 
The suggested hypothesis is that mutations within 
genes coding for mitochondrial DNA or in mtDNA it-
self, specifically Complex 1 genes, can be implicated in PD 
pathogenesis.  Complex 1 contains 46 protein subunits, 
seven of which are encoded by mtDNA.  A mutation 
causing a decrease in Complex 1 activity would lead to 
a drop in ATP production and increased oxidative stress 
and cellular deterioration from the accumulation of free 
radicals (Lezi and Swedlow, 2012). 
It is unclear why dopaminergic neurons of the substan-
tia nigra would be uniquely susceptible.  However, what 
is clear is that the failure of these nigral dopaminergic 
systems are responsible for the symptoms of PD.  Based 
on the research done on mitochondrial involvement in 
dopaminergic deterioration in PD or induced PD symp-
toms, there is sufficient justification to investigate treat-
ment options targeting the mitochondria, which work to 
encourage proper functionality and cellular respiration 
(Lezi and Swedlow, 2012). 
α-synuclein and PD
Researchers have discovered that a mutation on chromo-
some 4 will produce PD (Polymeropoulos, et al., 1996), 
the gene that codes for α-synuclein.  This protein can be 
found in the axon terminals and is involved in synaptic 
transmission in dopaminergic neurons.  A mutation in this 
gene can result in a mistranslated and subsequently mis-
folded α-synuclein that is toxic to the cell.  These proteins 
group together in large aggregates called Lewy bodies 
which devastate normal cell function.
The majority of PD cases are sporadic.  They occur 
without any family history or hereditary basis for the dis-
order.  Some researchers suggest that an unknown toxin 
in the environment, faulty metabolism, or infection may 
be the culprit in these cases.  There are two insecticides 
that are known to cause PD, and presumably there may 
be more.  These toxins might interfere with mitochon-
drial signaling which, when impaired, could cause these 
aggregations of α-synuclein to resist degradation and per-
sist in the cytoplasm of nigral neuron systems.
Symptoms and Their Physiology
The loss of the brain’s most important dopamine sup-
pliers, the neurons of the SNc, leads to a variety of 
symptoms.  Resultant motor symptoms include tremors, 
muscle rigidity, bradykinesia, and postural imbalance - 
the symptoms that normally come to mind when peo-
ple think of Parkinson’s disease.  These symptoms arise 
directly from neuron loss in the motor regulation cen-
ters of the brain (Carlson & Birkett, 2017).  Additionally, 
many other neural pathways are affected by damage to 
the substantia nigra, such as the areas where these do-
paminergic neurons project, namely, the basal ganglia and 
the nucleus accumbens.  The basal ganglia are involved in 
controlling movement, but they also project to the frontal 
lobes of the brain and play a role in thinking and execu-
tive functions.  The nucleus accumbens has been linked 
to behavioral regulation, Thus, dopamine irregularities in 
this region can lead to changes in personality (Carlson & 
Birkett, 2017).
The causes for some of the non-motor symptoms are 
pretty clear, while others are more complicated and de-
batable.  Some symptoms arise directly from a decrease in 
dopamine (DA) production in the substantia nigra.  Other 
symptoms are a result of the DA agonist prescribed to 
the patient.  This might be due to the dramatic fluctua-
tions of DA in the brain owing to the medication sched-
ule.  Still other symptoms might be due to an increased 
potency in certain dopaminergic systems that have not 
been impacted by the disease.  When the patient takes 
L-dopa, these functioning dopaminergic neurons release 
too much DA.  This DA flood triggers a deficit in exec-
utive functions, according to the Dopamine Overdose 
Hypothesis (Dirnberger & Jahanshahi, 2013).  
Other symptoms result from unrelated pathways that 
happen to be proximal to damaged areas of the brain. 
Lewy bodies are often present in the dopaminergic neu-
rons of those with PD.  Many of these misfolded proteins 
that cause neurodegeneration can be transferred from 
cell to cell (Lee, et al., 2011).  This perhaps explains how 
the serotonergic, noradrenergic, and cholinergic systems 
become impacted in later stages of PD. 
Treatments
Since there is no cure for PD, the standard treatment is 
symptom management, by way of DA agonists.  The most 
common one in use is L-dopa, a neurotransmitter (NT) 
precursor which dopaminergic neurons can convert to 
dopamine.  This maximizes its potency through increas-
ing the amount of NT present in the synaptic cleft with 
each firing of the surviving neurons.  When other systems 
are involved in degeneration, such as the serotonergic, 
noradrenergic, and cholinergic systems, agonists for each 
of those NTs can be used to alleviate symptoms.  Some 
symptoms arise from too much dopamine in the healthier 
dopamine pathways, or fluctuations of dopamine based 
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on medication schedule (Dirnberger & Jahanshahi, 2013). 
These symptoms can be treated by using different DA 
agonists at different times and by changing doses.  The 
reason for the variety of dopamine agonists is to reduce 
fluctuations and mitigate some symptoms that may arise 
from any one particular DA agonist.
Another possible medication is Deprenyl, which was 
initially discovered to be effective after the outbreak of 
PD among users of the drug MPTP.  The idea behind it 
was to inhibit the activity of the monoamine oxidase-B 
enzyme and hopefully block the toxins from attacking and 
damaging the neurons.  Although the drug does alleviate 
symptoms, it does not reverse, stop, or slow the progres-
sion of disease (Williams, 2010).
One surgical technique involved the grafting of nigral 
neurons taken from aborted fetuses, to replace the ones 
lost to PD.  This was shown to work particularly well in 
patients who responded well to L-dopa earlier in the dis-
ease.  Presumably, these patients had enough healthy neu-
rons in the basal ganglia to process and secrete dopamine, 
whether intrinsic or from grafted tissue.  Unfortunately, 
many of these patients later developed debilitating dys-
kinesias and the surgery is no longer recommended 
(Olanow, et al., 2003).
Upon closer inspection, it seemed as though the fetal 
tissue had been successful in making the proper con-
nections with the basal ganglia.  However, with time, the 
aggregate α-synuclein deposits made their way from dam-
aged host cells to transplanted healthy cells (Kordower, et 
al., 2011).  Any misfolded proteins responsible for neuro-
degeneration can be transferred from cell to a cell close 
by (Lee, et al., 2011).  It seems that adding healthy cells to 
the basal ganglia will not work unless a way is found to 
prevent the α-synuclein from aggregating in the first place 
and spreading to neighboring cells.
GPi and STN Related Therapies
The main output of the basal ganglia is from the internal 
division of the globus pallidus (GPi) and it is inhibitory. 
Researchers found that whenever there is a decrease of 
activity to the putamen and the caudate nucleus (which 
is a byproduct of SNc neuron death due to PD) there is 
an increase in inhibitory signaling from GPi to the motor 
cortex.  It was suggested that destroying this area might 
help mitigate some of the motor symptoms.  This strat-
egy worked well and was a pretty good option but the 
surgery was quite risky.  The optic tract is located quite 
proximal to the GPi and some patients were blinded by 
the surgery.  Due to advancements in imaging and surgical 
techniques, this option has become safer, and can be rec-
ommended for younger patients who no longer respond 
to L-dopa.  Neurosurgeons can get similar results by 
destroying the subthalamic nucleus (STN) (Guridi, J & 
Obeso, 2001), which has an excitatory effect on GPi. 
Another option that is growing in popularity due to re-
fined surgical techniques is deep brain stimulation (DBS). 
Here, instead of destroying GPi and STN, microelectrodes 
are placed in these regions for the patient to stimulate as 
needed.  This technique is as effective as brain lesions in 
suppressing tremors but with fewer risks (Esselink, et al., 
2009).  DBS might also be effective against depression and 
cognitive impairment in PD. 
Conclusion
There are some innovative techniques for treating PD 
and a lot of promising research on the horizon.  Through 
pursuit of the various pathogenesis hypotheses, we are 
getting closer to understanding the mechanisms of neu-
rodegeneration.  This information is crucial to finding a 
strategy to reverse the disease progression.  In the mean-
time, there are many interventions available to those 
suffering from PD that can dramatically improve quality 
of life.  It is a devastating diagnosis to receive but there 
is plenty of hope.  It is crucial that those diagnosed with 
PD are taught about the potential symptoms and how 
they can be treated.  Specifically the many non-motor 
symptoms not directly caused by degeneration of do-
paminergic neurons.  Treatment of these symptoms is 
achieved through some of the more creative and inno-
vative treatments discussed in this paper.  These non-mo-
tor symptoms are less known by the patients but were 
found to be more injurious to the patient’s quality of life 
than the classic symptoms (Duncan, et al., 2013).  As the 
research into PD genesis, pathways and mechanisms de-
velops, more therapies are being discovered to treat this 
complex and multifaceted disease.
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